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Abstract 
Photodynamic therapy (PDT) is an alternative cancer treatment, which works through 
the synergy of three components: a photosensitizer (PS), molecular oxygen (O2) and light of a 
specific wavelength (λ) to activate the PS and generate reactive oxygen species (ROS), 
primarily singlet oxygen (1O2). ROS are then responsible for the therapeutic action of PDT 
through the localized destruction of cancer tissues at the area of light irradiation. Therefore, 
PDT can be seen as photoinduced “drug delivery” processes. Porphyrins are PSs known for 
their lack of water solubility and strong aggregation tendency in aqueous solvents, 
characteristics that affect their photophysical properties and limit their application to biological 
systems. Modifications on porphyrins structures are desired to achieve PSs that are easy to 
prepare, well-characterized and that possess improved photophysical properties and enhanced 
aqueous solubility. 5,10,15,20-tetrakis(m-hydroxyphenyl)-21,23H-porphyrin (mTHPP), is the 
porphyrin analogue of the clinically approved chlorin temoporphin (mTHPC, Foscan®), 
prescribed for the palliative treatment of patients with advanced head and neck squamous cell 
carcinomas.  
Both mTHPP and mTHPC have proven to be 25-30 times as potent as the clinically 
used hematoporphyrin derivatives, e.g. photofrin in vivo; however, like other porphyrin 
compounds, mTHPP and mTHPC suffer from poor water solubility, forming non-fluorescent 
aggregates in a wide pH range in aqueous solution. Foscan® is adminstered in injectable form as 
an ethanol and propylene glycol mixture. Thus, there is a clear need to improve the water 
solubility, to promote deaggregation, without affecting the photochemistry of the porphyrin core 
of these PSs.  Cyclodextrins (CDs) are cyclic oligosaccharides composed of α-D-glucopyranose 
units (α-, β- and γ-CDs), that in aqueous media are able to encapsulate hydrophobic molecules 
in their cavities, usually resulting in increase of aqueous solubility, stability, and bioavailability 
of the molecule (drug). Therefore, several types of CDs are approved pharmaceutical excipients 
and are extensively used in drug formulations. The covalent attachment of a CD moiety to a 
porphyrin is a strategy that is meant to combine the drug encapsulation / solubilization 
capabilities of a CD macrocycle, with the photosensitizing / fluorescence and imaging 
properties of the porphyrin, thus creating a multimodal drug carrier. In this sense, a CD-
porphyrin conjugate could have increased aqueous solubility and enhanced photophysical 
properties of the porphyrin moiety and moreover, possesses the ability to encapsulate suitable 
drug molecules for cancer treatment. In general, there is an interest in developing potential 
useful drug candidates relying on already approved molecules, namely an approved safety 
profile for human use.  
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In this dissertation preparation, characterization and photophysiscal properties of a 
cyclodextrin-porphyrin conjugate (CD-mTHPP) are described. Specifically, mTHPP was 
successfully attached to βCD to form a 1:1 conjugate (CD-mTHPP). This was prepared in pure 
form in 40 % yield in an optimized up-scalable procedure. Additionally, its structure was fully 
characterized by NMR, MALDI-TOF MS and elemental analysis. Moreover, its photophysical 
properties were investigated by UV-Vis and fluorescence spectroscopy. CD-mTHPP revealed 
more than 1.7-fold improved absorbance and more than 20-fold increased fluorescence emission 
in phosphate buffer saline and improved solubility in water, when compared to mTHPP. The 
latter, although limited to µM range of concentration due to formation of small-sized aggregates 
was enough to conduct cell experiments. The use of mTHPP alone was impossible, under the 
same conditions due to massive aggregation. Consequently, the low aqueous solubility of CD-
mTHPP was drastically improved to the mM range of concentration by the addition of per-
methylated-βCD (pMβCD) that acts as solubilizer, through the formation of water-soluble 
inclusion complexes with CD-mTHPP (pMβCD/CD-mTHPP). The inclusion complexation was 
extensively studied regarding structure with NMR spectroscopy and regarding stoichiometry 
with UV-Vis experiments and these results were compared with the corresponding 
complexation of pMΒCD with mTHPP (pMβCD/mTHPP). Moreover, the binding constants for 
pMβCD/CD-mTHPP 1:1 complex and for the pMβCD/ mTHPP 2:1 complex were found from 
titration experiments to be extremely high, K(1:1) ≈ 3.8 x 106 M-1 and K(2:1) ≈ 4.9 x 1012 M-2, 
respectively. Although the stoichiometry of complexation of pMβCD/CD-mTHPP (1:1) is 
different from pMβCD/mTHPP (2:1), CD-mTHPP preserved the properties of mTHPP but with 
noticeable improvements in phosphate buffer saline (PBS): decreased aggregation to practically 
monomer form, increased up to 8-fold fluorescence emission intensity, good cell internalization 
with preferred localization into lysosomes (or endosomes) and the additional ability to carry 
suitable drug molecules, through inclusion in its cavity, as shown by NMR experiments. These 
results offer a robust methodology for preparing bimodal CD-porphyrin conjugates with 
improved properties, potentially useful for overcoming crucial limitations attributed to PSs used 
in PDT treatments. The methodology used to prepare CD-mTHPP can eventually be expanded 
to the preparation of other conjugates and even extended to other PSs. 
In the second part of this dissertation, positively charged cyclodextrin-based polymers 
were studied, with the focus in the capture and delivery of negatively charged drugs (e.g. 
nucleotides). Cyclodextrin-based polymeric materials (CD-polymers) are interesting as potential 
DDS because they are easily prepared in larger scales, their properties can be modified and offer 
potential advantages when compared to single CD derivatives i.e. keeping the same 
complexation ability for specific guest molecules, improving the solubility of drugs and acting 
as bioavailability modifiers. Amino-CDs derivatives are positively charged CDs studied as 
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biomimetic molecules. Per(6-aminoalkylamino-6-deoxy)-CDs are a family of amino-CDs, that 
have previously revealed good cell penetrating properties (CPCDs) and moderated interaction 
with DNA. Additionally, per(6-guanidino-6-deoxy)-CDs showed strong interactions through 
cavity inclusion with model nucleotides. To explore this new and interesting field of delivery of 
anionic drugs (nucleotides), two strategies have been employed to prepare cationic CD-
polymers, based on per(6-aminoalkylamino-6-deoxy)-βCD (βpen). Two different strategies 
have been used to prepare and characterize CD-polymers that involved: i) the reaction of βpen 
with preformed polymeric material namely poly-L-lysine (pLys) and ii) the preparation of a 
polymer from a monomeric material, followed by reaction with CD derivatives precursors of 
βpen. Several batches of βpen-polymers have been prepared and characterized, resulting in 
βpen-rich polymeric materials. These were shown able to complex suitable negatively charged 
molecules as shown by 2D NMR spectroscopy experiments. Moreover, they acted as release 
modifiers of nucleotides, as demonstrated using Franz cell experiments. Although the polymeric 
systems were not fully optimized, in the preliminary trails performed they showed the ability to 
regulate the release of adenosine 5’-monophosphate (5’-AMP) and of the anticancer drug 
gemcitabine (GEM).  
 
 
Keywords 
Bimodal System; Cancer; Cyclodextrin; Conjugates of Cyclodextrin-Porphyrin; Drug 
Delivery System; Porphyrin; Photodynamic Therapy; Polymers; Photosensitizer 
  
  
iv 
Resumo 
A terapia fotodinâmica (TF) é um tratamento para o cancro baseada em três 
componentes que trabalham em conjunto: um fotossensibilizador (FS), o oxigénio (O2) e luz de 
um comprimento de onda específico (λ) que activam o FS e geram espécies reactivas de 
oxigénio, principalmente o oxigénio singuleto (1O2). Estas espécies reactivas são responsáveis 
pela acção terapêutica que envolve a destruição localizada das células cancerígenas na área de 
irradiação. Portanto, a TF pode ser entendida como um modo de administração de fármacos 
foto-induzida. As porfirinas são conhecidas pela sua reduzida solubilidade e forte tendência para 
formar agregados que afectam as suas propriedades foto-físicas e limitam a sua aplicação 
biológica. Modificações na estrutura das porfirinas são desejadas para obter FS, fáceis de 
preparar, caracterizar e que possuam propriedades melhoradas como uma melhor solubilidade. 
5,10,15,20-tetrakis(m-hydroxyphenyl)-21,23H-porphyrin (mTHPP) é uma molécula análoga de 
uma clorina (mTHPC, temoporphin) aprovada como Foscan®, prescrita para o tratamento 
paliativo de doentes com carcinoma avançado das células escamosas na cabeça e no pescoço. 
mTHPP e mTHPC mostraram ser 25 - 30 vezes mais potentes que os derivados da 
hematoporfirina clinicamente aprovados, mas apresentam problemas de solubilidade que 
conduzem à formação de agregados que não fluorescem em soluções aquosas. Foscan® é 
administrado como injecção numa mistura de etanol e propileno glicol. Existe portanto, a 
necessidade de melhorar a solubilidade dos FS e evitar a formação de agregados em água, sem 
comprometer a propriedades fotofísicas / fotoquímicas características das porfirinas. As 
ciclodextrinas (CDs) são oligo-sacarídeos cíclicos compostos por unidades de α-D-
glucopyranose (α-, β- e γ-CDs), que em água são capazes de encapsular moléculas hidrofóbicas 
na sua cavidade resultando em melhorias na solubilidade, estabilidade e biodisponibilidade de 
fármacos. Alguns derivados de CDs já se encontram aprovados como excipientes e são usados 
actualmente em diversas formulações disponíveis no mercado. A ligação covalente de CDs a 
porfirinas é uma estratégia que promove a conjugação das propriedades como a melhoria de 
solubilidade, encapsulamento e solubilização de moléculas atribuído às CDs, e com as 
propriedades de visualização e características fotofísicas das porfirinas, criando potenciais 
conjugados entre CD-porfirinas úteis como sistemas de libertação de fármacos (SLF) 
multimodais. Neste sentido, os conjugados entre CD-porfirinas podem apresentar melhor 
solubilidade e propriedades fotofísicas, oferecendo ainda a habilidade de poder transportar, na 
cavidade da CD, fármacos para o tratamento do cancro. O interesse no desenvolvimento de 
fármacos baseados em moléculas já aprovadas pelas entidades para o uso em humanos foi 
igualmente reconhecido. 
Nesta dissertação será descrita a preparação, caracterização e propriedades de um 
conjugado CD-porfirina (CD-mTHPP). Especificamente, mTHPP foi ligada a βCD, formando o 
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conjugado CD-mTHPP, com a estequiometria 1:1. CD-mTHPP foi preparado com um 
rendimento de 40 % e através de um método que pode ser melhorado para uma estala superior 
(scale-up). CD-mTHPP foi caracterizado por ressonância magnética nuclear (RMN), 
espectrometria de massa (EM) e análise elementar. As suas propriedades fotofísicas foram 
investigadas por espectrofotometria de UV-Vis e fluorescência. Comparativamente com 
mTHPP, o conjugado CD-mTHPP revelou melhor absorbância (1.7 x superior), fluorescência 
(20 x superior) e melhor solubilidade em água. Contudo, a solubilidade é limitada a 
concentrações (µM) devido à formação de agregados, mas suficiente para realizar experiências 
em células. Não foi possível a utilização de mTHPP em condições semelhantes. A baixa 
solubilidade de CD-mTHPP é limitada a concentrações µM mas foi melhorada até mM, pela 
adição de βCD-per-metilada (pMβCD) usada como solubilizante, através da formação de 
complexos de inclusão com CD-mTHPP (pMβCD/CD-mTHPP). Os complexos de inclusão 
pMβCD/CD-mTHPP foram estudados quanto à estrutura por RMN e quanto à estequiometria 
por espectrofotometria de UV-Vis e os resultados foram comparados com complexos 
(pMβCD/mTHPP). As constantes de complexação para pMβCD/CD-mTHPP (1:1) e para 
pMβCD/mTHPP (2:1) foram determinadas por ensaios de titulação e são K(1:1) ≈ 3.8 x 106 M-1 
and K(2:1) ≈ 4.9 x 1012 M-2, respectivamente. Apesar da estequiometria de complexação de 
pMβCD/CD-mTHPP (1:1) ser diferente da estequiometria apresentada por pMβCD/mTHPP 
(2:1), CD-mTHPP preservou as propriedades de mTHPP com melhoramentos em solução 
aquosa (tampão fosfato salino): menor agregação, aumento da fluorescência, boa internalização 
nas células localizando-se preferencial nos lisossomas e a capacidade de transportar fármacos 
por inclusão na cavidade da βCD. Estes resultados são importantes porque oferecem a 
possibilidade de ultrapassar algumas das limitações dos PSs usadas na PDT. A metodologia 
usada para preparar CD-mTHPP pode ser expandida a outros conjugados e outros PS. 
Na segunda parte desta dissertação, pretendemos estudar polímeros baseados em CD 
com carga positiva potencialmente úteis na complexação e transporte de fármacos com carga 
negativa como nucleótidos. Polímeros baseados em CDs são interessantes pois podem ser 
preparados em grande escala, as propriedades podem ser modificadas e apresentam melhorias 
comparativamente com CDs, tais como: a melhoria na solubilidade de fármacos e acção como 
potenciais modificadores de biodisponibilidade. Amino-CDs são exemplos de CDs com carga 
positiva estudadas como moléculas biomiméticas. Per-amino-alquil-amino-CDs são uma 
família de amino-CDs, que dependendo do pH da solução podem apresentar aminas (-NH2) e 
catiões amónio (-NH4+) que revelaram boa capacidade de internalização em células e interacção 
moderado com o ADN. Finalmente, per-(6-guanidino-CDs) revelaram forte interacção com 
nucleótidos levando à sua inclusão.  
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Para explorar este novo e interessante campo de pesquisa envolvendo o transporte de 
fármacos aniónicos (nucleótidos), duas estratégias foram desenvolvidas para preparar polímeros 
baseados em per-6-amino-etil-amino-βCD (βpen). A primeira estratégia envolveu a reacção de 
βpen com polímeros preformados baseados em poli-L-lisina (pLys) e a segunda, envolveu a 
preparação de um polímero com base em monómeros, seguida de reacção destes com derivados 
de CDs precursores da βpen. Alguns polímeros contendo βpen foram preparados e 
caracterizados, revelando-se úteis na complexação de moléculas carregadas negativamente, 
como demonstrado por experiências de espectroscopia de RMN em duas dimensões (2D RMN). 
Além disso, foi mostrado que estes polímeros actuam como modificadores de libertação de 
nucleotídeos, através de experiências com células de Franz modificadas. Embora os sistemas 
poliméricos não tenham sidos optimizados, os resultados obtidos revelaram a capacidade de 
regular a libertação de adenosina 5'-monofosfato (5’-AMP) e o fármaco anticancerígeno, 
gemcitabina 5’-monofosfato (GEM). 
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1. Cyclodextrins (CDs) 
1.1 Structural features 
Carbohydrates (saccharides) are chemical compounds of carbon, oxygen and hydrogen 
described by the empirical formula Cx(H2O)y. These are involved in many important biological 
processes that include:  
i) the energy storage in plants (starch) and in animals (glycogen) 
ii) they are structural elements in cell walls of bacteria, plants (cellulose) 
and in the exoskeleton of arthropods (chitin) 
iii) they are linked to many lipids, proteins, make the structural framework of 
ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) 
iv) they are involved in cell recognition processes [1,2] 
Carbohydrates are categorized as mono-, di-, oligo- and polysaccharides. These are also 
designated as aldoses or ketoses depending on their structure i.e. if they are derived, 
respectively from an aldehyde or a ketone group. D-glucose in its open structure is a six-carbon 
atom monosaccharide aldose (Figure 1 A) and is one of the most abundant carbohydrates in 
nature. Carbohydrates display a diversity of biological functions, which are related to their 
chemical structure and in turn determine their reactivity. 
 
 
Figure 1. Structures of D-glucose (an aldose): A) its Fischer projection, B) α-D-glucopyranose and C) β-D-
glucopyranose. There are three forms in aqueous solution, together with negligible amounts of the furanose 
forms. 
 
A characteristic reaction of carbohydrates is the endocyclic or intramolecular 
hemiacetal formation, characterized by a nucleophilic attack of the terminal secondary hydroxyl 
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group (OH) to the carbonyl group of the ketone (R1-CO-R2) or aldehyde (R1-COH). In D-
glucose, for an intramolecular hemiacetal formation between the hydroxyl group on C5 and the 
aldehyde group at C1 (Figure 1 A), a cyclization reaction has to occur leading to the formation 
of D-glucopyranose. Depending on the stereochemistry of the OH group attached to C1, two 
different stereoisomers or anomeric forms are possible: α-D-glucopyranose (Figure 1 B) – a 
trans isomer, with the hydroxyl group on C1 in axial position relative to C6-OH; and, β-D-
glucopyranose (Figure 1 C) – a cis isomer, with the hydroxyl on C1 in an equatorial position 
with respect to C6-OH position. All other OH groups at C2, C3, C4 and C6-OH are in the 
equatorial position. In aqueous solutions, α-D-glucopyranose interconverts into β-D-
glucopyranose isomer via open form in an equilibrium that involves changes in optical rotation 
([α]20D) of both isomers called mutarotation, manifested through changes in the overall [α]20D  
of the substance (Figure 2) [3]. 
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Figure 2. In an equilibrated aqueous solution of D-glucose the observed optical rotation ([α]20D = 52.7) due to 
mutarotation, resulting from 36 % of α-D-glucopyranose and 64 % of β-D-glucopyranose. 
 
In D-glucose, each anomeric form can be involved in an intermolecular acetal formation 
reaction. The resulting chemical bond is a “glycosidic bond” and is responsible for the 
connectivity between many carbohydrates giving rise to disaccharides, oligosaccharides and 
polysaccharides. They are often named as α- or β-, depending on the stereochemistry of the 
initial anomeric carbon, followed by the numbering of the two positions involved in the 
connection between brackets (Figure 3). 
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Figure 3. Connectivity between two α-D-glucopyranose units, through α-(1, 4)-O-glycosidic linkage (bond). 
 
According to the IUPAC recommendations [4], other types of glycosides can be formed 
when the anomeric oxygen is substituted by other elements namely: thioglycosides (sulphur, -
SR); selenoglycosides (selenium, -SeR); N-glycosides (nitrogen, -NR1R2) or C-glycosides 
(carbon, -CR1R2R3). 
Naturally occurring cyclodextrins (CDs) are cyclic oligosaccharides resulting from 
sequential α-(1,4)-O-glycosidic linking of 6-, 7- and 8 α-D-glucopyranose units, represented as 
αCD, βCD and γCD, respectively (Figure 4) [5]. These macrocycles are industrially produced by 
enzymatic conversion of starch and other α-(1,4)-glucans, through the action of 
glucosyltransferase (CGTase, EC 2.4.1.19) [6] in an intramolecular transglycosylation reaction 
[7]
.  
 
Figure 4. Structures of the three native cyclodextrins: αCD, βCD and γCD. 
 
The structure of CDs was found and assigned to a cyclic geometry after a series of 
findings and discoveries classified by Szejtli [8] as the “discovery stage” in CD chemistry [9, 10]. 
The α-(1,4)-O-glycosidic linkage, between two consecutive α-D-glucose units and the 
hydrogen bonding network on the secondary side between adjacent hydroxyl groups, in 
positions 2 and 3 of the n glucopyranose units, explain its doughnut-shaped structure. The inner 
lining comprises the hydrogen atoms at positions 3 and 5 of glucopyranose (n-1) and the 
glucopyranose oxygen bridging atoms that render the cavity its lipophilic character, in 
opposition to its outer hydrophilic rims lined with hydroxyl groups [11] (Figure 5). 
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´  
Figure 5. Structural arrangement of glucopyranose units in γ-cyclodextrin connected through α-(1, 4)-O-
glycosidic linkages with the hydroxyl groups at the rims creating the primary and secondary faces [12]. 
 
X-ray and neutron diffraction studies in the crystalline state revealed that [13]: i) each 
glucose unit adopts a 4C1 chair conformation; ii) there is freedom of rotation about the C(6) – 
C(5) bond, resulting in OH(6) rotated either away (gauche-gauche) or towards (gauche-trans) 
the centre of the CD; iii) the secondary hydroxyls groups of adjacent glucose units are 
connected by intramolecular hydrogen bonding and, as a consequence iv) in native CDs rotation 
about C1-O-C4 is not possible. 
Native CDs are water-soluble compounds and their glycosidic bonds are stable in 
alkaline solution [14], whereas in strong acids they are prone to acid hydrolysis to give linear 
oligosaccharides (pH < 3.5; T > 60 ºC) [15]; however, the hydrolysis is considerably slower, 
compared to that observed for linear oligomers (maltohexaose, -heptaose, -octaose). 
The number of glucose units in the macrocycle determines the dimensions of the cavity 
namely: the annular diameter and the volume of α, β, and γCD. Additionally, the dimensions of 
the macrocycle determine the properties of CDs (Table 1) [13, 16] namely its water solubility and 
ability to complex different guest molecules. For example, the solubility of native CDs in water 
(γCD > αCD > βCD, Table 1) has been related to the number of glucopyranose units in each 
macrocycle: βCD is poorly soluble because is has the appropriate number of glucose units and 
has a complete hydrogen bonding network, comprising all seven glucopyranose units; the 
intermediate solubility of αCD is associated with the incomplete hydrogen bond in network 
between the six glucopyranose units, because one of the six glucopyranose units is distorted 
relative to all of the others; finally, γCD is larger and possesses a more flexible structure and 
thus an even better solubility [9]. 
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Table 1 – Some physico-chemical properties of native CDs, adapted from Easton & Lincoln [13]. 
CD Feature αCD βCD γCD 
Number of glucose units 6 7 8 
Molecular weight (g/mol) 972.9 1135.0 1297.1 
Annular diameter (Å) 4.7 – 5.2 6.0 – 6.4 7.5 – 8.3 
Annular depth (Å) 7.9 – 8.0 7.9 – 8.0 7.9 – 8.0 
Volume cavity (106 pm3) 174 262 427 
Optical rotation, [α]D (25 ºC) 150.0 ± 0.5 162.5 ± 0.5 177.4 ± 0.5 
Water molecules cavity 6 11 17 
Solubility (g/L, 25 ºC) 145 18.5 232 
 
 
1.2 Formation of inclusion complexes 
The most remarkable characteristic of native CDs is their ability to accommodate 
poorly water-soluble guest molecules of appropriate size and geometry that are able to fit into 
the CD hydrophobic cavity in aqueous solutions [9]. Inclusion is explained by the simplest 
complexation equilibrium, between one guest molecule (G, drug) and one host molecule (H, 
CD) (Figure 6). However, there is the possibility of multiple equilibria and involving various 
stoichiometries, between h molecules of H and g molecules of G (Figure 6, Eq. 1) resulting in 
an overall equilibrium constant (Figure 6, Eq. 2). 
 
A) 
B) 
Figure 6. A) Complexation equilibrium between a CD unit (H) and a guest molecule (G), with the 
corresponding release of high energy water molecules; B) Chemical equation describing the inclusion complex 
formation, between h moles of host (H) and g moles of guest (G) to form a hg moles of the complex (HG): 
general equilibrium equation (Eq. 1) and overall equilibrium constant Kcompl (Eq. 2). 
 
The magnitude of the binding constant (Kcompl) determines the stability of the complex 
and it is related to the chemical structure of both guest and host molecules. The driving force for 
the inclusion is the hydrophobic effect and stabilization of the complex was explained by a 
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series of H-G intermolecular interactions: van der Waals forces, dipole-dipole and hydrogen 
bonding interactions. In this respect, it was recognised that van der Waals forces justify the 
inclusion phenomena, whereas electrostatic interactions and hydrogen bonding usually dictate 
the spacial conformation of a given inclusion complex [17]. The magnitude of Kcompl can be 
improved through drug ionization, salt formation, use of co/solvents, metal complexation, 
polymer complexation and acid-base ternary complexes [8]. The binding process involves a 
combination of factors, comprising: i) the insertion of the hydrophobic part of the G molecule 
into the H cavity; ii) the dehydration of the organic guest and iii) the release of high-energy 
water molecules, located inside the CD cavity to the aqueous medium [18].The thermodynamic 
parameters ruling inclusion of G molecules by CDs have been studied and inclusion is usually 
characterized by: negative Gibbs energy change (∆Gº < 0) and enthalpy (∆Hº < 0) whereas the 
entropy (∆S) is small negative or positive. 
The determination of the binding constants (Kcompl) and of the stoichiometric 
coefficients can be achieved by measuring the changes in the analytical response of an 
experimental technique such as UV-Vis, fluorescence emission or NMR spectroscopy. A typical 
experiment involves the continuous addition of H molecule to a G solution or vice-versa, 
followed by recording of the changes observed. These values are then plotted and fitted to 
suitable equations, describing binding experimental models to determine the proper 
stoichiometry of complexation and the binding constant (Kcompl) for that specific stoichiometry 
[19]
. The method of continuous variations (or Job´s plot) is a graphical representation of any 
property (UV-Vis / NMR) that changes as a function of the molar ratio of H and G in a solution, 
keeping the concentration of [H + G] constant, that enables the determination of stoichiometry 
of the complex formed [20, 21]. 
 
 
1.3 Structure of inclusion complexes in solution 
Complexation / inclusion equilibrium involving CDs in aqueous media can be assessed 
by NMR spectroscopy. A common feature of all CD inclusion complexes is that the 1H NMR 
signals corresponding to the internal protons of the cavity (H3/H5) of a CD are affected after 
complexation with a suitable guest. Usually, H3 and H5 are shielded by the electrons of the 
incoming guest and the respective resonances move to lower frequencies (smaller ppm), when 
compared the initial host solution.  
In addition, NMR spectroscopy is useful to study the mode of complexation through 2D 
NMR experiments based on nuclear Overhauser effect (NOE), because the observed 
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correlations enable the detection of protons spatially close to one another in a distance up to ≈ 5 
Å. NOE arises from cross relaxation mechanism, explained by the mutual interactions of two 
spins through space acting as two magnetic dipoles (dipolar coupling). Dipolar interactions 
affect the spin population that are close in space, generate NOE and can be detected by two 
major NOE experiments, which are independently used, depending on the size of the molecules 
being analysed: i) Rotating frame nuclear Overhauser Effect SpectroscopY (ROESY) is used for 
molecules with molecular weight ≈ 1000 Da and ii) Nuclear Overhauser Effect SpectroscopY 
(NOESY) which is negative for larger molecules (molecular weight > 1000 Da) and positive for 
small molecules. A consequence of NOE effect and a successful 2D NMR experiment is that the 
geometry of the complex and the mode of complexation can be determined. 
Furthermore, one important aspect to be considered in NMR complexation studies is the 
exchange rate regime between two different states, which might involve a complex (A) and free 
guest molecule (B). In the fast exchange regime, the overall rate of the complexation (Kex) is 
much higher than the chemical shift differences (∆ν) between A and B and the signals are not 
distinguishable, but appear at an intermediate frequency, which is the weighted average between 
frequencies νA and νB, multiplied by the respective spin populations, PA and PB, so that the νobs = 
PAνA + PBνB. However, in slow exchange regime where ∆ν > Kex, clear signals for both A and B 
are observed and these species can be independently detected during a NMR experiment (Figure 
7) [22]. 
 
Figure 7. Chemical exchange processes [22]: (a) exchange between 
two states A and B, with different equilibrium constants (kA, kB), 
chemical shifts (νA, νB) and populations fractions (PA, PB) of each 
state, (b) variation of kex on NMR spectra with PA = 75 % and ∆ν = 
100Hz.  
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The crystal structure of CDs has been studied by X-ray crystallography, which in 
combination with other techniques such as NMR spectroscopy revealed the structure of 
cyclodextrin complexes in the solid state. The structure of several drug complexes has been 
investigated in the presence of CDs such as: i) non- steroidal anti-inflammatory drug (NSAID), 
acemetacin [23] and β-naphthyloxyacetic acid (NOA) [24] in solution, to mention just a few 
examples from our laboratory. Almost invariably, in solution, all possible intermolecular 
complexes are observed, while in the crystal state the most populated (or most stable) complex 
eventually crystallizes out. 
 
 
1.4 Chemical modifications 
Chemical modification is a way of introducing various substituents on a CD 
macrocycle, resulting in CD derivatives with different properties. The conversion of a CD 
molecule into a new derivative, both efficiently and selectively, has always been challenging 
due to the large number of OH groups in each CD macrocycle: 18 in αCD, 21 in βCD and 24 
OH in γCD and extensive heterofunctionalization has only recently been achieved [25]. Chemical 
modification could, nevertheless result in: i) improvements on the solubility of the CD 
derivative and its complexes; ii) a better fitting between the CD and the guest molecule with 
stabilization of the guest; iii) attachment of specific catalytic groups to the binding site (e.g., in 
enzyme modelling); or even lead to iv) the formation of insoluble or surface-immobilized CD 
polymers for different applications [9]. Most of the times, the type of CD derivative and selection 
of synthetic strategies to be applied are strongly dependent on the purpose of application. 
In 1978 Lenh and co-workers [ 26 ], while preparing and characterizing a series of 
substituted αCD derivatives, realized that the order of substitution is affected by the difference 
in hydroxyl group reactivity, namely between the primary side (6-OH) and the secondary side 
(2-OH / 3-OH).  Primary side 6-OH are more nucleophilic and less sterically hindered than the 
secondary side (2-OH / 3-OH); which results in easier reactivity of 6-OH [27]. By 1998, Kahn et. 
al. [27] suggested a classification for CD modification, which could comprise three categories: i) 
the “clever way”, achieved by the shortest route possible involved less synthetic steps; ii) the 
“long way”, followed a series of protection and de-protection steps and finally, iii) the 
“sledgehammer way”, where the reaction is left to react to give a mixture of products latter 
separated through extensive and time-consuming separation techniques. 
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Relevant findings regarding specific CD modification include but are not limited to: i) 
the preparation of mono-substituted CD derivatives described by Melton et. al. [ 28 ]; ii) 
modification of the original macrocycle configuration (from a natural 4C1 to an ‘induced’ 1C4 
configuration, through conversion into their mono- or per-3,6-anhydro CDs derivatives (Figure 
8) described by Ashton et. al. [29]; and, iii) per-6-halogenation of CDs was described by Defaye 
et. al. during trials to find alternatives to directly sulfonate the primary side of the CDs [30]. 
 
  
Figure 8. Formation of by-product mono-3,6-anhydro-βCD (“anhydro”) from βCD in strong alkaline 
conditions (NaOH/H2O), involving a nucleophilic attack of 3-OH to 6-OH leading to the inversion of 
configuration from a natural 4C1 to an induced  1C4. OTs = Tosylate. 
 
Mono-tosylation (tosyl group, Ts) of a βCD [31] (Figure 9 i) is a versatile methodology 
that offers the possibility of further mono-modifications. This reaction can be performed in 
aqueous alkaline conditions and takes advantage of the inclusion ability of CDs, that is explored 
through the insertion of the Ts moiety into the CD cavity. This is the reason often suggested for 
the high purity of the mono-substituted product (βmTs), obtained in low yields but easily 
purified by precipitation from the reaction mixture [ 32 ]. Alternatively, mono-tosylation can 
proceed in pyridine where, by changing the relative ratio of reactants used, higher yields and 
other substitution products can be obtained at the expense of time spent in a tedious 
isolation/purification procedure based on column chromatography. The preparation of per-6-
halogenated-CDs is another common modification reported by Defaye et. al. [30, 33] that proceeds 
through the in situ formation of the Vilsmeier-Haack reagent in dry dimethylformamide (DMF), 
in the presence of a halogen atom donor [bromine (Br2), N-bromosuccinimide (NBS) or iodine 
(I2) and triphenylphosphine (PPh3)] (Figure 9 ii). Per-alkylation and per-acylation is also 
possible. Furthermore, selective 2,6-modification can be achieved (e.g. 2,6-di-O-methyl-βCD) 
as well as 2- or 3-modifications [27]. 
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Figure 9. Different methodologies to convert CDs into: i) βmTs, a monosubtituted CD (conditions: TsCl, 
NaOH, H2O) and ii) βpBr, a per-substituted CD (conditions: DMF, Br2, PPh3). 
 
 
 
1.5 Derivatives as approved excipients 
The flexibility in chemical modifications of CDs, their established safety profile [34] and 
their extensive range of application as encapsulation / complexation agents of several active 
pharmaceutical ingredients (API) makes CD derivatives especially attractive from the 
pharmaceutical industry perspective. In fact, most of the derivatives studied are derived from 
βCD that possesses the appropriate dimensions of the cavity better suited for complexation of 
phenyl groups, a common group in the structure of many drug molecules already approved for 
human use (Table 2). This is in contrast with the small cavity size of αCD derivatives and the 
expensive γCD derivatives [35]. Some examples of typical host CD derivatives already marketed 
involve: i) βCD; ii) randomly methylated βCD (RM-β-CD); iii) hydroxypropyl-βCD (HP-β-
CD) and iv) sulfobutyl ethers (SBE-β-CD) (Table 2) [36].  
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Table 2. Some selected examples [37] of drugs molecules used in drug formulations containing CDs derivatives. 
 
 
Derivative Brand Name Route Administration Drug (label) Year Company 
SBE-βCD Vfend Intravenous Vorizonazole (A) 2002 Pfizer 
SBE-βCD Geodon Intra muscular Ziprazidone (B) 2002 Pfizer 
SBE-βCD Abilify Intra muscular Aripiprazole (C) 2006 BMS/Otsuka 
HP-βCD Sporanox Intravenous Itraconazole (D) 1997 Janssen 
HP-βCD Vibativ Intravenous Telavancin 2009 Astellas Pharma / Therevance 
RM-βCD Aerodiol Nasal spray Ostradiol (E) 2001 Servier 
βCD Brexin Rectal Piroxicam - Chiesi 
αCD Rigidur Intravenous Alprostadil (PGE1) - Ferring / Denmark 
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2. Porphyrins 
2.1 Structure and properties 
Porphyrins are naturally occurring compounds constituted by four pyrrole (Py) units, 
connected by methine bridges (=CH-) in a cyclic structure (Figure 10 A) [38]. This conjugated 
macrocycle has 22 pi electrons, of which only 18 are effectively delocalized and contribute to its 
aromatic character, following Hückel's law of aromaticity: [4 n + 2] pi electrons, with n = 4 [39]. 
Due to their tetravalent centre, porphyrins are able to form coordination complexes called 
metalloporphyrins with nearly any metal in nature, where they reveal biological activity as 
prosthetic groups (active site) [40]. Examples of several porphyrin-based prosthetic groups are 
iron (Fe2+) complexes present in: i) the cytochromes responsible for electron transfer processes; 
ii) the cytochrome P450 oxidases involved in the oxidation of organic substrates; iii) the heme 
group suited for oxygen transport (Figure 10 B) and in myoglobin, used in oxygen storage. 
Magnesium (Mg2+) complexes are common in the chlorophyll c1 green pigment (Figure 10 C) 
relevant in light harvesting processes during photosynthesis and cobalt complexes (Co2+) of 
porphyrins like in vitamin B12 (Figure 10 D) are important in biocatalysis processes. 
 
 
Figure 10. Examples of porphyrin macrocycle core structures: A) porphyrin numbering according to IUPAC 
[38]; B) heme B, an iron binding porphyrin located at the oxygen binding site of myoglobin; C) chlorophyll c1; 
D) vitamin B12. 
 
Their abundance in nature, the diversity of their structural features and the importance 
of the biological processes mediated by them has boosted the research regarding porphyrins, 
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which is mainly focused on medical applications of these macrocycles. An example is given by 
derivatives of hematoporphyrin (Hp), which were first studied and revealed interesting features 
like good tumour localization and photosensitization properties [41,42]. However, Hp derivative 
first isolated, were a mixture of compounds, which motivated studies on its purification [43] and 
was latter extended to the synthesis of new porphyrins with improved properties. 
Synthetic porphyrin derivatives enriched with different chemical functional groups, can 
be prepared through a diversity of methods [ 44 ], which involve the condensation reaction 
between pyrroles and aldehydes [45] (Figure 11).  
 
 
Figure 11. Synthesis of porphyrins according to Alder and co-workers [46], involving the condensation reaction 
of pyrrole with a substituted aldehyde in aerobic conditions, in the presence of a Lewis acid catalyst to obtain 
porphyrin (1) and the chlorin (2). The chlorin (2) can be oxidized back to porphyrin (1), with 2,3-dichloro-5,6-
dicyanobenzoquinone (DDQ) in toluene. 
 
Taking a freebase porphyrin as a reference structure shown in Figure 10 A, several 
modifications can be successful achieved, as explained in the full issue dedicated just to 
porphyrin nomenclature by the IUPAC [38] and more recent publications [47]. These modifications 
comprise: i) peripheral groups attachment to the pyrrole unit (β positions: 2, 3, 7, 8, 12, 13, 17, 
18); or to ii) the meso positions (5, 10, 15, 20 – R1, R2, R3, R4); iii) the reduction of one or more 
double bounds in the macrocycle resulting in chlorins like chlorophyll a (Figure 12 A) and 
chlorophyll b (Figure 12 B); iv) the fusion of other ring systems to the porphyrin core structure 
(phthalocyanins) and also by v) substituting a carbon atom of the ring by another atom like 
nitrogen (N) or sulphur (S), are examples of the diversity of structures currently available. 
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Figure 12. Structure of two chlorins: A) chlorophyll a and B) chlorophyll b. 
 
 
2.1.1 Photophysical properties 
One consequence of interaction of light with matter is the appearance of colour. The 
absorption of a quantized amount of energy (A) can promote the transition of one or more 
electrons in a molecule, from their electronic ground state (S0) to an electronic excited state (S1).  
The study of the excited state properties is important because using light, a new type of 
reactivity can be achieved. Excited states can be characterized based on their lifetime (τ, 
lifetime) and on the yield of the transition of interest, measured by quantum yield (φ) [48]. 
Following light excitation of S0 a molecule by absorption of light, the energy of the S1 can be 
dissipated by radiative and non-radiative relaxation mechanisms and these transitions can be 
easily understood following the Jablonski diagram – Figure 13 [49]. 
Two important radiative decay pathways are fluorescence and phosphorescence. In 
fluorescence, the transition from a singlet excited state (S1) to the singlet ground state (S0) (S1 
 S0) is an allowed transition and occurs very rapidly, with very short fluorescence lifetimes 
(τF ≈ 10-9 – 10-6 s) and high quantum yield of fluorescence (φF). In phosphorescence, the 
transition from the singlet-excited state (S1) to the triplet state (T2) (S1  T2) is “forbidden”, 
resulting in a slower relaxation rate, and longer phosphorescence lifetimes (τP ≈ 10-3 – 1 s) and 
lower quantum yield. 
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Figure 13. Jablonski diagram with electronic transitions and corresponding relaxation processes [49]. 
 
Due to their conjugated system of double and single bounds, porphyrins are coloured 
and present a characteristic UV-Vis absorption spectrum. A typical porphyrin (freebase) shows 
a strong absorption band (Soret band, 400 – 450 nm) and a group of small intense bands (Q 
bands I, II, III, IV, 500 – 700 nm) – Figure 14 [50, 51].  
An absorption band is characterized by its intensity (Abs, AU), a wavelength (λ, nm) 
and a molar extension coefficient (ε, M-1.cm-1) characteristic of the chromophore. For the 
porphyrins, ε values are typically greater than 105 M-1cm-1. The origin of each spectral band is 
related to the electronic transitions between the highest occupied molecular orbital (HOMO) 
and the lowest unoccupied molecular orbital (LUMO). The “four-orbital model” proposed by 
Gouterman and then extended to other porphyrin derivative structures explained the spectrum of 
one of the simplest synthetic porphyrin (5,10,15,20-tetrakis(tetraphenyl)-porphyrin, TPP) [52]. 
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Figure 14. Typical UV-Vis absorption spectrum of a porphyrin, 
with typical Soret and Q-bands [50]. 
 
The bands in a freebase tetraphenylporphyrin (TPP) spectrum were attributed to pi-pi 
electronic transitions between HOMO and LUMO orbitals. Taking into account the differences 
in the polarity of the electronic transitions and the symmetry group of a starting porphyrin, the 
interpretation of several spectral changes was possible. A simple example is illustrated in Figure 
15, where a TPP complexed with a metal (M) and their spectral changes were evaluated [53]. 
Upon metallation there is a symmetry group change, from a D2h in porphyrin (TPP) to a D4h in 
the metalloporphyrin (M-TPP) associated with HOMO-LUMO energy changes. This results in a 
simplified spectrum of a metalloporphyrin with less absorption bands as opposed to the 
spectrum of TPP (freebase). 
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Figure 15. Simplified Gouterman model for the transitions between a TPP (freebase) 
and the corresponding metalloporpyrin (M-TPP) [53]. 
 
A porphyrin spectrum can be classified according to the relative intensity of its four Q 
bands (I, II, III, IV), as suggested and interpreted by Dolphin [40]  through the following 
classification system: i) etio-type (IV > III > II > I); ii) rhodo-type (III > IV > II > I); iii) oxo-
rhodo-type (III > II > IV > I) and iv) the phyllo-type (IV > II > III > I). In addition to structural 
changes in the porphyrin structure, the UV-Vis spectrum of porphyrins can be affected by 
factors as diverse as: the solvent [54], the temperature [59], the pH of the solution [55] and the 
concentration of the porphyrin [56]. 
 
 
Figure 16. Typical emission spectrum of a porphyrin derivative: 5,10,15,20-
tetrakis(2-hydroxy-5-nitrophenyl)-porphyrin (T2H5NPPH2) [57]. 
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Porphyrins are also characterized by their typical fluorescence properties (Figure 16 
[57]), which enable their detection with higher sensitivity than the one achieved by UV-Vis 
spectroscopy. This is advantageous because from an analytical perspective, a smaller amount of 
material has to be used to obtain an equivalent analytical response. Porphyrins have a low 
energy gap between the lowest singlet (S1) and triplet (T2) states and a good intersystem 
crossing efficiency [40]. Consequently, they are considered good donors of triplet excitation, 
enabling excited molecules to relax to their triplet state. This is a property intimately related to 
their ability to generate singlet oxygen (1O2) and explains why porphyrins are so widely used as 
photosensitizers (PS) (section 2.2.4). 
 
 
2.1.2 Metal coordination ability 
One of the most remarkable characteristics of porphyrins is their ability to coordinate 
metals in their core, which has an approximate diameter of 3.7 Å [ 58 ]. A study on the 
complexation reaction of synthetically modified tetraphenylporphyrin (TPP) with zinc ion 
(Zn2+) revealed that metallation is a very slow process (kinetically unfavourable) and is 
thermodynamically very stable (K ≈ 1 x 1029) [58]. The stoichiometry of complexation with most 
metals is 1:1, although Na+, K+, Li+ showed to form 2:1 complexes with one metal atom located 
below and the other one above the porphyrin macrocycle plane [58]. Formation of metal-oxo 
compounds is a type of connectivity characteristic of transition metals and oxygen commonly 
found in many metalloporphyrins. Metal-oxo connectivity showed to be responsible for: i) 
dimerization of protoferriheme and deuteroferriheme [59]; or ii) connectivity of an extra ligand to 
chelates of Mg2+, Cd2+ and Zn2+, to form penta-coordinated complexes with square-pyramidal 
structure [58]. The affinity of porphyrins to metals was also illustrated by the experimental 
determination of molar absorption coefficients of porphyrin esters, based on copper titration [60]. 
 
 
2.1.3 Aggregation of porphyrins 
The possibility of having different porphyrin derivatives possessing useful 
photophysical properties and complexation ability, made the interest in the research grow even 
more. However, despite the reported advantages, in certain circumstances porphyrins can 
present undesired properties such as poor water-solubility and high tendency to aggregate 
especially in aqueous solvents [61], thus impairing their photophysical properties and hampering 
their effective delivery. 
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The great similarity between porphyrin structure and that of chlorophyll has been 
recognised, following studies to understand light harvesting processes in plants [62, 63]. It has 
been shown that chlorophyll is part of large protein complexes responsible for photosynthesis 
called photosystems I and II. Therefore, it is important not only to evaluate the properties of 
porphyrins as a single molecule, but also to assess them when a porphyrin is part of large 
molecular structures such as dimers, trimers or larger porphyrin aggregates. 
Brown and co-workers [59] described the aggregation behaviour of protoporphyrin IX, 
deuteroporphyrin IX, hematoporphyrin IX and coproporphyrin in a comparative study using 
diluted buffer solutions and they have shown that: aggregation was promoted by an increase in 
concentration and was attributed to Fe-oxo-complexation, stabilized by additional bonding from 
the side chain groups of the macrocycles. Even synthetically modified porphyrins, often 
described as “water-soluble” porphyrins, motivated studies due to their high tendency for 
aggregation in aqueous media [64]. The extent of aggregation of porphyrin solutions in aqueous 
media is dependent of factors like: the concentration of the active species in solution [65]; the 
ionic strength of the solvent [65]; the temperature [66] and the pH of the solution.  
The driving forces responsible for the aggregation phenomenon arise from a 
combination of factors. These include the cooperative formation of hydrogen bonds, van-der-
Waals, dipole-dipole interactions, the hydrophobic effect and any other change that modifies  
the porphyrin core structure, like formation of a metalloporphyrin, for example [67]. Studies on 
the nucleation of water-soluble porphyrins in aqueous environment revealed different 
aggregation mechanisms [68] and kinetic studies [59] on naturally occurring porphyrins performed 
in aqueous solvents, revealed formation of micelles prior to extensive aggregation. 
Important considerations that support dimerization/aggregation have been derived from 
UV-Vis spectroscopy. It is widely accepted that: i) the effect of aggregation is manifested by a 
decrease in intensity and shape broadening of the Soret band; ii) the Soret band splitting might 
occur, if the orientation of an aggregate of two porphyrins held together by hydrogen bonds 
changes [67] and during a dilution experiment performed on a solution porphyrin keeping 
constant the number of monomer units in the light path, the appearance of one isobestic point is 
usually attributed to dimerization phenomena [69, 70]. 
Two modes of interaction have been proposed resulting in two modes of aggregation [71] 
that differ on the geometry of the spatial arrangement between the porphyrin macrocycles – 
Figure 17 [72, 66]: 
• H-type aggregate, characterized by a plane-to-plane stacking associated with a 
hypsochromic shift (blue shift, low λ) and Soret broadening 
  
20 
• J-type aggregate, characterized by an edge-to-edge interaction resulting in a 
bathrochromic shift (red shift, high λ) and a Soret splitting 
 
Figure 17. Two different modes of aggregation found in porphyrins [72]: plane-to-
plane interactions (H – aggregate) and edge-to-edge interaction (J-aggregate). 
 
A different study suggested at least six modes of interactions between protoporphyrins 
and 5,10,15,20-tetrakis(tetraphenylporhyrin) (TPP) in aqueous media, leading to fibres, tubules, 
helical ribbons and sheets with different photophysical / photochemical properties [67]. Micali et. 
al. described how the geometry of aggregation changes, from fractal to rod like arrangements, 
by tuning the concentration and ionic strength of water-soluble porphyrin [5,10,15,20-
tetrakis(4-sulfonatophenyl)-porphyrin (TPPS4)] [65]. The so-called “molecular wires” were 
prepared exploring the complexation ability of cyclodextrins, by independently connecting the 
same TPP derivative to two different molecules namely an adamantane moiety and a 
cyclodextrin derivative [73]. TPP / OETPP derivatives were modified with a bicyclic compound 
(bicycle [2.2.2] octene) to rigidify and maintain a planar conformation of the tetrapyrrolic 
macrocyles in solution [74]. Ordered monolayers, nanoparticles [75] and even nanoporous solid 
materials based on porphyrins have been proposed [65]. 
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2.2 Applications in photodynamic therapy (PDT) 
Porphyrins are well-known for their extended field of application, largely because of the 
easiness in preparation/modification and due to their interesting photophysical properties. Their 
metal complexes can act as catalysts in many organic relevant reactions like epoxidation of 
olefins [76] and selective functionalization of inactivated C-H bonds by hydroxylation [77]. They 
have been utilized as sensors for nitrous oxide [78], oxygen [79] or in electrochemical sensors for 
determination of inorganic anions [58]. Methods for water treatment were developed based on 
porphyrins as well as hydrogen fuel cells designed based on cobalt porphyrins [80].  
In medicine, porphyrins can be used both as imaging agents based on their fluorescence 
properties [81 ] or as photosensitizers in photodynamic therapy (PDT) [82 ].  PDT is of major 
importance to the current work. 
 
 
2.2.1 Principles of PDT  
PDT is comprised of three independent elements: a light source (λ), a photosensitizer 
(PS) and molecular oxygen (O2). The individually inert components act in combination to 
trigger type II photochemical reactions, with the corresponding production of singlet oxygen 
(1O2) leading to cell death by apoptosis or by necrosis [83]. PDT is an alternative treatment to 
radiotherapy and chemotherapy presenting many advantages. In comparison to conventional 
methods, PDT is a non-evasive method, reveals good cosmetic results (Figure 18), can be 
repeated without fear of overdosing or developing resistance and, through the use of an optical 
fiber, the desired therapeutic effects can be localized only to the irradiation site [82, 84]. 
 
 
Figure 18. Cosmetic effect achieved after PDT treatment: before (A) and 
after (B) PDT treatment [85]. 
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2.2.2 Molecular oxygen (O2) 
One key element in PDT is molecular oxygen (O2). Usually, the valence electrons of 
most organic molecules that occur in nature, in their ground state, have their electrons in a 
singlet state configuration. However, O2 is a particular molecule because the valence electrons 
in its ground state, occupy a two degenerate orbitals, with low energy corresponding to a more 
stable triplet state (3O2) (Figure 19). 
 
Figure 19. Molecular orbital diagram of molecular oxygen (O2). 
 
Singlet oxygen (1O2) is an important reactive oxygen species (ROS) and has great 
impact in biological processes like cell migration, circadian rhythms, stem cell proliferation and 
neurogenesis [86]. Once generated 1O2 is very reactive with common substrates and, if its action 
is not controlled, it can have potentially harmful effects in biological systems and lead to 
photooxidative damage, with potential DNA damage [87]. Nature has evolved to control all of 
these processes: in plants during photosynthesis, any excess of 1O2 produced is blocked by the 
action of carotenoids [88, 62]; whereas in animal cells, polyphenol antioxidants can protect and 
scavenge harmful 1O2 and avoid its uncontrolled reactivity and undesired effects. 
Reactions that involve electronic transitions with change in electron spin multiplicity 
are quantum mechanically “forbidden” or “not allowed transitions” and have very small 
probability of occurrence [89].  The conversion of 3O2 to 1O2 (singlet oxygen) is mediated by the 
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photosensitizer (PS) molecule and through the controlled use of light (wavelength λ; irradiation 
time) the cytotoxic action of 1O2 can be achieved. This action is fast because 1O2 is a short-lived 
species (10-10-10-9 s) [90] and is limited to a short distance (0.05 µm). 
 
2.2.3 Photosensitizers (PS) 
A substance that is able to absorb energy and transfer part of its energy to another 
molecule, enabling a physical or chemical modification in this molecule is a photosensitizer 
(PS). The first PS for the treatment of early-stage lung cancer and bladder cancer was a mixture 
of porphyrins derivatives based on hematoporphyrin (Hp, Protofrin®, 1993) [91]. Nearly a decade 
later an improved PS was approved and was based on a pure reduced porphyrin derivative: a 
chlorin, namely 5,10,15,20-tetrakis(m-hydroxyphenyl)-chlorin (mTHPC, 2003, temoporfin, 
Foscan®) [92]. In addition to Foscan® and Protofrin only four other PSs have been approved for 
clinical PDT: i) 5-aminolevulinic acid (ALA, Levulan®); ii) its methyl ester ,MAL (Metvix®); 
iii) verteporfin (Visudyne®) and iv) talaporfin (Laserphyrin®; only in Japan) [93] (Figure 20). 
Moreover, hexyl levulinate (hexvix, Cysview®, USA) has been marketed for in situ imaging of 
bladder cancer. The aminolevulinic acid derivatives are endogenously converted by natural 
biosynthetic pathways to protoporphyrin IX and thus express their PS properties. 
 
Figure 20. Chemical structure of some clinically approved photosensitizers. 
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Foscan® used in a typical PDT treatment comprises a two-step process: i) first, PS 
(Foscan®) is injected in a single shot, lasting at least six minutes and using an indwelling 
intravenous cannula; then and only four days later ii), the entire surface of the tumour is 
irradiated with laser light (specific λ) using a fibre-optic cable to induce the desired therapeutic 
effects. Extreme care is taken not to illuminate other areas of the body, because the light 
sensitization is still not selective. Therefore, as a precaution, the patient should avoid exposure 
to bright light for 6 months after the treatment [94]. 
 
 
2.2.4 Porphyrin as a PS 
An example of the PS action on a molecule results in the generation of 1O2 and 
porpyrins can act as efficient PS: first, the PS in its ground state PS(S0) is promoted to an 
excited singlet state PS(S1), by absorption of light (λ) of a specific wavelength; then, through an 
efficient intersystem crossing (ISC), it relaxes and traps part of its energy in its triplet state 
PS(T1); finally, because the lifetime (τP) of a triplet state of the PS(T1) is longer than that of a 
singlet state PS(S1), there is more time to react efficiently with other substrates, namely with 
molecular oxygen (3O2) trapped in tissues. Two important mechanisms are often proposed to 
explain the reactivity of excited species PS(T1) and these are described as follows [95]: 
i) In type I – PS(T1) transfer an electron or abstracts hydrogen atoms from the 
substrate (S), generating species (cations / radicals) that then react with 3O2 yielding 
oxidized products; 
PS(T1) + RH  PS(T1)H+ + R-  PS(T1)H+ + 3O2 – type I 
PS(T1) + RH  PS(T1)H• + R•  PS(T1)H• + 3O2 
ii) In type II – follow from a collision of the excited sensitizer PS(T1) with molecular 
oxygen (triplet state, 3O2), singlet oxygen is generated and can then react with 
biological substrates (S) leading to photodegradation products; 
PS(T1) + 3O2  PS(S0) + 1O2  1O2 + S – type II 
 
The exact mechanism by which 1O2 is produced has been a matter of debate. Although 
now it is accepted that a type II photochemical reaction is involved in 1O2 generation [96, 97], it 
cannot be excluded that the overall PDT effect might result from a combination of type I / type 
II mechanisms. The overall yield of type II photochemical reaction might be affected by 
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photobleaching and quenching of fluorescence. Photobleaching occurs due to PS exposure to 
light, which can lead to irreversible changes in PS structure due to photon-induced chemical 
damage and covalent modification. A practical consequence is that PS absorbance and 
fluorescence intensity are lost. The number of times a PS can absorb and become excited before 
it starts photobleaching depends on the local environment and on the structure of PS [98 ]. 
Quenching results in fluorescence loss and involves a non-radiative energy loss that occurs 
because of oxidizing agents, the presence of salts, heavy metals or halogenated compounds [98].  
 
 
2.2.5 Other photosensitizers 
The photosensitizer (PS) property is not limited to porphyrin structures and many other 
molecules proved successful in generating singlet oxygen (1O2). Some examples are 
perylenequinones (PQs), hypericin (HC), quinones and rhodamines Figure 21) [99]. 
 
 
Figure 21. Structures of some PSs based on different chemical entities: quinones, perylenequinones, hypericin 
and rhodamines. 
 
Although all of these molecules can potentially be useful as PSs, none of them was so 
successful as the porphyrins or any of their derivatives. In the past few decades, the ultimate 
goal has been to develop an “ideal photosensitizer molecule” that would display a set of unique 
characteristics which define the “ideal PS”: a good chemical purity / stability; high quantum 
yield of singlet oxygen production; significant absorption in the long wavelength region (700 
nm – 800 nm); preferential tumor localization (targeting); minimal dark toxicity; delayed 
phototoxicity and display good water solubility suitable for injectable solvents used in 
formulation [100, 92]. 
In a quest to find the best PS molecule, three generations of PS have been considered: 
the first refers to PSs based on hematoporphyrin derivative (HpD) and Photofrin®; the second 
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generation, intended to chemically modify porphyrin structure into its derivatives and iii) the 
third generation comprises the attachment of tags to existing PS molecules to increase their 
selectivity [93]. A matter of recent focused research has been to provide bimodal cancer 
treatments, combining photo- and chemotoxicity capability in a singular system. 
 
 
2.2.6 Photochemical internalization (PCI)  
Photochemical Internalization (PCI) is a recently proposed technology based on the 
same principles as PDT but with an important difference: the PS has to be localized 
intracellularly in endocytic vesicles, together with a therapeutic agent. Therefore, after 
irradiation of light (specific λ), there is the generation of 1O2 which leads to the local burst of 
membranes of endosomes with the release of the drug into the cell - PCI mechanism of action 
(Figure 22) [ 101 ]. PCI acts as a precise photocontrolled drug delivery system of large 
macromolecules therapeutics, that otherwise would be degraded in the lysosome and excreted / 
eliminated from the cell. 
 
 
Figure 22. Photochemical internalization (PCI) mechanism of action, showing light induced release of drug (D) 
and photosensitizer (PS) into the cytosol after burst of the endosome [101]. 
 
Amphinex-based PCI of bleomycin (Figure 23) uses 5,10,15,20-tetraphenylchlorin 
substituted by two adjacent sulfonated groups (TPCS2a) as PS, to treat patients with local 
recurrence or advanced/metastatic, cutaneous or sub-cutaneous malignancies [102]. 
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Figure 23. Components of amphinex medicine: a photosensitizer (TPCS2a) and the drug (bleomycin). 
 
 
3. Multifunctional drug delivery systems (DDS) based on CDs 
3.1 DDS purpose 
In opposition to the systemic administration of medicines, it is expected that a drug 
delivery system (DDS) can deliver the desired agent (medicine), in the right amount, 
specifically to the affected tissue resulting in the therapeutic treatment leaving the host tissue 
undamaged following the magic bullet concept, as suggested by Ehrich [103 ]. Examples of 
extensively studied and established DDS include liposomes, polymers, micelles, nanoparticles 
and antibodies and have been extensively studied (Figure 24) [104]. 
 
 
Figure 24. DDS examples: A) Liposome; B) polymer; C) micelle; D) nanoparticle and E) antibody [104]. 
 
 
3.1.1 Passive vs active targeting  
The type and mode of administration of the DDS is dependent on the desired effect and 
on the specific targeting strategies, which are divided into “active” or “passive” drug targeting 
strategies. These have been reviewed by Sinko and co-workers [105]: 
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Active targeting involves the attachment of a specific chemical group (or tag) to the 
DDS, in order to attach the DDS directly to the specific site of action. Examples are: i) tumour 
specific antigens or receptors; ii) antibody-directed enzyme prodrug therapy (ADEPT); iii) 
gene-directed enzyme prodrug therapy (GDEPT) / virus-directed enzyme prodrug therapy 
(VDEPT); antibody-targeted, triggered, electrically modified prodrug type strategy 
(ATTEMPTS) and membrane transporters. On the other hand, passive drug targeting strategies 
[106]
 take advantage of the enhanced permeability and retention effect (EPR) of large DDS [107], 
which due to their prolonged blood circulation time can effectively penetrate into cancer cells 
possessing irregular morphology, density and high vasculature of these tissues, as opposed to 
healthy tissues. Some examples comprise i) polymer-directed enzyme prodrug therapy (PDEPT) 
and ii) polymer-directed enzyme liposome therapy (PELT). 
Figure 25 shows a schematic representation between active and passive targeting 
approaches, comparing an ideal case with a realistic scenario. Clearly, active and passive 
targeting strategies to treat cancer still face many limitations that impair their extended and 
successful application [104]. These can be summarized as follows:  
i) variable EPR effect or extravasation of DDS to the tumour 
ii) variable degree of penetration of DDS into tumours 
iii) active targeting faces many physical barriers due to high cell density in tumour 
cells, that lead to blockage or loss of the tag attached to the DDS 
iv) inadequate formulation of the DDS with a systematic failure to show significant 
therapeutic benefit 
v) difficulty to reach good correspondence between animal models and humans 
vi) difficulties in achieving personalised healthcare treatments 
 
The safety profile of these materials and their performance cannot be assessed relying 
on the same principles, as those used for single drug molecules due to the complexity and big 
number of components in a DDS. Therefore, the characterization of these DDS, regarding 
physico-chemical properties, is often limited to a distribution or average value. There is a lack 
of reproducibility in its preparation and although, in the majority of cases nanomedicines (DDS) 
applied in cancer treatment managed to reduce toxicity, they have failed to improve efficacy 
(response rates / survival times) which decreases their commercial attractiveness [104]. 
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Figure 25. Comparison between a conceptual and realistic DDS targeting strategies: passive drug targeting 
(conceptual (A) vs realistic (B)) and active targeting (conceptual (C) vs realistic (D)) [104]. 
 
 
3.1.2 Polymeric DDS 
The use of synthetic polymeric DDS as carriers has been recognised and a good 
polymeric drug carrier should be decorated with chemical functional groups to enable, 
simultaneously: i) polymer-drug conjugates solubilisation; ii) attachment of the drug to the 
polymer matrix and iii) attachment of the carrier to the binding site [108].  
The structural features and properties of CDs make them suitable building blocks to be 
used in polymeric reactions. CDs can be grafted to many natural and synthetic polymers 
through a variety of methods [109] resulting in different polymer architectures (Figure 26) [110]. 
Additionally, CDs being generally recognised as safe substances (GRAS) do not pose as many 
concerns regarding toxicity, as other non-GRAS compounds and the possibility of combining 
them with other biocompatible materials has been recognised. Examples of polymers combined 
with CD include dextrans [111, 112], hyper-branched [113] as well as linear poly-ethylenimine (PEI) 
[114]
, poly-(ε-lysine) [115] or poly(vinylalcohol) (PVA) [116]. Some CD-based polymers are suitable 
for gel formation [117], DNA transfection [118] and can act as carriers of various drugs. 
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In polymeric materials, a CD can modulate the release profile of drugs [119] and it has 
been proposed that this action was due to the combined action of several CD units acting 
cooperatively to solubilise and stabilize drugs in a polymeric matrix [109]. Examples include: i) 
the increase in the complexation efficiency and drug bioavailability by addition of water-soluble 
polymers to simple CD solution of the drug [120]; ii) increased of the dissolution rate of poorly 
soluble drugs like indomethacin [121] and iii) improved mechanical properties of tablets [122].  
 
 
Figure 26. Examples of CD-pendent polymers: A) CD-grafted linear polymer; B) CD-pendant graft 
copolymer; C) CD-conjugated dendrimer and D) CD-flanking block copolymer [110]. 
 
Interestingly, CD-polymers can also have an opposite effect as CDs can hold the drug 
more tightly in the polymer matrix, thus delaying its release or even blocking the active 
molecule inside the polymer [123]. This has been attributed to a reduction of diffusivity of the 
guest in the polymer matrix, especially after complexation of the guest because there is: i) an 
increase in the molecular weight of the complex (CDPs/drug); ii) possible formation of poorly 
soluble complexes, in which the host (drug) is covalently bonded to the polymer backbone; and 
also iii) a reduction of the pore size in the polymer matrix when CD acts as a crosslinking agent. 
Moya-Ortega et. al. [ 124 ] proposed that the preparation of polymeric CDs can be 
achieved, using three different strategies: i) the key-lock assembly, where two constituents are 
mixed together and are allowed to spontaneous assemble in aqueous solutions, one having CD 
units and the other possessing suitable guest molecules to enable complexation equilibrium; ii) 
the covalent cross-linking of CDs through the use of proper monomeric units like epoxides and 
isocyanates; and, iii) through polymerization of CDs monomers, previously modified with 
reactive acrylic or vinyl moieties. 
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3.1.3 CD and small interfering RNA (siRNA) delivery 
RNA silencing is a control mechanism for gene expression that enables the detection 
and avoids transcription of non-endogenous cell RNA. Small interfering RNA (siRNA) is 
involved in RNA silencing and it mediates the suppression of genes corresponding to double 
stranded RNA, through targeted RNA degradation [ 125 ]. The research and development of 
strategies to deliver siRNA into cells have been widely explored, mainly due to the high 
specificity in the inhibition of the target of interest [126]. 
The first targeted delivery of siRNA in humans with cancer was a CD polymer 
construct called CALAA-01®. This molecular assembly (Figure 27) was developed based on 
two different difunctional monomers: a βCD derivative (A) and a difunctional charged spacer 
(B), arranged in a linear fashion where the βCD is part of the polymer backbone. Another 
interesting feature is the appendage of an adamantylamine (AD) moiety, modified with a steric 
stabilization agent (poly-ethylene glycol (PEG) moiety) and a specific transferrin receptor (Tf) 
(Figure 27) [127]. This system was used to deliver a siRNA against the ribonucleotide redutase 
subunit 2 (RRM2) gene products, which is an established cancer target. 
CALAA-01 tolerability, safety profile and maximum tolerated dose (MTD) proved to 
be successful in the treatment of patients with relapsed or refractory cancer, when intravenous 
administrated [128]. Additionally, polycationic amphiphilic cyclodextrins (paCDs) were used as 
gene-delivery systems, combining properties of both lipids and cationic polymers in a nonviral 
gene vector [118].  
 
 
Figure 27. CALAA-01® a βCD polymer DDS construct able to deliver siDNA into humans [127]. 
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3.1.4 Camptothecin (CPT) – CD-based polymer 
Camptothecin (CPT) is a molecule initially isolated from the tree Camptotheca 
acuminate that revealed anticancer activity in animal models. CPT can display two different pH 
dependent forms: i) an active and poorly water-soluble lactone and ii) an inactive, carboxylate 
form favoured at physiological pH. Therefore, once administered CPT is rapidly converted into 
its carboxylate form though a lactone-ring opening and losses its potential antitumor function 
[ 129 ]
. Two chemically modified CPT based drugs (topotecan and irinotecan) are currently 
approved for use in humans. 
A CPT conjugated to a linear polymer CD-based polymer (CRLX101) revealed good 
safety profile and has been approved for intravenous administration in humans, for the treatment 
of advanced solid tumours [130]. CRLX101 consists of a β-CD, difunctionalized with the natural 
amino acid cysteine (CDDCys) and polyethylene glycol (PEG). Small drug molecules such as 
CPT can be attached to each polymer unit via a linker (Figure 28). 
 
  
Figure 28.  Structure of CRLX101 polymer and camptothecin (CPT). 
 
 
3.1.5 CD-Porphyrin DDS  
Light can trigger photochemical reactions and in the case of photoactivated compounds, 
three of the most important criteria to judge a good a carrier system comprising a PS are: i) its 
biocompatibility; ii) the ability to cross biological membranes to reach the active site and iii) the 
ability to preserve the PDT properties of the PS [131].  
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One possibility to increase PS selectivity to cancer tissues is through attachment of site-
specific tags directly to the PS. Some examples include: 
i) Attachment of porphyrins derivatives to peptides conjugates that revealed 
good DNA binding properties [132] 
ii) Modification of porphyrin derivatives with cationic groups, showed good 
mitochondria-targeting capabilities and minor dark toxicity [133] 
iii) Modification of porphyrin with specific groups over-expressed in cancer cells 
like: folate or arginyl glycyl aspartic peptide (RGD) revealing good targeting 
properties and cellular uptake by cancer cells [134] 
The focus on bimodal systems based on CD-porphyrins conjugates, that is, systems that 
are able to display simultaneously the properties of porphyrins (photophysical, localization) and 
CDs (water solubility; inclusion/complexation ability) is a recent area of research with a 
promising future.  
 
 
3.2 Aims of the dissertation  
The goals of this thesis can be divided into two main parts.  
The first part involves: 
• The efficient preparation, purification and characterization of a new bimodal 
system (CD-mTHPP), consisting of a βCD covalently bound a porphyrin 
(5,10,15,20-tetrakis(m-hydroxyphenyl)-21,23H-porphyrin, mTHPP), which is a 
chemical analogue of an already approved commercial PS (Foscan®). CD-
mTHPP is expected to possess improved aqueous solubility and preserve all 
photophysical mTHPP properties, with the advantage of having an extra CD 
cavity to complex suitable guest molecules, to enable biological studies on CD-
mTHPP system. 
• The drastic improvement of solubility of CD-mTHPP in aqueous solutions and 
the complete recovery of UV-Vis and fluorescence properties to achieve 
concentrations that could enable complete characterization of CD-mTHPP its 
use in parenteral formulations. 
• The chemical modification of selected anticancer drugs to be tested as guest 
molecules, using the above mentioned bimodal carrier in aqueous environment. 
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The second part involves: 
• the preparation of positively-charged CDs, namely per(6-aminoethylamino-6-
deoxy)-βCD (βpen) and its incorporation in polymeric materials to be tested for 
the inclusion of specific anionic guest molecules and to study them as release 
modifiers of nucleotides or nucleotide drugs, through semi-permeable dialysis 
membranes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
RESULTS AND DISCUSSION 
  
 
  
35 
4. A CD-porphyrin conjugate (CD-mTHPP) as a water soluble 
bimodal DDS 
4.1 Introduction 
The development of a pure and well-characterized CD-pophyrin conjugate that 
desirably, would combine the distinct properties of both porphyrin and CD macrocycles in a 
single nanosized molecular system has been a matter of relevant research, concerning primarily 
water-soluble photoactive systems and, to a much lesser extent, water-soluble bimodal drug 
delivery systems. These CD-pophyrin conjugates could display: i) the imaging, photoactive and 
electroactive properties attributed to the porphyrin moiety ii) the capacity to generate efficiently 
1O2 from 3O2 by the action of light iii) improved aqueous solubility and ability to carry, 
solubilise and stabilize desired drug molecules ascribed to CDs [135].  
Great effort has been devoted to the characterization of CD-porphyrin conjugate 
photophysical properties given its extensive application as model systems in binding studies, 
catalytic, photocatalytic and photo-induced processes [136]. For example, a conjugate between 
βCD unit and 5,10,15,20-tetrakis(pentafluorophenyl)-porphyrin was prepared and its 
characterization revealed that their photophysical properties were not affected by connection of 
the porphyrin to the CD macrocycle. Additionally, a 5,10,15,20-tetrakis(p-hydroxyphenyl)-
porphyrin (pTHPP) was connected to a βCD unit and, when studied in aqueous solvents, 
revealed self-aggregation that was attributed to porphyrin-to-porphyrin interactions with 
participation of the CD cavity. The addition of a guest solution of 1-adamantol to this solution, 
promoted the spatial rearrangement of the aggregates but the photophysical properties of the 
conjugate were preserved [135]. 
The covalent attachment of a 5,10,15,20-tetrakis(pentafluorphenyl)-porphyrin to βCD 
and γCD has been described and the CD-porphyrin conjugates isolated (monomers, dimers, 
trimers and tetramers) have been studied as potential DDS, taking advantage of CD ability to 
include in its cavity relevant cytotoxic drugs, suitable for cancer treatment [137]. 
One the other hand, considering the preparation of porphyrin-cyclodextrin conjugates, 
the efficiency of the reaction and the purity of the product can be really challenging. Thus, one 
of the first examples of a CD-porphyrin conjugates described in the literature was prepared from 
the reaction of a βCD-iodide with 5,10,15,20-tetrakis[4-(methylsulfoxyl)phenyl]-porphyrin, in 
25 % yield. The same authors also reported the preparation of a CD-porphyrin dimer (30 % 
yield), from the reaction of 5,15-bis(methylsulfoxyphenyl)-10,20-diphenylporphyrin with the 
same βCD derivative, carried out in DMF, at 60 ºC, during 24 h [138]. More recently, a CD-
porphyrin monomer was obtained in 30 % yield, prepared from reaction of  6-O-monotosyl-
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βCD (βmTs) with 5,10,15,20-tetrakis(p-hydroxyphenyl)-21,23H-porphyrin (pTHPP) in a 
reaction conducted at 140 ºC, for 24 h, in DMF [135]. The conjugation of a 5,10,15,20-
tetrakis(pentafluorophenyl)-chlorin bearing a Ν-benzylisoazolidine ring (FC) with four β-
cyclodextrin unit, resulted in a water soluble tetramer prepared in DMF at room temperature and 
obtained in 24 % yield [139]. In most of the examples described above, there is poor literature 
evidence of chemical purity (e.g. in the form of elemental analysis, TLC (RF), mass 
spectrometry data).  
Thus, most CD-porphyrin conjugates show important limitations such as the small 
yields obtained, the time-consuming purification methods and incomplete characterization. CD-
porphyrin conjugates, also lack of sufficient water solubility that often results in extensive 
aggregation and in the loss of their photophysical properties in aqueous medium. Additionally, 
there is also a strong desire in developing potential useful drug candidates, based on already 
marketed or approved molecules with a well-characterized safety profile [140]. 
In the light of the current the limitations of commercially available PSs and taking into 
account the approved status of CDs, the purpose of this chapter is to describe the efficient 
preparation, complete purification and characterization of a water-soluble CD-porphyrin 
conjugate. This bimodal conjugate will be composed by: i) one porphyrin unit (5,10,15,20-
tetrakis(m-hydroxyphenyl)-21,23H-porphyrin, mTHPP), used because it is the porphyrin 
precursor to an already marketed chlorin (mTHPC), i.e. having one pyrrole double bond 
reduced, the drug Temoporfin, commercial available as Foscan®. According to European 
Medicine Agency, 2005 “Foscan® is indicated for the palliative treatment of patients with head 
and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, 
surgery or systemic chemotherapy” [94]. 
 
 
4.2 Results and discussion 
4.2.1 Preparation / purification of CD-mTHPP 
Previous literature precedents exist describing the covalent connection of porphyrins to 
cyclodextrins in order to obtained supramolecular systems with catalytic potential or redox 
properties; or, to study the photophysical properties of the resulting CD-porphyrin conjugates. 
In our group, the preparation of CD–porphyrin conjugates was explored through: i) the 
connectivity of one βCD unit to a protoporphyrin IX (PpIX) moiety [ 141 ] and ii) by the 
attachment of a mono-substituted βCD derivative and mTHPP in alkaline conditions [142]. The 
original purification strategy for the purification of the latter comjugate (CD-mTHPP) was 
  
37 
based on a methodology involving: i) dialysis of the crude mixture; ii) extensive washings with 
methanol; followed by iii) size exclusion chromatography on Sephadex G-25. This lead to the 
desired conjugate (CD-mTHPP) isolated with an excess (30 % m/m) of mono-3,6-anhydro-βCD 
as an impurity, revealed by MALDI-TOF mass spectrometry. The isolated product (CD-
mTHPP) revealed good water solubility and enabled cell inclusion studies with encouraging 
results, but failed to show reproducible phototoxicity results, owing to the lack of 
reproducibility in the preparation / purification of CD-mTHPP. Thus, there was an urgent need 
for the development of a more efficient purification strategy to improve the purity of CD-
mTHPP, its yield and to scale-up the reaction with reproducible results. 
CD-mTHPP was prepared from the reaction of 6-O-monotosyl-βCD (βmTs), with a 
commercially available porphyrin namely, 5,10,15,20-tetrakis(m-hydroxyphenyl)-21,23H-
porphyrin (mTHPP). The reaction was performed under anhydrous conditions, in dry 
dimethylsulfoxide (DMSO), at 40 ºC under constant magnetic stirring for a total of 72 h (Figure 
29).  
 
Figure 29. Preparation of the conjugate (CD-mTHPP) from reaction of βmTs with mTHPP in DMSO. 
 
Initially, mTHPP was dissolved in alkaline DMSO, to generate the appropriate 
allyloxide species (Ph-O-), expected to displace the good leaving tosyl group (-OTs) present in 
βmTs to generate of the desired CD-mTHPP conjugate, comprised by one mTHPP and one βCD 
connected through a non-hydrolysable ether bond. TLC (silica gel 60, iPrOH / EtOAc / H2O / 
NH3 (5:3:3:1, v/v)) was used to monitor the reaction progress. CD-mTHPP was eluted as a 
red/brown spot (RF = 0.61), revealed red fluorescence when irradiated at UV light (λ = 254 nm) 
and turned green upon revealing/burning with a 4 % H2SO4 ethanolic solution. The pure CD-
mTHPP molecule was isolated from the reaction crude in four steps: 
1. The crude product mixture was solubilised in water and dialysed through a 
benzoylated dialysis tubing (MWCO = 2000 Da), at neutral (pH ≈ 7) against 
water to remove dimethylsulfoxide (DMSO), traces of NaOH, tosic acid and 
water soluble βCD related by-products 
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2. Liquid-liquid extraction was performed on the dialysed mixture, using ethyl 
acetate / water to wash away and recover from the dialysed  crude, unreacted 
mTHPP and some of its salts 
3. Column chromatography (silica gel 60, iPrOH / EtOAc / H2O / NH3 (5:3:3:1, 
v/v)) was employed to isolate the desired product (CD-mTHPP) from unreacted 
porphyrin (mTHPP) and other reaction by-products, not removed in the 
previous steps 
4. A second dialysis at acidic pH ≈ 5 was required, to remove from the reaction 
mixture any excess of ammonia used in the mobile phase, in its ammonium 
chloride salt form 
5. Freeze-drying was performed to remove the excess of water and obtain a black 
powder (CD-mTHPP) 
 
Under optimised conditions, pure CD-mTHPP was achieved in 40 % yield, calculated 
with respect to the amount of reacted porphyrin (mTHPP). Additionally, following the 
purification strategy developed, nearly one-third (30 %) of the whole amount of porphyrin 
(mTHPP) was efficiently recovered and can be reused.  
The strongly alkaline conditions used to promote the formation of mTHPP alkoxide 
species, also favour undesired reactions that help to explain the moderate obtained yield. These 
are: i) the hydrolysis of the sulfonic ester in βmTs, with the consequent formation of βCD and 
ii) the formation of mono-3,6-anhydro-βCD (Figure 8) via the deprotonation of the βCD–OH3 
and nucleophilic attach to C6, leading to glucopyranose ring inversion and displacement of the 
tosyl (OTs) moiety. Moreover, the tetravalency of mTHPP, could possible result in cis-dimer 
(CD-mTHPP (2:1), trans-dimer (CD-mTHPP (2:1), the trimer (CD-mTHPP (3:1) and the 
tetramer (CD-mTHPP (4:1). In addition, the formation of many βCD--Na+ salts, complicated the 
purification of the product mixture. Although, the final strategy was successful and 
reproducible, it was preceded by numerous trials and methods. A short account of which is 
mentioned in the chapter below. 
Initially, size exclusion chromatography (Sephadex G 25) was used directly after 
reaction, to purify small portions of crude solubilised in water. The sample was applied twice, 
on the same column (L x OD = 40 cm x 1.9 cm), varying the amount loaded by a factor of 20 
and, but no band separation was observed (Figure 30 A/B). The inefficiency of separation was 
corroborated by TLC (silica gel 60, iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v)): three spots were 
observed (black arrows), that glowed red under UV light (λ = 254 nm) and turned green after 
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being revealed with 4 % H2SO4 ethanolic solution (Figure 30 C). This observation indicated that 
the crude had more than one labelled product containing porphyrin, probably corresponding to 
the desired coupling products. To verify this assumption, a sample of the crude was analysed by 
mass spectrometry and the MALDI-TOF MS spectrum was recorded (Figure 30). 
 
 
Figure 30. MS (MALDI-TOF) spectrum of crude, after size exclusion chromatography (Sephadex G 25). 
Insets: two column chromatography separations varying the amount applied: A) 1 mg crude in 2 mL of H2O 
and B) 20 mg of crude in 5 mL H2O; C) TLC monitoring of the fractions collected. 
 
The MS spectrum revealed the presence of the expected coupling product (CD-
mTHPP), in a small amount (≈ 10 % m/m) and along with other coupling products, namely: CD-
mTHPP (2:1) ≈ 14 % (m/m) and CD-mTHPP (3:1) ≈ 2 % (m/m). Additionally, a large excess of 
CD salts ≈ 43 % (m/m) and unassigned CD-related by-products were detected accounting for the 
remaining mass sample ≈ 30 % (m/m). The high amount of unrelated CD by-products can be 
explained by the excess βmTs used in the original procedure (4 molar eq. βmTs / 1 molar eq. 
mTHPP), that under strong alkaline conditions can be lead to the undesired reactions, like 
discussed previously. Therefore, this experience proved that size exclusion chromatography was 
inadequately used as purification technique and the ratio of reactants used (βmTs / mTHPP) 
could be reduced. Evidently, whatever their compositions are, the products in aqueous solution 
interacted with each other, forming supramolecular complexes of various compositions that are 
eluted indiscriminately by Sephadex. This outcome places doubts on the validity of the 
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previously published purification procedures [138] by size exclusion chromatography alone. 
Apparently, the prerequisite for a successful separation was the interactions of the solutes with 
the column packing material, indicating the use of silica gel was necessary. 
Therefore, a second trial was carried out and the crude isolated was washed 
exhaustingly with MeOH, as alternative putification strategy that resulted in the isolation of a 
black insoluble solid. An aliquot of this solid sample was analysed by MALDI-TOF MS and the 
MS spectrum (Figure 31) revealed a relatively pure mixture, comprised of: two coupling 
products CD-mTHPP (46 % m/m) and CD-mTHPP (2:1) (46 % m/m) in an equal ratio and 
contaminated with traces of CD-mTHPP (3:1) (5 % m/m) and mono-3,6-anhydro-βCD (3 % 
m/m). This trial revealed that other coupling products (CD-mTHPP (2:1) and CD-mTHPP (3:1)) 
could be selectively isolated, based on liquid-to-liquid extraction if the current purification 
method is further developed. Additionally, the continuous TLC monitoring during all of these 
trials was crucial, not only to assess the reaction progress but also to judge the efficiency of the 
purification trials. 
Recalling the related work [135], where a similar conjugate (CD-pTHPP) prepared from 
the reaction of βmTs with 5,10,15,20-tetrakis(p-hydroxyphenyl)-21,23H-porphyrin (pTHPP). 
The conjugate CD-pTHPP was painstakingly purified using RP-HPLC, with octadecylsilane 
(C18) modified silica, as a stationary phase, and a linear gradient mobile phase starting from 
ammonium acetate (AcNH4, pH = 5) and ending in acetonitrile (ACN). It was also reported the 
use of TLC (silica (RP-8), iPrOH : EtOAc : H2O : NH3 (5:1:3:2, v/v)). This data suggested that 
our coupling products should be eluted from a silica stationary phase, using a mixture of 
solvents with different affinities i.e. comprised of both aqueous and organic components. 
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Figure 31. MS (MALDI-TOF) spectrum of a trial, where the crude was isolated after extensive MeOH 
washings. 
 
Therefore, a series of TLC trials were conducted to improve the separation of several 
crude samples, using silica gel 60 as stationary phase and iPrOH :EtOAc : H2O : NH3 (5:3:3:1, 
v/v)  as mobile phase. Figure 32 A shows the TLC of the crude diluted 1/10 in MeOH against 
βCD, mTHPP and βmTs solutions used as controls. It shows that: i) mTHPP is eluted as a red / 
brown spot that is not retained (RF = 1.0), shows red fluorescence under UV light (λexc = 254 
nm) and turns green when revealed with acidic solution (4 % H2SO4/EtOH); ii) the coupling 
products behave like mTHPP but, due to the attachment of CD units, it turns black after burning 
with 4 % H2SO4/EtOH; iii) finally, βCD, βmTs and any βCD related by-product are not UV 
active and will be revealed as black spots, upon burning with acidic solution. These 
observations agree with previous TLC data (Figure 30 C) and were corroborated by MALDI-
TOF MS (Figure 30).  
A sample of the same crude mixture previously treated by size exclusion 
chromatography, was applied and treated by preparative TLC chromatography (silica gel 60, 
iPrOH : EtOAc : H2O : NH3, (5:3:3:1, v/v)). Two TLC plates were loaded with 5 mg crude / 0.5 
mL water (Figure 32 B) and with 20 mg crude / 0.5 mL (Figure 32 C) and after elution it was 
observed that only a limited amount of crude could be loaded onto a single plate, without 
compromising the degree of separation that corresponded to < 5 mg crude / 0.5 mL water. 
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Figure 32. Degree of separation achieved in purification of crudes containing CD-mTHPP: A) TLC of 
aggregated CD-mTHPP in aqueous solution (D2O, NMR tube) and preparative plates illustrating two 
separations where the amount of crude applied was varied: B) 5 mg crude / 0.5 mL H2O and C) 20 mg crude / 
0.5 mL H2O. Silica gel 60, iPrOH : EtOAc : H2O : NH3, 5:3:3:1 (v/v).  
 
Therefore, five plates were loaded each with 5 mg crude solubilised in water (0.5 mL). 
The TLC plate was developed, the five different bands isolated (1 to 5 – Figure 32 B) and 
subjected to MALDI-TOF MS analysis: i) band 1 spectrum revealed the presence of unreacted 
mTHPP and mTHPP salts; ii) band 2 corresponded to the desired conjugate product CD-mTHPP 
and iii) bands 3, 4 and band 5 proved to be a mixture of CD-based by-products, other coupling 
products and unassigned impurities. The biggest drawback related with the usage of preparative 
TLC to purify CD-mTHPP is that the conjugate was strongly bonded to the fine silica gel 
particles and could not be efficiently recovered.  
This experiment revealed that a good degree of separation could be achieved once the 
proper ratio of silica/crude was found, which motivated further trials on the purification of these 
crudes using column chromatography. Different batch samples were applied to different column 
dimensions (L, cm) x (OD, cm) and the ratio between the amount of sample to be treated (crude, 
mg) and silica used to pack the column, was varied as described by Table 3. A proper 
purification was achieved through the use a relatively long column ((L, cm) x (OD, cm) = 62 
cm x 2.2 cm), packed with 80 g of silica gel 60, loaded with 20 mg of crude solubilised in water 
/ mobile phase (1:1) (# 4 Table 3).  
 
Table 3. Dimensions of the columns used to treat the crude of the coupling reaction. 
# Dimensions (L, cm) x (OD, cm) Silica (g) Crude (mg) 
ratio 
(silica, g / crude, mg) Notes 
1 32 x 2.2 40 53 0.8 Failure 
2 62 x 2.2 67 31 2.1 Failure 
3 53 x 4.4 167 113 1.5 Failure 
4 62 x 2.4 80 20 4.0 Success 
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In some circumstances, different bands were noticed during CD-mTHPP elution from 
the column, which can be understood in the light of: i) aggregation characteristic of porphyrin-
related compounds in aqueous solvents;  ii) the ability of porphyrin to coordinate with different 
positive ions (Na+, NH4+) and iii) the promotion of acid-base equilibra between differently 
protonated species, motivated by the use of ammonia (NH3) in the mobile phase.  
Figure 33 A shows a TLC (silica gel 60, iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v)) of a 
sample of CD-mTHPP collected from an NMR (D2O) into which it aggregated. The supernatant 
(Liquid, Figure 33 A), the solid that remained aggregated inside the NMR tube, solubilised in 
MeOH and iii) the conjugate CD-mTHPP and iv) mTHPP, both solubilised in MeOH were 
spotted: i) the aggregated form of CD-mTHPP (“solid”) revealed two strongly coloured spots 
with different RF, as opposed to a single spot revealed by the supernatant (liquid) which proves 
how aggregation can affect the separation efficiency. Further, evidence supporting aggregation 
and the presence of multiple species in equilibrium was revealed by the application of a pure 
sample of CD-mTHPP to the top of the column: Figure 33 B shows that during elution two 
different bands were collected from the column corresponding to the exact same compound as 
corroborated by MALDI-TOF MS spectra of each fraction. 
 
Figure 33. Evidence of aggregation during separation of CD-mTHPP using A) TLC and B) column 
chromatography. Silica gel 60, iPrOH : EtOAc : H2O : NH3, 5:3:3:1 (v/v). 
 
Aggregation and the presence of ammonia can modify the retention of CD-mTHPP in 
the column. However, once collected these fractions were dialysed at slightly acidic pH (4 < pH 
< 5), which converts any excess of free ammonia into its water-soluble ammonium 
hydrochloride salt (NH4Cl) that can then be cleared out from the isolated CD-mTHPP.  
  
44 
Additional efforts were conducted to extract and purify other coupling products namely 
CD-mTHPP (2:1) and CD-mTHPP (3:1) that have been identified by MS in prior experiments. 
Due to the high content of βCD units attached to the mTHPP core in CD-mTHPP (2:1) and CD-
mTHPP (3:1), probably, these conjugates would present an improved water solubility and 
complexation ability when compared with CD-mTHPP on its own. These separation 
experiments were supported by the following observations: after CD-mTHPP was successfully 
isolated from the column, the presence of slightly coloured (green / brown) residue that 
remained at the top of the column was observed suggesting the presence of other porphyrin 
containing products, probably with high CD content. 
Therefore, by applying the same purification strategy after the isolation of CD-mTHPP 
by column chromatography (silica gel 60, iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v), the mobile 
phase was changed and the column was flushed with to pure absolute ethanol (EtOH), followed 
by water (H2O). Two fractions were selectively collected and revealed: i) red fluorescence 
under UV-Vis light (λexc = 254 nm) and ii) good water solubility. The MALDI-TOF MS (Figure 
34) of the fraction collected with EtOH revealed the presence of a dimer, CD-mTHPP (2:1) (m/z 
= 2916.6), with trace amounts of CD-mTHPP (m/z = 1139.6). The small differences observed 
between the experimental values and those expected for CD-mTHPP (m/z = 1135)  and for CD-
mTHPP (2:1) (m/z = 2912) are explained by a small offset of the mass spectrometer, 
corresponding to m/z = 4. 
 
 
Figure 34. MS (MALDI-TOF) spectrum of a conjugate of higher stoichiometry (CD-mTHPP (2:1)) isolated by 
column chromatography: silica gel 60, first washed with iPrOH : EtOAc : H2O : NH3, 5:3:3:1 (v/v) followed by 
absolute EtOH. 
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Therefore, the strategy employed lead to the isolation of very small amount of other 
coupling products (CD-mTHPP (2:1)) present in most crudes. Due to the very small amounts of 
CD-mTHPP (2:1) collected, the isolation of this extra product was not further explored. 
However, in a larger scale reaction, the isolation of this extra coupling product could result in an 
interesting future perspective. 
 
 
4.2.2 Molecular characterization of CD-mTHPP 
Following the successful preparation and purification of CD-mTHPP, several methods 
were used to characterize CD-mTHPP namely: nuclear magnetic resonance (NMR) 
spectroscopy, elemental analysis, UV-Vis and emission fluorescence spectroscopy, TLC and by 
mass spectrometry (MALDI-TOF).  
NMR spectroscopy was used to determine the structural features of the CD-mTHPP in 
pure DMSO-d6. This solvent was used because it enables the conjugate solubilisation in mostly 
monomeric form. and the observation of fast exchange protons (hydroxyl –OH and pyrrole -
NH) of both starting materials namely: βCD (Figure 35 B) and mTHPP (Figure 35 A).  
 
 
Figure 35. 1H NMR spectra (DMSO-d6, 500 MHz, 25 º C) of A) mTHPP and of B) βCD, illustrating the 
characteristic peaks of both macrocycles. 
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Figure 36 shows the 1H NMR spectrum of CD-mTHPP in DMSO-d6 and it reveals that 
the isolated product presents structural features of both a βCD (Figure 36 A, black / blue colour) 
and mTHPP (Figure 36 A, red colour) macrocycles, previously illustrated in Figure 35. The CD-
mTHPP exchangeable protons are observed: i) hydroxyl groups of βCD (CD-OH2/3/6, 4.0 ppm – 
6.0 ppm inset); ii) hydroxyls of mTHPP (Ph-OH, ≈ 10.0 ppm) and also iii) the characteristic 
highly shielded pyrrole protons (-NH) of mTHPP that resonates at ≈ - 3 ppm, due to the 
anisotropic effect of the aromatic macrocycle. All CD unit resonances are observed in the 
aliphatic region (3.0 ppm - 6.0 ppm): i) the characteristic anomeric proton connected to the 
carbon (C1) (CD-H1, ≈ 5 ppm) and all remaining proton signals (CD-H2/H3/H4/H5/H6/H6’, 3.0 
ppm – 5.0 ppm). Finally, the signals from the mTHPP macrocycle are observed in: i) the 
aromatic phenyl ring protons (Ph-H,  7.0 ppm - 8.0 ppm); ii) the pyrrole ring protons (Py-Ha/Hb, 
8.0 ppm - 10.0 ppm).  
The 1H NMR of CD-mTHPP (Figure 36 B) also supports the correct and desired 
connectivity, between one phenyl group of mTHPP and one glucopyranose unit of βCD 
macrocycle like illustrated in Figure 36 A. Firstly, the signal of the anomeric proton (CD-H1, ≈ 
5.0 ppm) is split into two unequal signals: a smaller blue coloured H1 ≈ 4.9 ppm, Figure 36 C 
and a bigger black coloured H1, ≈ 4.8 ppm Figure 36 C). Secondly, the integration of the isolated 
signal at ≈ 4.05 ppm, corresponding to only one proton is assigned to a CD-H5 signal (blue 
colour, Figure 36 C). These isolated signals corroborate the expected attachment of one phenyl 
ring of mTHPP to one glucopyranose unit of the βCD macrocycle, like indicated by the blue 
coloured α-D-glucopyranose unit in Figure 36 A. 
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Figure 36. 1H NMR spectrum (DMSO-d6, 500 MHz, 25 ºC) of CD-mTHPP: B) a full expansion, from -3.5 ppm 
to 11.0 ppm; C) an expansion in the aliphatic region, from 4.0 ppm to 6.0 ppm region. 
 
2D HSQC NMR experiment (Figure 37 A) was used to assess the identity of CD-H6, 
which is revealed as differently phased contours (red contour, ≈ 4.45 ppm, -CH2) when 
compared to all other CD protons (black contours, -CHs). Therefore, having assigned CD-
H6,2D COSY NMR experiment (Figure 37 B) leads to CD-H5 (≈ 4.05 ppm ,Figure 37 B). This 
corroborates the identity of CD-H5 and of CD-H6 of the glucopyranose unit, responsible for the 
ether bond between the mTHPP and βCD forming the desired conjugate (CD-mTHPP). 
 
Figure 37. 2D NMR experiments (DMSO-d6, 25ºC) of CD-mTHPP: A) HSQC spectrum and B) COSY 
spectrum. 
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Although, the 1H NMR of CD-mTHPP is illustrative of the chemical modification 
achieved, more experimental evidence was required to fully characterize the identity and the 
purity of the CD-mTHPP. MALDI-TOF mass spectrometry (positive mode, α-cyano-4-
hydroxycinnamic acid matrix) was recorded (Figure 38) and shows a single major peak at m/z = 
1796.8. This result is in excellent agreement with the expected value for the protonated 
molecular ion [M+H]+ = 1795.7 of CD-mTHPP, estimated for a molecular structure of 
C86H98N4O38. Additionally, no other high molecular weight coupling products were detected and 
CD-mTHPP was isolated in excellent purity. 
 
 
Figure 38. MS (MALDI-TOF) of CD-mTHPP (positive mode, 2,5-dihydroxybenzoic acid (DHB) matrix): m/z 
calcd. for C86H98N4O38: 1795.70 [M]. Found: 1796.8 [M+H]+ (100 %), 1817.0 [M+Na]+ (33 %). 
 
Further purity evidence was obtained from elemental analysis. The experimental result 
found (C: 51.18; H: 5.93; N: 3.11) revealed excellent agreement with estimated result for a 
chemical formula of C86H98N4O38.9H2O.NH4Cl (C: 51.34; H: 6.02; N: 3.48). The addition of 
one molar eq. of ammonium chloride (NH4Cl) agrees with the isolation / purification procedure 
of CD-mTHPP, which involved: i) the use of ammonia (NH3) in the mobile phase during 
column chromatography purification and is followed by ii) removal of NH3 in acidic conditions 
(pH ≈ 5, H2O / HCl) as a ammonium salt NH4Cl though dialysis. 
  
49 
 
4.2.3 Photophysical and other properties of CD-mTHPP 
Solubility and aggregation 
The porphyrin formation of aggregates in aqueous solutions has been studied in the 
literature and it is known to be dependent of factors like: i) the pH; ii) the ionic strength of the 
solution; iii) the concentration or iv) the solvent used to prepare the solutions [143, 68]. A CD-
porphyrin conjugate based on 5,10,15,20-tetrakis(p-hydroxyphenyl)-porphyrin (pTHPP) was 
prepared and studied in aqueous solutions, revealing poor aqueous solubility and a big tendency 
to aggregate. The corresponding loss in absorption/fluorescence properties was attributed to 
self-association, between CD cavity and the pTHPP phenyl rings [148]
. 
 
The pure conjugate CD-mTHPP, isolated as a pure black solid, at room temperature is 
insoluble in water as it is. However, if CD-mTHPP is first dissolved in a small amount of 
organic solvent (DMSO or MeOH), it can then be made water-soluble (µM range of 
concentration) and studied in aqueous media. Invariably, in aqueous solutions CD-mTHPP 
always revealed a great tendency to aggregate and precipitate in the mM range of concentration. 
CD-mTHPP showed good solubility in organic solvents (EtOH, MeOH or DMSO) but not in 
diethyl ether (EtOEt) where it was insoluble. This differential solubility towards EtOEt offered 
a tool for successful purification strategy for CD-mTHPP (see section 10.1.4). 
The solubility and aggregation tendency of CD-mTHPP and mTHPP were visually 
inspected in citrate and phosphate aqueous buffered solutions (pH = 3.8, 4.8, 6.0) and in 
phosphate buffer saline (PBS, pH = 7.4). CD-mTHPP (and mTHPP) was solubilised first in 
DMSO and further diluted to solutions (180 µM), with varying contents of DMSO (4 % and 9.1 
%). Figure 39 shows the side pictures taken that illustrate the colour change and aggregation of 
buffered aqueous solutions, as the pH and amount of DMSO are changed keeping the 
temperature constant (10 – 15 ºC) over a period of 48 h.  
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Figure 39. Solubility test of CD-mTHPP (180 µM) 
and mTHPP (180 µM), in buffered solutions (3.8 < 
pH < 7.4) modified with 4 % and 9.1 % of DMSO. 
 
This experiment revealed that for solutions of 180 µM concentration: i) CD-mTHPP 
shows better solubility than mTHPP, independently of the amount of DMSO added to solution; 
ii) increasing the DMSO content in a solution of mTHPP, from 4 % to 9.1 %, improved the 
solubility of mTHPP but seemed to have no effect in aqueous solutions of CD-mTHPP; finally, 
iii) the aggregation rate in solutions of mTHPP was higher than the aggregation rate observed 
for aqueous solutions of CD-mTHPP.  
 
UV-Vis / fluorescence spectroscopy 
The evaluation of the photophysical properties of CD-mTHPP (3.6 µM) in aqueous 
solutions (4 % DMSO/PBS) and in pure DMSO were assessed by UV-Vis absorption and 
fluorescence. The results were compared to solutions of mTHPP. The absorption spectra of CD-
mTHPP and mTHPP were recorded in DMSO (Figure 40 A) and in 4 % DMSO/PBS (Figure 40 
B).  
The typical features of a porphyrin (mTHPP) spectrum are preserved in the conjugate 
(CD-mTHPP) spectrum in DMSO (Figure 40 A), with a strong Soret band (420 nm) and small 
Q bands (515 nm, 549 nm, 590 nm, 648 nm). In pure DMSO, molecules are less prone to 
aggregation and there is a nearly complete match of the UV-Vis absorption spectra of mTHPP 
and CD-mTHPP (Figure 40 A). However, in 4 % DMSO/PBS, the UV-Vis spectra of both 
porphyrin and conjugate (Figure 40 B) suffer some modifications: i) the maximum absorption 
achieved in 4 % DMSO/PBS is reduced when compared to pure DMSO and became broader; ii) 
the intensity of the Soret band in CD-mTHPP (421 nm; 0.19 a.u.) is nearly double the intensity 
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of mTHPP (428 nm; 0.11 a.u.); and iii) the Soret band of CD-mTHPP is sharper than the Soret 
band of mTHPP (Figure 40 B). These results that at 3.6 µM concentrations, aqueous solutions of 
CD-mTHPP display a less aggregated profile when compared to mTHPP solutions in 4 % 
DMSO/PBS. 
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Figure 40. Absorption spectra for CD-mTHPP (3.6 µM, red line) and for mTHPP (3.6 µM, black line) in A) 
100 % DMSO and B) 4 % DMSO/ PBS. 
 
Additionally, Figure 41 shows the mTHPP and CD-mTHPP fluorescence spectra, 
following with excitation at the Soret band recorded for diluted 3.6 µM solutions, prepared in 
DMSO (Figure 41 A) and in 4 % DMSO/PBS (Figure 41 B). In DMSO (Figure 41 A), mTHPP 
(654 nm; 17.5 a.u.) shows slightly higher fluorescence intensity than CD-mTHPP (651 nm; 14.6 
a.u.). However, in aqueous solutions 4 % DMSO/PBS, despite the overall fluorescence intensity 
is significantly lower than in DMSO, the conjugate in 4 % DMSO/PBS (650 nm; 5.6 a.u.) 
revealed much higher fluorescence intensity than mTHPP (651 nm, 0.2 a.u). This corresponds to 
a 23-fold increase in emission fluorescence intensity (Figure 41 B), indicating that CD-mTHPP 
recovers its emission properties at small (µM), but biologically relevant concentrations. 
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Figure 41. Fluorescence emission spectra of CD-mTHPP (3.6 µM, black line) and for mTHPP (3.6 µM, red 
line), following excitation at the Soret in: A) 100 % DMSO, with λexc = 421 nm for both CD-mTHPP and 
mTHPP; and B) in 4 % DMSO/ PBS, with λexc = 421 nm for CD-mTHPP and λexc = 428 nm for mTHPP. 
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These UV-Vis / fluorescence results revealed that in aqueous diluted solutions (3.6 
µM), prepared in 4 % DMSO/PBS the aggregation phenomenon needs to be considered as it 
affects photophysical properties of both mTHPP and CD-mTHPP. Additionally, the conjugate is 
photoactive in aqueous 4 % DMSO/PBS solutions, preserving the typical UV-Vis and 
fluorescence spectral features of mTHPP. CD-mTHPP shows significantly less aggregation than 
mTHPP solutions, resulting in improved absorbance and emission fluorescence intensities 
especially in 4 % DMSO/PBS. 
 
pH dependence of UV-Vis properties 
Given the well-documented influence of pH on the aggregation state of porphyrins and 
consequent effect on photophysical properties [143], it is reasonable to expect that CD-mTHPP 
could display a similar pH dependence of its properties in aqueous solutions. Therefore, a 
comparative study between CD-mTHPP and mTHPP was performed to evaluate how the pH 
affects the photophysical properties and to determine at which the pH, both UV-Vis and 
fluorescence bands reach their maximum intensity. If successful, this experiment would result in 
the proper choice of a suitable pH to prepare aqueous solutions of CD-mTHPP. 
The absorption spectra were recorded for diluted solutions (2 µM) of mTHPP (Figure 
42 A) and of CD-mTHPP (Figure 42 B), prepared in buffered solutions modified with 4 % of 
DMSO, as a function of the pH. The typical UV-Vis characteristics of the porphyrin and 
conjugate are preserved, with a strong Soret band (λ ≈ 420 nm) and small absorption bands (Q 
bands), observed between 450 nm < λ < 700 nm. Variations on the wavelength and relative 
intensity of the bands were observed as the pH of both solutions was changed and, for 
simplicity, the changes on wavelength of the Soret (λSoret) and its intensity (absorbance) were 
recorded as a function of pH and were respectively plotted in Figure 42 C and D. 
Figure 42 C reveals that in acidic pH (2 < pH < 3), the λSoret of CD-mTHPP is 440 nm 
and when pH > 4, λSoret it drops abruptly to lower wavelength remaining approximately constant 
420 nm < λSoret < 422 nm, thereafter, until pH = 11 resulting in a hypsochromic shifting by 18 
nm. mTHPP shows a high λSoret (440 nm) at acidic pH (< 3), but for 4 < pH < 6 λSoret gradually 
decreases down to 422 nm. λSoret remains constant until pH = 7 and rises gradually again, 
achieving a maximum at 432 nm at pH = 9, followed by a decrease in λSoret = 419 nm between 9 
< pH < 11 which is in contrast with the constant value observed for the conjugate. 
Figure 42 D shows that mTHPP shows higher absorbance than CD-mTHPP, for pH < 3 
and for strong alkaline solution (pH > 10) and in the physiological range (6 < pH < 7). In all 
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other pH ranges namely in 3 < pH < 5 and between 8 < pH < 9, the absorption for CD-mTHPP 
is higher than for mTHPP.  
To the best of our knowledge, the pH variation of UV-Vis spectral properties has not 
been assessed for any CD-porphyrin conjugate. However, the dependence of mTHPP UV-Vis 
spectra has been assessed and compared with similar PS: i) the changes observed 4 < pH < 6 
were related to different protonation of the imino nitrogens of the porphyrin core, and ii) the 
maximum absorbance was achieved at pH = 7 [55].  Interestingly, both mTHPP and CD-mTHPP 
reached their maximum absorbance at pH = 7, which is advantageous considering that most 
biological experiments are performed at physiological pH (= 7.4).  
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Figure 42. Absorption spectra as a function of pH change for A) mTHPP and for B) CD-mTHPP. Graphical 
representation of C) the Soret maximum (λSoret, nm) and of D) its intensity (Absorbance, a.u.) recorded for 
diluted solutions (2 µM) in 4 % DMSO/PBS*, (* - varying pH). 
 
Less aggregated porphyrin solutions are expected to reveal improved UV-Vis spectral 
properties, than solutions where aggregation takes place. The aggregation of mTHPP and CD-
mTHPP prepared in 4 % DMSO/PBS (pH = 7.0) was estimated, by the calculation of the full 
width at half maximum (FWHM) evaluated for the Soret band in the corresponding UV-Vis 
spectra. It was found that FWHM for mTHPP (33 nm) > CD-mTHPP (5 nm), indicating that 
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mTHPP has a higher tendency to aggregate than CD-mTHPP. This result is in line with our 
previous reported studies in 0.5 % DMSO/PBS solutions, where the aggregation tendency of 
mTHPP and CD-mTHPP was evaluated [144]. It has been shown that CD-mTHPP revealed much 
smaller particles (≈ 13 nm, DLS) than mTHPP (≈ 2000 nm, DLS) and mTHPP, revealed a much 
bigger tendency to aggregate, than CD-mTHPP.  
Even though, diluted solutions were used (2.0 µM; 3.6 µM), aggregation of porphyrins 
proved to be a time-dependent and dynamic process in aqueous solutions, occurring even in the 
µM range of concentrations [68]. Probably, during the time it takes to: i) prepare of the initial 
stock solution; ii) diluting it to the desired concentration and iii) record the UV-Vis spectra of 
these solutions each solution both mTHPP and CD-mTHPP behave differently. Therefore, time 
between trials also affects the overall UV-Vis absorption spectra and needs to be assessed 
through carefully designed experiments. 
 
pH dependence of fluorescence properties  
Emission fluorescence spectra were recorded for dilute solutions (2 µM) of mTHPP 
(Figure 43 A) and for CD-mTHPP (Figure 43 B). mTHPP shows a two band fluorescence 
spectra with peaks (λ ≈ 660 nm and 725 nm) over the region 4 < pH < 11 that turns into a single 
band spectra (λ ≈ 680 nm) in acidic solutions (pH < 4). Likewise, CD-mTHPP reveals a spectra 
three bands spectra (λ ≈ 623 nm, 660 nm and 730 nm) for 4 < pH < 11, which turns into a single 
band spectra (λ ≈ 677 nm) when pH < 4. Figure 43 C shows that there are not significant 
changes on the wavelength of the strongest fluorescence band (λMAX) as the pH is changed, for 
solutions of mTHPP and CD-mTHPP. However, for (3 < pH < 11), the changes in intensity of 
the strongest fluorescence band recorded at λΜΑΧ (Figure 43 D) are more pronounced for CD-
mTHPP than for mTHPP, except in very acidic (pH = 2) where mTHPP fluorescence intensity is 
higher than CD-mTHPP. The magnitude of the changes is roughly the same for mTHPP and 
CD-mTHPP and at pH = 7, it reached the maximum emission fluorescence intensity: CD-
mTHPP (70.6 a.u., λexc = 422 nm) ≈ 2.6 times higher than mTHPP (26.4 a.u., λexc = 422 nm), 
when excited at the Soret maximum. 
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Figure 43. Fluorescence emission spectra as a function of pH for A) mTHPP and B) CD-mTHPP. Graphical 
representation of C) the intensest fluorescence band (λMAX, nm) and of D) its intensity (fluorescence, a.u.) 
recorded following excitation at Soret maximum for diluted solutions (2 µM) in 4 % DMSO/PBS*, (* - varying 
pH). 
 
These results are in excellent agreement with measurements performed in collaboration 
with University of Catania [144], considering that: fluorescence emission intensity of CD-mTHPP 
(5 µM, 0.5 % DMSO/PBS, ≈ 9 a.u.) vs mTHPP (5 µM, 0.5 % DMSO/PBS, ≈ 2 a.u.), when 
excited at λexc = 512 nm. 
The fluorescence spectral properties of mTHPP and other photosensitizers have been 
studied as a function of the pH in phosphate buffered saline (PBS) modified with: i) 50 % (v/v) 
of methanol (MeOH) and by using non-ionic surfactant ii) Titron X-100 (20 %) modified with 
0.6 % (v/v) of PBS [55]. mTHPP revealed no fluorescence in PBS solution in a region 4 < pH < 
10 and showed a fluorescence emission peak at 679 nm (λexc = 417 nm) in acidic pH < 4; its 
emission fluorescence intensity improved in solutions containing 50 % (v/v) MeOH/PBS, where 
two peaks were observed in 4 < pH < 10; however, when pH < 3, the spectrum changes and 
only one peak was observed at 683 nm. The improvement of the emission fluorescence spectra 
of mTHPP (0.03 µM) in PBS, upon addition of 50 % MeOH was attributed to a decrease in 
aggregation. A reasonable explanation for the changes observed in the spectra for pH < 4 has 
been attributed to the protonation of the imino nitrogen of pyrrole group, which changes the 
porphyrin ring symmetry and results in a shift of the emission peaks [145].  
  
56 
In comparison with these published results, our results were obtained in aqueous 
solvents, in the presence of a limited amount of organic modifier (4 % v/v DMSO/PBS) as 
opposed to that reported (50 % v/ v MeOH) and, in addition, our concentration (2 µM) is nearly 
70 times higher than the one reported (0.03 µM) mTHPP. The improved emission fluorescence 
properties of CD-mTHPP seems to be an intrinsic property of the molecule in aqueous 
solutions, where it reveals much less tendency to aggregate than mTHPP in the same conditions 
(2 µM, 4 % DMSO/PBS pH = 7.0), evidently due to the attachment to the CD moiety. 
 
 
4.3 Conclusions and future perspectives 
The synthesis of CD-porphyrin conjugate (CD-mTHPP) was accomplished by applying 
crucial modifications to a previous completely inappropriate purification methodology. The 
optimized improved procedure involved the use of column chromatography (silica gel 60, 
iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v)) and dialysis to recover the pure CD-mTHPP. The 
conjugate was obtained in 40 % yield, based on reacted mTHPP. The moderate reaction yield is 
unavoidable, as many side products and processes are in operation and compete with the 
formation of CD-mTHPP, but even this value it is much better than most literature reported 
yields. Most of unreacted mTHPP can be successfully recovered and reused.  
CD-mTHPP was obtained as a single molecular structure, constituted by one molecule 
of CD covalently connected to one molecule of porphyrin. Its physical-chemical properties were 
assessed by TLC, 1H NMR spectroscopy, elemental analysis, MALDI-TOF mass spectrometry 
and UV-Vis / fluorescence spectroscopy. In its pure state, CD-mTHPP preserves the porphyrin 
properties, namely it displays a typical UV-Vis absorption, red fluorescence and it is water-
soluble in µM range of concentration, which are appropriate for in vitro biological studies. 
In comparison to mTHPP in the µM range of concentrations, CD-mTHPP revealed 
improved emission fluorescence intensity (1.7-fold higher) in aqueous solutions modified with 4 
% DMSO, which can be maximized using 4 % DMSO/PBS (pH = 7.0). CD-mTHPP showed 
much smaller tendency for aggregation than for the mTHPP in the same medium. However, the 
presence of aggregates at higher concentrations (mM range) indicates that efforts to improve its 
water solubility are required. 
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5. Large solubility enhancement of CD-mTHPP complexed with 
of per(2,3,6-O-trimethyl)-βCD (pMβCD) and comparison 
with pMβCD complexes of mTHPP  
5.1 Introduction 
Methylated cyclodextrin (CD) derivatives are recognised for their distinctive properties: 
high solubility in commonly used organic solvents as well as in water and for their ability to 
accommodate guests molecules, through formation of cavity inclusion complexes [ 146 ]. In 
comparison to native CDs, the inclusion properties of methylated CDs are strongly related to the 
absence of sufficient hydroxyl groups (-OH), which gives extra flexibility in their cavity 
structure, due to lack of hydrogen bonding between adjacent OH groups  in the secondary side 
[147]
. The flexibility can be very advantageous because it allows the host to bend its macrocycle, 
in order to better accommodate more efficiently the incoming guest molecule [17]. Two examples 
of methylated CDs are heptakis(2,6-di-O-methyl)-βCD (DIMEB) and heptakis(2,3,6-tri-O-
methyl)-βCD (pMβCD) (Figure 44). 
 
Figure 44. Two methylated βCD derivatives: A) DIMEB and B) pMβCD. 
 
Methylated CDs became promising hosts for the complexation of chiral molecules, 
useful in separation of enantiomeric mixtures and very efficient solubilizers of porphyrins [148], 
namely 5,10,15,20-tetraphenylporphyrin (TPP) derivatives and water-soluble porphyrins often 
characterized by their high tendency to aggregate in aqueous solvents [67], as described in 
section 2.1.3. Methylated CDs are efficient solubilizers of water-soluble TPP derivatives, 
through formation of strong and water-soluble inclusion complexes characterized by 1:1 or 2:1 
stoichiometries and high binding affinities [148]. The structure of these complexes has been 
determined through 1D and 2D NMR experiments. For example, the 1H NMR spectrum of 
pMβCD changed after the gradual addition of water-soluble 5,10,15,20-tetra(p-
sulfonatophenyl)-porphyrin (TPPS4): i) new peaks were observed and attributed to the 
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formation of inclusion complexes (pMβCD / TPPS4); ii) at the right stoichiometry ratio between 
(pMβCD / TPPS4) = 2:1, a pure complex solution was obtained and a completely different 
spectrum was observed, solely assigned to the presence of the complex; iii) 2D NMR 
experiments, revealed interaction of the CD cavity internal protons (CD-H3/H5) and the phenyl 
rings of the TPPS4 and iv) dipolar interactions of 3-OMe with CD-H3/H5 were detected, 
revealing that this methyl group is pointing towards the inside of the pMβCD cavity [149]. In a 
different example the water insoluble 5,10,15,20-tetra(p-pyridyl)-porphyrin (TPyP) interacted 
with two pMβCD molecules, with two of the four pyridyl moieties being deeply inserted into 
the pMβCD cavity [150]. These porphyrin-pMβCD inclusion complexes are so unusually strong, 
that dye inclusion single crystals (DISC) have been prepared and their X-ray structure 
determined (Figure 45) [151].  
 
 
Figure 45. Structure of the inclusion complex 
between pMβCD and TPP, following a H:G = 2:1 
stoichiometry [151]. 
 
Similar findings were also reported from the interaction of pMβCD with 5,10,15-(tris-
(3,5-dicarboxylatophenyl)-20-phenylporphyrin), corresponding to the formation of an inclusion 
complex of different stoichiometry H:G = 1:1 [152]. 
UV-Vis and fluorescence spectroscopy have been used to determine both the 
stoichiometry and the binding constants of porphyrin and methylated CDs complexes: i) a 
solution of 5,10,15,20-tetrakis(p-carboxyphenyl)-porphyrin in the presence of pMβCD, 
prepared in 0.1 M aqueous buffer (pH = 7) revealed an increase in Soret intensity, when 3 molar 
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excess of pMβCD are added to the solution; the stoichiometry of the complex pMβCD: 
porphyrin was 2:1 [148]. In  another example, 5,10,15,20-tetrakis[4-(3-
pyridiniumpropoxy)phenyl]porphyrin tetrakisbromide (TPPOC3Py) was treated with increasing 
amounts of pMβCD solubilised in ethylene glycol : water (3:1) and an increase in the Soret 
intensity was observed and the curve fitting suggested a mixed equilibrium, between two 
stoichiometries comprising a 1:1 and a 2:1 equilibria [149]. 
In the previous section 4.2.1, the synthesis and characterization of CD-mTHPP 
conjugate in its pure state was described and its aggregation and poor water solubility was 
observed. This impaired important studies namely inclusion studies in aqueous solution, in 
order to document the ability of CD-mTHPP to carry guest molecules, specifically drugs with 
anticancer properties. Therefore, it was envisaged that by using pMβCD as solubilizer, the 
photophysical properties of CD-mTHPP in aqueous solvents could be improved and the 
biological studies resumed. In this chapter, UV-Vis, fluorescence and NMR spectroscopies will 
be used to study complexation of pMβCD with mTHPP and with CD-mTHPP, namely:  
i) Evaluate improvements in aqueous solubility of CD-mTHPP and mTHPP in 
the presence of pMβCD 
ii) Determine a suitable range of concentrations (mM) to enable the NMR 
studies on the structural features of pMβCD complexes with CD-mTHPP and 
mTHPP 
iii) Determine the equilibrium constant (K), the stoichiometry of complexation 
and mode of complexation mTHPP and CD-mTHPP 
iv) Proceed with cell internalization experiments and 
v) Study of complexation of poorly soluble molecules into CD-mTHPP, 
solubilised by pMβCD 
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5.2 Results and discussion  
5.2.1 Linear concentration range for mTHPP and CD-mTHPP in 4 
% DMSO/PBS solutions 
Prior to the evaluation of the improvements in aqueous solubility of CD-mTHPP and 
mTHPP promoted by addition of pMβCD, through a typical titration experiment based on UV-
Vis / fluorescence, a preliminary UV-Vis study was required to determine a suitable 
concentration range (µM), under which titration experiments could be performed considering 
aggregation negligible. 
UV-Vis spectroscopy was used to determine the linear range of concentration by 
application of Beer-Lambert law, which is followed when diluted solutions of chromophore are 
used. Deviation from linearity is observed when concentration of the chromophore is increased, 
signifying the onset of aggregation. The UV-Vis spectra of mTHPP solutions recorded in 
DMSO (Figure 46 A) and in 4 % DMSO/PBS (Figure 46 B), reveal the typical UV-Vis spectra 
expected for CD-mTHPP in DMSO (Figure 46 C) and in DMSO/PBS (Figure 46 D): i) an 
intense peak at ≈ 420 nm (Soret band) and ii) four weak bands between 450 – 700 nm (Q 
bands). 
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Figure 46. UV-Vis spectra of increasing amounts of: A) mTHPP (0 – 20 µM) in DMSO; B) mTHPP (0 – 5.6 
µM) in 4 % DMSO/PBS; C) CD-mTHPP (0 – 5.6 µM) in DMSO and D) CD-mTHPP (0 – 5.6 µM) in in 4 % 
DMSO/PBS. 
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However, when the concentration of mTHPP (or CD-mTHPP) is increased both the 
aggregation and the intensity of the absorption bands (Soret and Q-bands) increase. For any 
given concentration (C = 3.84 µM) of active species (mTHPP and CD-mTHPP) in solution, the 
value of the full width at half-maximum (FWHM) can be calculated and used to judge 
aggregation tendency. Table 4 shows that in 4 % DMSO/PBS: FWHMmTHPP (58 nm) > 
FWHMCD-mTHPP (25 nm), whereas in DMSO: FWHMCD-mTHPP (14 nm) > FWHMmTHPP (8 nm) 
which suggest that in aqueous solutions (4 % DMSO/PBS), mTHPP and CD-mTHPP have a 
much higher degree aggregation than in pure DMSO. Moreover, in aqueous solutions and 
keeping the concentration constant (C = 3.84 µM), CD-mTHPP is much less aggregated than 
mTHPP, because FWHMCD-mTHPP = 25 nm < FWHMmTHPP = 58 nm which is in perfect 
agreement with previous reported data [144]. 
The summary of parameters (Table 4) obtained from the linear fittings, displayed as 
insets in Figure 46 reveal that: i) both CD-mTHPP and mTHPP possess a good linearity over a 
narrow range of concentrations (0 µM - 5 µM), both in DMSO (expected, since DMSO is a 
monomerizing solvent) and in 4 % DMSO/PBS, with most of the experimental data being 
explained by the linear fitting applied (calibration curve R2 ≈ 1.0; ii) the molar absorption 
coefficient (ε) of both compounds is higher in DMSO than in 4 % DMSO/PBS due to 
aggregation; and iii) although, CD-mTHPP is less aggregated in 4 % DMSO/PBS than in 
mTHPP, the ε value for the detection of mTHPP is higher than the ε value for the detection of 
CD-mTHPP independently of the solvent used – in DMSO (εmTHPP = 344501 M-1.cm-1 > εCD-
mTHPP = 146700 M-1.cm-1) whereas in 4 % DMSO/PBS (εmTHPP = 50400 M-1.cm-1 > εCD-mTHPP = 
45400 M-1.cm-1). 
 
Table 4 – Experimental data on the calibration curves of mTHPP and CD-mTHPP, based on linear fitting 
adjustment (y = mx + b, with b = 0). 
Example Solvent R2 ε (M-1.cm-1) Linear range FWHM (C = 3.84 µM) 
mTHPP DMSO 0.9996 344501 0 – 4 µM 8 nm 
mTHPP DMSO/PBS 0.9915 50400 0 – 5 µM 58 nm 
CD-mTHPP DMSO 0.9999 146700 0 – 5 µM 14 nm 
CD-mTHPP DMSO/PBS 0.9778 45400 0 – 5 µM 25 nm 
 
This suggests that the presence of aqueous buffered solutions (PBS) greatly affects the 
UV-Vis properties of mTHPP and CD-mTHPP, even when small amounts of organic modifier 
(4 % DMSO, v/v) are used in the preparation of solutions. However, if diluted solutions are used 
(0 µM – 4 µM) aggregation can be minimized to a reasonable level and titration experiments 
can be resumed. 
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Similar findings were observed for 5,10,15,20-tetrakis(m-hydroxyphenyl)-chlorin 
(mTHPC) in MeOH, which showed good linearity over the concentration range 4.6 µM to 734 
µM, but in opposition to our experiments, were determined following the intensity of the Q 
band I [153]. However, this can be compared with mTHPP in DMSO (Figure 46 A) considering 
that at concentration of ≈ 10 µM it is no longer possible to record the intensity of Soret; 
therefore, it is possible to follow the Q-band I and go well above 20 µM in concentration. The 
good linearity in aqueous behaviour of mTHPP in the range 0 µM – 5 µM agrees well, with 
linearity of 5,10,15,20-tetrakis(N-ethylpyridinium-2-yl)-porphyrin (TEPyP) in aqueous buffer, 
which showed deviations from Beer’s law above 6 µM [150]. Pasternack and co-workers studied 
interactions of water-soluble porphyrins like tetra(N-methylpyridyl)-porphyrin (TMPyP), 
5,10,15,20-tetrakis(p-carboxyphenyl)-porphyrin (H2TPPC) and 5,10,15-tris(p-sulfonatophenyl)-
20-phenylporphyrin (H2TPPS3) in aqueous buffered solutions at pH = 7.5 and found that these 
obeyed Beer-Lambert Law over a wide range of concentrations. However, in the presence of 
0.1M KNO3 added to their buffered solutions of TMPyP, H2TPPS3 and H2TPPC substantial 
deviation from linearity was revealed, attributed to monomer-dimer equilibria of the free-base 
forms [154]. 
 
5.2.2 Titration experiments with pMβCD 
Given the limited water solubility of CD-mTHPP and considering the reported ability of 
per(2,3,6-trimethyl-6-deoxy)-βCD (pMβCD) to form inclusion complexes with 
tetraphenylporphyrin (TPP) [148], pMβCD was used as a solubilizer to improve the water 
solubility of CD-mTHPP. mTHPP was used as a model compound because its pMβCD 
complexes have been characterized and it was used as a starting material in the preparation of 
CD-mTHPP, possessing similar structural features to the conjugate (Figure 47).  
 
Figure 47. Structure of the conjugate (CD-mTHPP) and of 5,10,15,20-tetrakis(m-hydroxyphenyl)-porphyrin 
(mTHPP). 
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Titration experiments based on UV-Vis and fluorescence spectroscopy have been 
conducted, using 2 µM concentration to minimize aggregation phenomena and were prepared in 
4 % DMSO/PBS (pH = 7.4). Solutions of porphyrin (mTHPP) and conjugate (CD-mTHPP) 
were titrated with pMβCD. Their UV-Vis (Figure 48 A) and fluorescence spectra (Figure 48 B) 
were recorded, following the addition of increasing amounts of pMβCD (molar eq.).  
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Figure 48. Spectral changes in A) UV-Vis absorbance and B) emission fluorescence intensity spectra for a 
solution mTHPP (2 µM; 4 % DMSO/PBS), as pMβCD is added to the solution until it reaches 6.5 molar eq. 
 
The initial UV-Vis spectrum of mTHPP (2 µM; black line, Figure 48 A) upon addition 
of pMβCD solution gradually changes, from a broad Soret peak with negligible intensity (0.17 
a.u.; 432 nm), to a well-defined spectrum with a sharp and intense Soret peak (0.59 a.u.; 414 
nm), with increasing intensity as amount of pMβCD in solution is increased. This corresponds 
to a 3.4-fold increase in absorption maximum intensity, associated to a hypsochromic shift of 
the Soret (≈ 18 nm) after addition of 6.5 molar excess of pMβCD (Figure 48 A). The addition of 
more pMβCD resulted in no significant increase in the absorbance and a single isobestic point 
was observed at (λ = 423 nm, abs = 0.15 a.u.; Figure 48 A). Likewise, the initial fluorescence 
spectra (2 µM; black line, Figure 48 B) changes from a nearly negligible fluorescence intensity 
(27 a.u.; 654 nm), to a reasonable intense fluorescence emission (578 a.u.; 647 nm) after 
addition of 6.5 molar eq. of pMβCD. There is a total 21-fold increase associated with a 
hypsochromic shift of 7 nm (Figure 48 B). No increase in fluorescence emission was observed, 
upon further pMβCD addition. 
The increase in UV-Vis and fluorescence intensity has been shown in the literature 
through titration experiments: i) 5,10,15-tri(3,5-dicarboxylatophenyl)-20-phenyl-porphyrin (20 
µM; phosphate buffer, pH = 7) with 2,6-dimethyl-βCD [152]; charged 5,10,15,20-tetrasubstituted 
porphyrins TPPOC3Py (-C6H4-O-(CH2)3-Py+Br-, where Py+ = alkylpyridinium, with pMβCD 
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[149]
 or even through the use of differently substituted CD derivatives like heptakis(2,6-di-Ο-n-
octyl)-β-cyclodextrin (Oc-βCD) in the titration of TPP [155]. The appearance of a single isobestic 
point has been attributed to dimerization processes [69, 70]. This was observed for mTHPP (2 µM) 
titrated with pMβCD in aqueous solutions, which corroborates well with previous observations 
regarding high propensity of mTHPP to aggregate in aqueous media. However, as expected 
from the addition of pMβCD, this leads to the breakup of these dimeric species and to a 
reasonable recovery of the UV-Vis absorption intensity. 
The same experiments were performed for diluted solutions of CD-mTHPP (2 µM; 4 % 
DMSO/PBS) and as pMβCD was added to the host solution, both the UV-Vis absorption 
(Figure 49 A) and fluorescence spectra (Figure 49 B) were recorded: i) UV-Vis spectrum of 
CD-mTHPP changed from a broad and weak Soret (0.13 a.u.; 422 nm), to a sharper peak and 
intense Soret band (0.21 a.u.; 414 nm) after the addition of 3 molar eq. of pMβCD above which 
no absorbance increase was noticed. This corresponded to a 1.6 fold increase in absorption 
maximum intensity associated to a hypsochromic shift of 8 nm (Figure 49 A). No isobestic 
points were observed. Fluorescence spectral changes starting from an initial solution of CD-
mTHPP (32 a.u.; 650 nm), following the addition of a total of 3 molar eq. of pMβCD, resulted 
in a 8-fold improvement of the fluorescence intensity associated to a hypsochromic shift of 3 
nm and a much improved final fluorescence spectrum (256 a.u.; 647 nm) (Figure 49 B). 
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Figure 49. Spectral changes in A) UV-Vis absorbance and B) emission fluorescence intensity spectra for a 
solution CD-mTHPP (2 µM; 4 % DMSO/PBS), as pMβCD is added to the solution until it reaches 3.0 molar 
eq. 
 
These experiments revealed that the addition of pMβCD to aqueous buffered solutions 
of CD-mTHPP and mTHPP, promotes improvements in their UV-Vis absorbance and 
fluorescence emission. This suggests that the pMβCD complexes should display similarities 
given the structural similarities between the porphyrin and the conjugate. The amount of 
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pMβCD added to mTHPP (6.5 molar eq.) is 2.2 higher than the one added to CD-mTHPP (3.0 
molar eq.), which probably indicates a different stoichiometry between the two complexes. 
 
 
5.2.3 Stoichiometry estimation and stability of pMβCD complexes 
Following the titration experiments by UV-Vis and fluorescence described previously, 
it is possible to estimate the stoichiometry of the complexation equilibrium, through a different 
graphical representation of the analytical data collected. Figure 50 A shows the changes in the 
absorption maximum (Soret intensity) for a 2 µM solution of mTHPP, plotted against molar 
equivalents of pMβCD added to the solution during the titration. The changes on maximum 
intensity of fluorescence spectra upon excitation at the Soret maximum is shown in Figure 50 B. 
In both UV-Vis and fluorescence experiments, the intensities gradually increase and a plateau is 
reached when two molar eq. of pMβCD are added to mTHPP (2 µM) (black arrow). 
Consequently, the complex is formed by adding two moles of pMβCD to one mole of mTHPP, 
in an equilibrium following a two-to-one (2:1) stoichiometry. 
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Figure 50. Titration experiment of mTHPP (2 µM) with pMβCD (300 µM) in 4 % DMSO/PBS. For every 
pMβCD addition the A) absorption and B) fluorescence maximum were followed until an excess of 6.5 molar 
eq. are present in solution. 
 
The 2:1 stoichiometry of the complex pMβCD/mTHPP agrees with a reported example 
given by iron-tetrakis(4-sulfatophenyl)-porphyrin (Fe-TPPS) in the presence of pMβCD, where 
two molecules of pMβCD engulf a Fe-TPPS molecule, from opposite sides leading to a 
symmetrical substituted complex: Fe-TPPS/pMβCD (1:2) [156].  
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Likewise, the differences in the analytical response recorded for CD-mTHPP, namely 
the increment in fluorescence (Figure 51 B) and absorbance (Figure 51 A) revealed 
complexation equilibrium involving a 1:1 stoichiometry.  
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Figure 51. Titration experiment of CD-mTHPP (2 µM) with pMβCD (300 µM) in 4 % DMSO/PBS. For every 
pMβCD addition the A) absorption and B) fluorescence maximum were followed until an excess of 3 molar eq. 
is present in solution. 
 
In the literature, 1:1 complexes of pMβCD were reported with unsymmetrical 
substituted tetraphenylporphyrins like 5,10,15–tris(3,5-dicarboxylatophenyl)-20-phenyl-
porphyrin. These were formed through inclusion of the only non-polar phenyl group, leaving 
excluded from the pMβCD cavity the bulky and polar substituent (3,5–dicarboxy-phenyl ring) 
[152]
. The preferred 1:1 stoichiometry for these complexes is similar to the stoichiometry found 
for pMβCD/CD-mTHPP and can be explained due to the steric hindrance offered by the βCD 
unit of CD-mTHPP that blocks the access of more pMβCD units to adjacent phenyl groups in 
CD-mTHPP structure. 
These results show that pMβCD increased the solubility of both mTHPP and CD-
mTHPP in aqueous solutions, leading to the decrease in aggregation attributed to the formation 
of water-soluble complexes of different stoichiometries. 
Non-linear least square fitting method was used to determine the binding constants of 
complexation (K), based on UV-Vis titration data represented in Figure 50 A (pMβCD/mTHPP)  
and Figure 51 A (pMβCD/CD-mTHPP). Equations describing a 1:1 model of complexation 
were applied for pMβCD/CD-mTHPP leading to K(1:1) = 3.8 ± 1.59 x 106  M-1 (goodness of fit, 
R2 = 0.9954). The value of K(1:1) for the conjugate is in line with that reported for a similar 
conjugate, prepared from reaction of 5-(p-aminophenyl)-10,15,20-tris(p-sulfonatophenyl)-
porphyrin with 6-deoxy-6-formyl-βCD, with pMβCD forming a 1:1 complex: K(1:1) = 3.0 × 106 
M-1, determined in 0.1 M ammonium carbonate, pH = 8.5) [157]. It also agrees with K(1:1) = 1.1 x 
107 M-1, found for complexation of pMβCD 5,10,15-tris(3,5-dicarboxylatophenyl)-20-
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phenylporphyrin in phosphate buffer (0.1 M, pH = 7.4) [152]. In another example, βCD-dimers 
connected through flexible spacers were able to accommodate anionic porphyrins namely: 
5,10,15,20-tetra(4-carboxyphenyl)-porphyrin (TCPP) and TPPS4 and two different modes of 
complexation were identified for 1:1 complexes, with K(1:1) ≈ 106 M-1, determined in phosphate 
buffer (0.1 M, pH = 7) [ 158 ]. The strength of the binding of pMβCD with tetra(phenyl)-
porphyrins depends on the charge of the included phenyl group, because anionic 5,10,15,20-
tetra(4-sulfonatophenyl)-porphirin (TPPS4), K(1:1) = 2.0 ± 1.3 x 104 M-1 revealed stronger 
binding constant than cationic 5,10,15,20-tetrakis[4-(3-pyridiniumpropoxy)phenyl]-porphyrin 
(TPPOC3Py), K(1:1) = 2.3 ± 0.9 x 103 M-1 determined in ethylene glycol (EG)-water (H2O) (3:1) 
[149]
. The binding of non-ionic tetraphenylporphyrins is even stronger. 
The complex pMβCD/mTHPP, through the application of a 2:1 model of complexation 
revealed an overall binding constant KT = K(1:1) x K(2:1) = 4.9 x 1012 M-2. The shape of the 
titration curve does not show two distinct binding steps (Figure 50 A) and thus a negligible 
concentration of intermediate 1:1 complex can be assumed in the determination of KT for 
pMβCD/mTHPP. This value is much larger than the values found for similar complexes of 
pMβCD: i) KT = 2.16 x 107 M-2 with cationic porphyrin TPPOC3Py, and ii) KT = 1.2 x 109 M-2 
with anionic TPPS4, determined in EG-H2O (3:1) [149]. Explanations for this unusually high 
stability of pMβCD with tetraphenylporphyrins have been proposed and are related with the 
absence of strong hydrogen-bonding network in pMβCD, that in native βCDs keeps the cavity 
rigid, but in pMβCD facilitates porphyrin binding via the induced fit mechanism [17]. This model 
is usually applied to explain the binding between a substrate and a CD’s cavity, whereby the 
substrate not matching the exact dimensions of a cavity, forces small changes in the CD 
structure enabling a better accommodation of the guest. A striking example of this phenomena 
is the double self-inclusion of two pMβCD moieties, covalently attached to the 4-positions of 
the phenyl groups of 10,20-bis(3,5-dicarboxylatophenyl)-5,15-diphenylporphyrin, which 
involves a 360° rotation of two glucopyranose units in the pMβCD moieties [146]. Therefore, 
pMβCD has an extremely strong tendency to include porphyrins in its cavity. 
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5.2.4 Structural features of pMβCD complexes 
Nuclear Magnetic Resonance (NMR) spectroscopy was used to identify and determine 
the structure of the complexes of pMβCD, with CD-mTHPP and with mTHPP. The 1H and 13C 
NMR spectral assignment of pMβCD has been described in the literature [159]. 1H NMR spectra 
were supported by 2D NMR experiments based on correlation spectroscopy through bonds 
(HSQC; HMBC; COSY; TOCSY) and through-space dipolar correlation spectroscopy, that 
relies on nuclear Overhauser effect (NOESY; ROESY). 
 
mTHPP / pMβCD 
The addition of mTHPP solubilised in MeOD-d4 to an aqueous solutions of pMβCD (10 
mM), leads to a gradual change in the typical 1H NMR spectrum of pMβCD (Figure 52 B) that 
involves: the reduction of pMβCD original signals (Figure 52 B) and the corresponding increase 
of new resonance peaks, gradually evolving to a new 1H NMR spectrum attributed to the 
resonances of pure pMβCD/mTHPP complex (8.9 mM / 5.6 mM, R = 1.6, Figure 52 A), in 11 
% MeOD / D2O. These features are typical of a slow exchange process between free and 
complexed components in the NMR time-scale, according to the equations described in section 
1.2. The slow exchange regime is typically associated with very strong binding, confirming the 
very high titration constant, derived from the titration experiments. 
The overall increase in solubility of the mTHPP (≈ 5.6 mM) promoted by the addition 
of pMβCD, results in a well-resolved aromatic region of the spectra (7.0 – 10.0 ppm) (Figure 52 
C). The formation of inclusion complexes between mTHPP and pMβCD was corroborated by 
the strong shielding noticed by the cavity proton of pMβCD cavity (CD-H3, ≈ 0.53 ppm).  
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Figure 52. 1H NMR spectra (500 MHz, 25 ºC) recorded in the aliphatic region (2.0 ppm – 6.0 ppm): A) pure 
complex pMβCD/mTHPP (2:1) (8.67 mM / 5.6 mM, R = 1.54) in 11% MeOD-d4/D2O; B) pMβCD (8.67 mM) in 
D2O and C) an expansion of the aromatic region (7.4 ppm – 8.6 ppm). 
 
Further experimental evidence, supporting the existence of new species (complex: 
pMβCD/mTHPP) was obtained from the 2D NMR HSQC experiments. These observations 
were possible due to a slow exchange equilibrium between mTHPP, pMβCD (free / 
uncomplexed) and the complex pMβCD/mTHPP. In the presence of a large excess of pMβCD 
(pMβCD/mTHPP ≈ 4 (9.75 mM / 2.44 mM, R = 4), all mTHPP added to the pMβCD solution is 
complexed and the remaining free pMβCD is in equilibrium with the complex, as observed by 
the multiple peaks corresponding to the uncomplexed (free) pMβCD and the complex 
(pMβCD/mTHPP, green arrows, Figure 53 A). Following the addition of more mTHPP, the 
initial 2D HSQC spectrum evolves to a new 2D HSQC spectrum with only the complex is 
observed in solution (pMβCD/mTHPP ≈ 2, 8.89 mM / 5.56 mM = 1.6, Figure 53 B). 
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Figure 53. 2D NMR HSQC spectra (25 ºC) expanded in the aliphatic region (2.0 – 5.5 ppm) in the presence of: 
A) excess of host pMβCD/mTHPP ≈ 4 (9.75 mM / 2.44 mM, R = 4.0) and B) in equilibrium with 
pMβCD/mTHPP ≈ 2 (8.67 mM / 5.56 mM = 1.6). 
 
The 2D NMR ROESY experiments were conducted to determine the structure of the 
inclusion complex formed pMβCD/mTHPP (Figure 54 A), with an estimated stoichiometry of 
two-to-one (2:1) illustrated by the proposed model of inclusion (Figure 54 B).  
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Figure 54. A) 2D NMR ROESY spectrum (25 ºC) of the complex pMβCD/mTHPP (2:1) (8.67 mM / 5.6 mM, R 
= 1.6) in 11 % MeOD-d4 / D2O revealing through-space correlations between βpen and mTHPP, namely: i) two 
set of pyrroles (Py-Hout/in) and with ii) the included phenyl rings (Ph-Hin); B) proposed inclusion model 
following a 2:1 stoichiometry. 
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In complex pMβCD/mTHPP, two pMβCD units approach one mTHPP unit through 
opposite sides and capture two phenyl groups (blue Phin, Figure 54 B), which show strong 
dipolar interactions with CD-H3/H5 (Figure 54 A, ii). pMβCD captures the two opposed phenyl 
groups, through inclusion from the secondary side of the macrocycle which implies that 
pMβCD internal protons (CD-H3/H5) are closer to the pyrrolic protons included (Py-Hin) than to 
those not included (Py-Hout); these show interactions with 3-Me, CD-H3 and CD-H5 (Figure 54 
A, i). 
 
 
CD-mTHPP / pMβCD 
Similarly, to evaluate the effect of adding pMβCD to a CD-mTHPP solution, the 1H 
NMR spectrum of a solution containing pMβCD was gradually recorded, following the addition 
of CD-mTHPP diluted in DMSO. Figure 55 A shows the 1H NMR spectrum of a solution 
containing pMβCD/CD-mTHPP (4.79 mM / 2.49 mM; R = 1.92) and reveals peaks assigned to 
the complex pMβCD/CD-mTHPP (*, Figure 55 A) and a reasonable amount of free pMβCD 
present in solution, when compared to the pMβCD spectrum (Figure 55 B).  
The similarity between the chemical shifts observed for the complex pMβCD/CD-
mTHPP (*, Figure 55 A) and the pure pMβCD complex of the porphyrin (pMβCD/mTHPP, 
Figure 52 A), indicates that both complexes possess similar structural features. Using 
approximately the same ratio (R) between host : guest to prepare both complexes 
(pMβCD/mTHPP, R = 1.6 and pMβCD/CD-mTHPP, R = 1.9), in pMβCD/CD-mTHPP there is 
still an large excess of pMβCD in solution (Figure 55 A), which means that a different 
stoichiometry must be ruling the complexation of pMβCD/CD-mTHPP. The stoichiometry of 
pMβCD/CD-mTHPP complex was determined from the integration of the 1H NMR signals 
(Figure 55 A), namely through integration of the signals in the aromatic region (24 H) attributed 
to Py-H and Ph-H and those in the aliphatic region (7 H), where CD-H3 signal is expected (≈ 3.1 
ppm). The value determined corresponds to a ratio of 24 H : 7.7 H, which is in agreement with 
the expected 24 H : 7 H suggesting a 1:1 stoichiometry, like determined from UV-Vis / 
fluorescence titration experiment. 
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Figure 55. 1H NMR spectra (500 MHz, 25 ºC) recorded in the aliphatic region (2.0 ppm – 6.0 ppm): A) 
pMβCD/CD-mTHPP (4.79 mM / 2.49 mM; R = 1.92 in 4 % DMSO/D2O; B) pMβCD (5 mM) in D2O and C) an 
aromatic region expansion (6.5 – 9.5 ppm). 
 
Additionally, the 1H NMR spectrum of CD-mTHPP in the presence of an excess of 
pMβCD (pMβCD/CD-mTHPP, 4.79 mM / 2.49 mM; R = 1.92, Figure 55 A) reveals extra 
unexpected 1H NMR peaks and features that are not observed for mTHPP (pMβCD/mTHPP, 
8.67 mM / 5.6 mM, R = 1.6, Figure 52 A), even though the concentration of mTHPP (5.6 mM) 
was higher than CD-mTHPP (2.49 mM). The new 1H NMR features comprise: i) small extra 
peaks (blue arrows) and ii) splitting of 3-Me peak (green arrow), both observed in Figure 55 A. 
Likewise, the complex pMβCD/CD-mTHPP revealed a 2D ROESY (Figure 56) with 
similar dipolar correlation peaks, to those observed for the complex pMβCD/mTHPP with a 2:1 
stoichiometry (Figure 54 A), namely: the engulfment of one phenyl ring by the pMβCD 
macrocycle (Figure 56, region ii) and the two set of pyrroles (Py-Hin/out) shifted into to signals, 
due to the approach of pMβCD cavity (Figure 56, region i). The proposed mode of inclusion for 
this 1:1 pMβCD/CD-mTHPP complex is shown in Figure 57.  
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Figure 56. A) 2D NMR ROESY spectrum (25 ºC) of the complex pMβCD/CD-mTHPP (4.79 mM / 2.54 mM, R 
= 1.88) in 4 % DMSO/D2O revealing through-space correlations between βpen and CD-mTHPP, namely: i) 
two set of pyrroles (Py-Hout/in) and with ii) the included phenyl rings (Ph-Hin); B) proposed inclusion model 
following a 1:1 stoichiometry. 
 
In the presence of excessive pMβCD in solution two things can happen, which might 
explain the extra 1H MNR features observed, namely: i) formation of diastereoisomeric forms of 
pMβCD/CD-mTHPP (1:1) complexes (Figure 57), which explains the split in 3-Me peak (green 
arrow, Figure 55 A) or/and ii) formation of other inclusion complexes of higher stoichiometries 
(Figure 58), either through inclusion of one of the remaining phenyl groups in the 1:1, 
pMβCD/CD-mTHPP complex (blue arrows, Figure 55 A) or through the formation of dimers. 
 
 
Figure 57. Diastereoisomeric forms of pMβCD/CD-mTHPP (1:1) complexes: A) cis-pMβCD/CD-mTHPP and 
B) trans- pMβCD/CD-mTHPP. 
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Figure 58. Formation of other inclusion complexes of higher stoichiometries, by attachment of free pMβCD 
units to the complex pMβCD/CD-mTHPP (1:1). Multiple possibilities of approach A)  cis-pMβCD/CD-mTHPP 
and B) trans-pMβCD/CD-mTHPP.  
 
A product of the coupling reaction between 5-(p-aminophenyl)-10,15,20-tris(p-
sulfonatophenyl)-porphyrin and 6-deoxy-6-formyl-βCD, formed a 1:1 complex with pMβCD 
with similar structural features [157]; however, the possibility of other pMβCD complexes has 
never been questioned.  
In conclusion, both mTHPP and CD-mTHPP form stable water soluble, inclusion 
complexes with pMβCD. pMβCD/mTHPP complex follows a well-defined 2:1 stoichiometry; 
whereas pMβCD/CD-mTHPP, follows a major 1:1 stoichiometry but the existence of other 
complexes may not excluded, especially in the presence of excess of pMβCD. Aqueous 
solutions of pMβCD/mTHPP reveal no signs of aggregation enabling NMR experiments using 
concentrations up to 5.6 mM, whereas pMβCD/CD-mTHPP proved soluble in concentrations up 
to 2.5 mM. Additionally, pMβCD/mTHPP (2:1) and pMβCD/CD-mTHPP (1:1) showed very 
large binding constants in the order of 106 M-1 and 1012 M-2 for K(1:1) and K(2:1), respectively. 
These results suggest that in aqueous solution pMβCD is exclusively stationed on the mTHPP 
moiety in CD-mTHPP, leaving the βCD moiety available for further encapsulation of the guest. 
This possibility was studied next using selected guest molecules. 
 
  
75 
5.2.5 Complexation of selected guest molecules 
After enhancing the solubility of CD-mTHPP in 4 % DMSO/D2O, through the use 
pMβCD acting as solubilizer, the complexation studies of selected guest molecules could be 
carried out.  
Given the large binding constant of pMβCD/CD-mTHPP (1:1) K(1:1) = 106 M-1, it is 
expected that once formed, this pMβCD complex of CD-mTHPP is stable enough not to be 
dissociated by any extra pMβCD. Thus, depending on the ratio of CD-mTHPP to pMβCD used 
in the preparation the water-soluble complex pMβCD/CD-mTHPP (1:1), there is always the 
question of knowing if the excess of pMβCD used as solubilizer will compete with the expected 
ability of the water-soluble complex (pMβCD/CD-mTHPP, 1:1), to include and carry suitable-
sized molecules. The presence of pMβCD as solubilizer poses more difficulties regarding the 
evaluation of analysis of inclusion phenomena by NMR spectroscopy, due to the large 
overlapping in the aliphatic region of the spectrum namely where the conjugate internal cavity 
protons (CD-H3/H5) signals are expected (3.2 ppm – 4.9 ppm). Therefore, to evaluate the 
formation of inclusion complexes between complexed CD-mTHPP and any guest molecules, 2D 
NOE experiments will be performed in parallel, both for CD-mTHPP alone and in the presence 
of the guest molecule. 
To assess the availability of the cavity of CD-mTHPP to accommodate suitable guest 
molecules, two model molecules have used: i) 1-adamantanamine (ADA-NH3Cl), followed by 
N-desmethyltamoxifen (NDTAM.HCl) an anticancer drug (tamoxifen, TAM) major metabolite 
molecule. 
 
1-Adamantanamine hydrochloride (ADA-NH3Cl) 
Starting from a clear solution of pMβCD/CD-mTHPP (R = 0.91) prepared in 4 % 
DMSO/D2O, the initial 1H NMR spectrum was recorded (Figure 59 A). Then, ADA-NH3Cl 
(0.36 µmol) dissolved in 4 % DMSO/D2O was added to the solution and a second spectrum was 
recorded (Figure 59 B), followed by 2D NMR experiments. A complete solubilisation was 
achieved during the preparation of the complex pMβCD/CD-mTHPP and after addition of 
ADA-NH3Cl and their characteristic aliphatic: H4/H4’ (1 ppm), H2’/H3 (1.75 ppm) and H2 (2.2 
ppm) (Figure 59 B) could be detected. Given that the intensity of CD-H1 of free pMβCD (5.1 
ppm), does not change after the addition of ADA-NH3Cl the integrity of the complex initially 
formed (pMβCD/CD-mTHPP, R = 0.91) is not affected. Following the addition of ADA-NH3Cl 
to the solution of pMβCD/CD-mTHPP, the fine structure of spectra changed in the region 
between 3.4 ppm – 3.8 ppm, corresponding to the region where the internal protons of 
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pMβCD/CD-mTHPP are expected (blue colour CD-H3/H5, Figure 59 A), which can attributed to 
the inclusion phenomenon. An expansion over the aromatic region (Figure 59 C) reveals a 
complete overlapping and good resolution, indicating that the structure of the inclusion complex 
formed (pMβCD/CD-mTHPP, 1:1) does not changed by the addition of ADA-NH3Cl. 
 
 
Figure 59. 1H NMR spectra (4 % DMSO-d6/D2O, 500 MHz, 25 ºC) of A) CD-mTHPP : pMβCD = (2.21 mM / 
2.00 mM; R = 1.10) and B) after the addition of ADA-NH3Cl (0.36 µmol; 0.71 mM). C) expansion of 1H NMR, 
comprising the aromatic region (6.5 ppm – 9.0 ppm). 
 
To determine if the small changes in the aliphatic region of interest (3.4 ppm – 3.8 ppm) 
are due to complexation of ADA- NH3Cl in the cavity of CD-mTHPP, through-space 
interactions were determined by a 2D ROESY NMR experiment (Figure 60 A). The expansion 
over the region of interest, reveal strong interaction of protons of the base of adamantane moiety 
(H4/H4’) with the internal proton pMβCD/CD-mTHPP (CD-H5). This suggests a preferred 
orientation for the inclusion complex, with the charged amino group (-NH3Cl) facing the 
secondary side of the cavity, with the adamanatane moiety being deeply inserted into the cavity, 
like illustrated by much stronger interaction of cavity proton H3 with all other 1-
adamantanamine protons (Figure 60 B). 
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Figure 60. A) 2D NMR ROESY spectrum (25 ºC) revealing through space intermolecular interactions, 
between CD-mTHPP cavity protons (CD-H3/H5) and ADA-NH3Cl peaks; B) proposed model of inclusion. 
 
Gemcitabine-adamantanamide (GEM-ADA amide)  
GEM-ADA amide prepared in our group (see section 10.3.1) was tested as possible 
guest in a complexation study with CD-mTHPP, in the presence of pMβCD used as a 
solubilizer. A host solution CD-mTHPP : pMβCD (1.14 mM / 1.67 mM, R = 0.68) was 
prepared using an excess of pMβCD. Under these conditions, although the 1H NMR spectrum 
(Figure 61 A) shows no peaks attributed to free pMβCD, the signals (green areas *, Figure 61 
A) due to other inclusion species, possibly involved in solution were observed, once again, in 
the presence of an excess of pMβCD (≈ 1.46 molar excess). The identity of the signals was 
corroborated by 2D NMR ROESY experiment. After addition of GEM-ADA amide in excess (≈ 
2 molar eq.) to this solution (4 % DMSO/ D2O), it was observed that GEM-ADA is poorly 
water-soluble and to ease its solubilisation, the solution was sonicated and vortexed before the 
1H NMR and 2D NMR experiments were conducted to evaluate complexation equilibrium. The 
typical 1H NMR spectrum of pMβCD/CD-mTHPP, after addition of GEM-ADA amide 
revealed: i) the peaks corresponding to the adamantane moiety, between 2.0 ppm – 1.0 ppm 
(blue circle, Figure 61); ii) the aromatic protons of the pyrimidine ring (blue H5/H6) as well as 
iii) the hydroxyl groups (-OH) of the pentose unit, in position 3’ and 5’ of the in GEM-ADA 
amide shown in the expansion (Figure 61 C). 
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Figure 61. 1H NMR spectra (4 % DMSO-d6/D2O, 500 MHz, 25 ºC) of A) CD-mTHPP / pMβCD (1.11  mM / 
1.67 mM; R = 0.68) and B) after the addition of an excess of GEM-ADA amide (1.20 µmol; 2.45 mM) and C) 
an expansion comprising the aromatic region (5.0 ppm – 9.0 ppm). 
 
The 2D ROESY NMR experiment performed (Figure 62 A) revealed through-space 
interactions, between pMβCD/CD-mTHPP internal protons (CD-H3/H5, 3.6 ppm – 3.8 ppm) and 
GEM-ADA amide. The strong off-diagonal contours suggest the formation of inclusion 
complexes, with ADA moiety in GEM-ADA amide (blue circle, Figure 62 A) being deeply 
inserted into CD-mTHPP cavity, interacting with CD-H3/H5 internal protons of the conjugate. 
The proposed model of inclusion suggests a similar mode of interaction to that shown by 
pMβCD/CD-mTHPP and ADA-NH3Cl. Additionally, 2D experiments applied to the structural 
characterization of GEM-ADA amide suggested that ADA moiety is spatially distant from the 
pentose and pyrimidine moieties, which corroborates the proposed geometry of inclusion 
involving the insertion of ADA moiety into CD-mTHPP cavity of the complex pMβCD/CD-
mTHPP (1:1) (Figure 62 B). 
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Figure 62. A) 2D ROESY NMR spectrum (500 MHz, 25 ºC) revealing through space intermolecular 
interactions, between CD-mTHPP cavity protons (CD-H3/H5) and GEM-ADA amide peaks; B) proposed 
model of inclusion. 
 
N-desmethyltamoxifen hydrochloride (NDTAM.HCl) 
N-desmethyltamoxifen hydrochloride (NDTAM.HCl) is a major metabolite of the 
anticancer drug tamoxifen (TAM), whose properties are reviewed in section 6.1. CD-mTHPP 
ability to include NDTAM.HCl was evaluated in 4 % DMSO/D2O in the presence of pMβCD 
acting as solubilizer. Although, NDTAM.HCl has improved solubility comparatively to TAM, 
due to the strong red colour of pMβCD solutions of CD-mTHPP it was difficult to evaluate 
visually the complete solubilisation of NDTAM.HCl of its addition to a pMβCD/CD-mTHPP 
solution. The ideal compromise would be reached through the addition of only the right amount 
of free pMβCD, matching the exact stoichiometric ratio resulting in: i) the complete 
solubilisation of CD-mTHPP; ii) ensure that all pMβCD in solution is complexed with the 
conjugate and there is no free pMβCD able to interact with the guest molecule (NDTAM.HCl) 
and finally, iii) this would maximize the inclusion of NDTAM.HCl by the soluble complex 
pMβCD/CD-mTHPP 
Therefore, a series of trials using different ratios of CD-mTHPP, pMβCD and 
NDTAM.HCl have been performed to judge the complexation / inclusion of NDTAM.HCl in 4 
% DMSO/D2O (Table 5). 
 
1H NMR spectrum of pMβCD : CD-mTHPP (1.96 mM : 1.06 mM : R = 1.83) in 4 % 
DMSO/D2O (Figure 63 A) shows that: i) in the aliphatic region (3.0 ppm – 4.0 ppm), there is a 
big overlap between protons of free pMβCD (*, Figure 63 A) used in excess, and the signals of 
complex pMβCD/CD-mTHPP. This solution was red coloured and visually showed no signs of 
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aggregation, corroborated by the very well-resolved spectrum in the aromatic region (6.0 ppm – 
9.0 ppm, Figure 63 C) (Trial # 1, Table 5).  
However, to avoid the excess of pMβCD in solution, more CD-mTHPP (0.40 µmol) 
was gradually added as a solid, until no 1H NMR signals corresponding to free pMβCD were 
observed. Unfortunately, the increase in concentration of conjugate from 1.06 mM to 1.86 mM, 
lead to cloudiness in the solution which is due to the poor solubility of CD-mTHPP in 4 % 
DMSO/D2O (Trial # 2, Table 5). This was corroborated by extra experiments, where the 
addition of CD-mTHPP as a solid to an aqueous solutions of pMβCD resulted in precipitation, 
which was not observed if CD-mTHPP was added prior to an initial solubilisation in DMSO. In 
the presence of a large excess of CD-mTHPP with respect to pMβCD (2.32 mM : 0.66 mM : R 
= 3.51), the solution immediately precipitates and a 0.45 µm filter had to be used to remove 
most of insoluble material and clarify the solution (trial # 4, Table 5), The addition of 
NDTAM.HCl (0.51 µmol) to the clear solution resulted in cloudiness (trial # 5, Table 5), which 
indicated that NDTAM.HCl by itself shows limited solubility in solutions of pMβCD/CD-
mTHPP in 4 % DMSO/D2O. 
 
Table 5. Ratio of CD-mTHPP, pMβCD and NDTAM.HCl used in the preparation of solutions for NMR 
experiments to test inclusion of NDTAM.HCl in CD-mTHPP. Total volume of NMR tube 0.5 mL. 
# Trial CD-mTHPP 
n (µmol), A 
pMβCD 
n (µmol), B 
NDTAM.HCl 
n (µmol) R (B/A) Notes / Observations 
1 0.53 0.98 - 1.83 Clear solution 
2 0.93 0.98 - 1.05 Addition of CD-mTHPP / Cloudiness 
3 0.93 0.98 0.43 1.05 Precip. 
4 1.16 0.33 - 0.28 Heavy Precip. / Filtration 
5 1.16 0.33 0.51 0.28 Cloudiness 
 
Figure 63 B (trial # 3) shows the 1H NMR spectrum of trial # 2 after addition of 
NDTAM.HCl (0.43 µmol), which resulted in cloudiness. NDTAM.HCl signals are observed in 
the aromatic region of the spectrum (6.8 ppm – 8.0 ppm), with peaks corresponding to the 
phenyl rings aromatic protons (Ph-Ha/b/c) indicated as black arrows in Figure 63 C. Therefore, 
even though different ratios of pMβCD/CD-mTHPP are used to prepare clear solutions, the 
addition of NDTAM.HCl results in cloudiness. 
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Figure 63. 1H NMR spectra (4 % DMSO- d6/D2O, 500 MHz, 25 ºC) of CD-mTHPP / pMβCD A) before (# trial 
1, Table 5); B) after the addition of NDTAM.HCl (# trial 3, Table 5) and C) an expansion comprising the 
aromatic region (5.0 ppm – 9.0 ppm). 
 
The inclusion complex formation of pMβCD/CD-mTHPP with NDTAM.HCl is 
expected to occur through interaction of the protons of βCD cavity of CD-mTHPP and the 
phenyl rings (Ph-Ha/b/c) of NDTAM.HCl. Additionally, the inclusion is expected to occur 
through the secondary side of the CD unit and chemical shift differences (shielding of the inner 
protons CD-H3/H5) is expected. Besides, previous work in our laboratory has shown that 
NDTAM forms a strong enough complex with native βCD (K = 7 x 103 M-1) via tritopic binding 
i.e. inclusion of each of the phenyl rings (Ph-Ha/b/c) in the cavity of βCD at any time [141]. 
Due to big overlap in the aliphatic region of spectrum (3.4 ppm – 3.8 ppm), where the 
internal protons of cavity of the conjugate in the complex are expected, this region is indicated 
in blue CD-H3/H5 in Figure 63 A. 
Therefore, 2D HSQC NMR spectrum was used to determine and compare the chemical 
shifts differences of CD-H3/H5 of the conjugate in pMβCD/CD-mTHPP, righ before (trial # 4, 
Table 5) and immediately after the addition of the NDTAM.HCl (trial # 5, Table 5). The 
comparison between 2D HSQC spectra before (Figure 64 A, i) and after the addition of 
NDTAM.HCl (Figure 64 A, ii) revealed that the signals corresponding to complexed pMβCD 
(CD-H6’/CD-H3/CD-H4) and the only peaks changing are those attributed to the complexed 
conjugate conj (CD-H6’/CD-H3/CD-H4). Furthermore, the two internal protons revealed 
significant shielding (blue boxes, Figure 64 A), which agrees with the formation of an inclusion 
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complex between NDTAM.HCl phenyl moieties and the conjugate pMβCD/CD-mTHPP 
internal protons, namely: CD-H3 (shielded, 0.06 ppm) and CD-H5 (shielded, 0.106 ppm). 
 
 
Figure 64. 2D experiments in 4 % DMSO- d6/D2O of pMβCD/CD-mTHPP: A) 2D NMR HSQC spectra (25 ºC) 
in the presence of NDTAM.HCl (ii, trial # 5) and in the absence of it (i, trial # 4); and B) 2D NMR NOESY 
spectra (25 ºC) in the presence of NDTAM.HCl (i, trial # 2) and in the absence of it (ii, trial # 3). 
 
Likewise, 2D NOESY experiments was performed to judge any dipolar interactions 
after addition of NDTAM.HCl, comparing solutions prior to (trials # 2, Figure 64 B ii) and after 
the addition of NDTAM.HCl (trials # 3, Figure 64 B i). The signals detected in the aromatic 
region are attributed to phenyl rings of NDTAM.HCl show one correlation with one of 
pMβCD/CD-mTHPP internal cavity protons (CD-H3 or CD-H5). Assuming that CD-H3 is 
closest to the secondary rim of βCD than CD-H5, the strongest signal would be primarily due to 
interactions with CD-H3, which from the 2D ROESY corresponds to a chemical shift of ≈ 3.72 
ppm. Consequently, from the 2D HSQC the chemical shifts observed earlier, are attributed to 
CD-H3 (≈ 3.8 ppm) than for CD-H5 (≈ 3.5 ppm), the protons of the conjugate involved in 
complexation. 
This experiment showed that NDTAM.HCl although is poorly soluble in 4 % 
DMSO/D2O solution, can be solubilised using pMβCD/CD-mTHPP. Inclusion complexes are 
formed between NDTAM.HCl and the cavity of the conjugate in the complex, which can 
potentially result in a suitable drug delivery system for the delivery of TAM derivatives to 
cancer cells. 
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5.2.6 Cell internalization of pMβCD/CD-mTHPP 
An important pre-requisite for an effective therapeutic effect of a specific drug is its 
ability to get in contact with the affected tissue or organ, either by systemic administration or 
more recently through active or passive targeting. Thus, the evaluation of cell inclusion is an 
important biological parameter to determine if: i) the molecules cross the biological membranes 
and reach the desired target tissue, ii) if it targets a specific cell compartment. Confocal 
microscopy can be used successfully to determine cell internalization or even the specific 
localization of molecules into different cell compartments and for this purpose, it relies on the 
fluorescence properties of suitable fluorescence dyes [160]. The use of porphyrins, or porphyrin 
related compounds like CD-mTHPP, in cell experiments offers the potential advantage of good 
photophysical properties (fluorescence) that enables easy detection by confocal spectroscopy 
without the need to use additional fluorescence dyes. However, this is hardly the case because 
of limited aqueous solubility of porphyrins and their conjugates, which impairs most of these 
applications. Recalling CD-mTHPP synthesis, the successful use of pMβCD as efficient 
solubilizer and its ability to complex relevant guest molecules it is important to assess if: CD-
mTHPP on its own and upon complexation with pMβCD is able to cross cellular membranes 
and be localized specifically in one or more cell compartments. 
Confocal microscopy was used to record images of cells exposed to the solutions with 
the compounds (CD-mTHPP and pMβCD/CD-mTHPP) incubated at 37 ºC with an atmosphere 
saturated in 5 % CO2. Two cell lines were tested: i) a breast cancer cell line MCF7 and ii) a 
prostate cancer cell line DU145 incubated for different time intervals (3h – 15 h). Two different 
media were used, namely phosphate buffered saline (PBS) and Roswell Park Memorial Institute 
medium (RPMI3). 
In the first experiment cell internalization trial was performed in MCF7 cells, incubated 
for 3 h in PBS in the presence of CD-mTHPP (10 µM) revealed poor internalization. The 
presence of 0.45 (Table 6 B) and 1.00 molar eq. of pMβCD, even when laser intensity was set at 
100 % to record the pictures, the results were not satisfactory. However, when CD-mTHPP (10 
µM) used alone (Table 6 A), a small improvement was noticed and small red fluorescent dots 
were observed.  
In a second trial DU145 cells were incubated for 15 h and pictures were recorded using 
a laser intensity set at 30 %. In PBS, with CD-mTHPP (8 µM) showed some cells 
internalization. The observed dotted fluorescence implied lysosomal or endosomal localization 
and not diffuse cytoplasmic dispersion (Table 6 C). Additionally, the plates revealed good cell 
density after 15 h incubation period, indicating that the dark toxicity, if any, should be very 
small. There was an improvement in the cell internalization of CD-mTHPP (8µM), when 
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DU145 cells are incubated in the presence of 0.5 molar eq. of pMβCD (Table 6 D). However, 
when DU145 are incubated for the same period in RPMI in the presence of CD-mTHPP (8 µM), 
better internalization was revealed qualitatively corresponding to intense dotted red 
fluorescence. Cell density during observations revealed that DU145 cells were not affected by 
the conditions used and dark phototoxicity should remain within acceptable levels in RPMI 
(Table 6 E). Interestingly, in the presence 0.5 molar eq. of pMβCD added to CD-mTHPP (8 
µM), dotted and intense red fluorescence always restricted to dotted structures was observed 
and these pictures were preferred (Table 6 F). 
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Table 6. Confocal pictures of cell internalization experiments: A) MCF7, CD-mTHPP (10 µM, PBS), 3 h (laser: 
100 %); B) like A) in the presence of 0.45 molar eq. of pMβCD; C) DU145, CD-mTHPP (8 µM, PBS), 15 h 
(laser: 30 %); D) like C) in the presence of 0.50 molar eq. of pMβCD; E) DU145, CD-mTHPP (8 µM, RPMI), 
15 h (laser: 30 %); F) like E) in the presence of 0.50 molar eq. of pMβCD (molar eq. = molar equivalent). 
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5.3 Conclusions and future perspectives 
In this chapter, it was shown that the pure CD-mTHPP conjugate revealed good 
properties acting as a bimodal molecular carrier. pMβCD used in stoichiometric amounts 
enhances the water solubility of CD-mTHPP, through the formation of completely water-soluble 
complexes following a defined 1.1 stoichiometry. 
The addition of an equimolar amount of pMβCD to solutions of CD-mTHPP (2 µM, 4 
% DMSO/PBS, pH = 7.4) resulted in 1.6-fold increase of UV-Vis absorbance and a 8-fold 
increase in fluorescence emission spectroscopy. The use of an excess of pMβCD enables the 
preparation of concentrated solutions of CD-mTHPP (≈ 2.5 mM) suitable for structural analysis 
with no visual sign of aggregation. mTHPP was used as a model compound and similar 
improvements were observed, but a 2:1 stoichiometry was ruling the slow equilibrium between 
pMβCD and mTHPP. In both cases, pMβCD was anchored on mTHPP moiety, leaving the βCD 
cavity of CD-mTHPP free for inclusion. 
Indeed, successful inclusion experiments of CD-mTHPP in the presence of the model 
compound 1-adamantanamine (ADA-NH3Cl) revealed that the cavity of CD-mTHPP in the 
complex with pMβCD is available for inclusion with other molecules. Anticancer drug 
molecules, derivatives of tamoxifen (NDTAM.HCl) and of gemcitabine (GEM-ADA amide) 
proved successful guest molecules included into the cavity of pMβCD/CD-mTHPP. The 
complexes, once formed, were not affected by the presence of excess of pMβCD in aqueous 
buffered solution (4 % DMSO/PBS, pH = 7.4), indicating the very high strength of binding. 
Indeed, the binding constants (K) for pMβCD/CD-mTHPP 1:1 complex was  K(1:1) ≈ 3.8 x 106 
M-1 and for the pMβCD/ mTHPP 2:1 was K(2:1) ≈ 4.9 x 1012 M-2.  
Finally, CD-mTHPP reveal good cell DU145 internalization properties, when incubated 
for a long period of time (15 h) using diluted solutions (8 µM – 10 µM) prepared in RPMI. CD-
mTHPP crossed the cell membrane, reached the cytoplasm and localized inside intracellular 
compartments. However, in the presence of ½ molar equivalent of pMβCD the intensity of the 
fluorescence emission was increased suggesting that the use of pMβCD may allow increase of 
administered concentration of CD-mTHPP, alone or in a complex with suitable drug, thereby 
improving the delivery properties in aqueous media. The empty cavity of the βCD unit in the 
nanoaggregate (CD-mTHPP) has been previously shown [144] to accommodate the nitrous oxide 
(NO) photodonor guest, thereby forming a supramolecular aggregate with diameter of about 16 
nm, which preserved the fluorescence of the porphyrin core and was able to generate nitric 
oxide and singlet oxygen under illumination with visible light, conferring combined 
phototoxicity to cells, in agreement with the results presented here. 
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6. Modifications on selected anticancer drugs as guest molecules 
6.1 Introduction 
The discovery of new chemical entities (NCEs) is not as successful as it was in the 
beginning of the XIX century and currently, fewer NCE do actually reach the market. Currently 
drug discovery programs focus on identification of specific molecular targets, like enzymes, 
involved in critical biological activities and on the ability to design molecules (drugs) that 
interact with these specific targets by blocking its action. [161, 162]. 
Therefore, in an early stage of any formulation, the modulation of physicochemical 
properties of many NCEs can be achieved through proper chemical modification. An example 
of a critical property of any drug is its water-solubility that is related to bioavailability of the 
drug. It was estimated that 50 % of all the drugs approved for use as medicine display low 
aqueous solubility and most of the drugs administered orally, belong to class II (high 
permeability, low solubility) and class IV (low permeability, low solubility) of 
biopharmaceutical classification system (BCS) [163, 164].  
Thus, a common challenge addressed by pharmaceutical technology is to find strategies 
to overcome the lack of water solubility of commonly administered drugs [165]. Reformulating 
any existing marketed drug should be cheaper, faster and safer than the effort considered for any 
NCE, as much of the information about the drug and biological effects are already known and 
can be used in advance [166]. Alternatively, direct chemical modifications of the structure of 
drugs may result in the modification of their physicochemical properties such as solubility. 
In this chapter, one will explore the chemical modification of two drugs routinely used 
in cancer treatment (tamoxifen, TAM) and gemcitabine (GEM). The purpose of these chemical 
modification is: i) to increase the aqueous solubility of TAM, through preparation of of 
tamoxifen citrate salt (TAM-Cit) and one of its biological active metabolites, N-
desmethyltamoxifen (NDTAM.HCl); ii) to prepare a starting material (NDTAM.HCl), suitable 
for chemical attachment to a fluorescence dye (fluorescein, FITC) resulting in NDTAM-FITC 
useful for cellular localization / distribution studies conducted by confocal microscopy; and, iii) 
preparation of and gemcitabine (GEM) attached to an adamantane (ADA) moiety tailored for 
complexation studies with CD-mTHPP and CD-polymers. 
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6.2 Results and discussion 
6.2.1 Preparation of tamoxifen derivatives 
Tamoxifen 
Cancer is associated with unusual growth of living cells in an organism. Many forms of 
breast cancer are a result of wrong signalling messages sent by sex hormones like estrogens. 
Estrogens are responsible for breast growth in women during puberty and they are delivered to 
the cells by serum proteins in blood. Once inside the cell, estrogens enter the cell nucleus and 
bind to a complex receptor protein (estrogens receptor), which then enables the synthesis of a 
protein involved in breast growth [167]. 
Tamoxifen (TAM) is an anticancer drug, very specific in its action. TAM exists in two 
different isomeric forms: E-isomer (cis-TAM) and Z-isomer (trans-TAM) [168]. E-isomer has 
agonist properties and only the Z-isomer of tamoxifen has pharmacological relevant properties 
acting as an antagonist of estrogens, i.e. it acts as a selective estrogen receptor modulator 
(SERM) compound. 
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Figure 65. Structure of (Z)-tamoxifen and (E)-tamoxifen isomers and of (Z)-tamoxifen active liver metabolites: 
N-desmethyltamoxifen hydrochloride (NDTAM.HCl), tamoxifen-N-oxide (TAM-N-oxide) and 4-
hydroxytamoxifen (4-OH-TAM). 
 
Once inside the body TAM is converted into its active metabolites: 4-
hydroxytamoxifen; N-desmethyltamoxifen (NDTAM) and tamoxifen-N-oxide (Figure 65) that 
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revealed enhanced affinity in the prevention of cancer, by blocking the specific site (estrogen 
receptors) competing with the natural hormone (estrogen) [168]. The water solubility of tamoxifen 
is very limited (0.1 mg/L, 20 ºC) [169] and its citrate salt is commercially used instead, due to its 
improved solubility (0.3 mg/L; 20°C) [170]. Commercial, tamoxifen citrate is sold as Novaldex® 
used in therapy for hormone receptor-positive breast cancer in pre-menopausal women. 
 
Tamoxifen citrate (TAM-Cit) 
The first approach to modify the TAM molecule by preparing its citrate salt was based 
on a reported procedure [171]. In their work it was described the formation of citrate salt (TAM-
Cit) in a 2:1 or in a 1:1 stoichiometry. This suggested the possibility of isolating TAM-Cit, with 
varying stoichiometries because the commercially available TAM-Cit sold by Sigma-Aldrich 
shows a 1:1 stoichiometry [170].  
In our hands, the reaction took place in acetonitrile (ACN) using approximately a two-
fold molar excess of citric acid and the product was isolated directly from the solution, as it 
precipitates as a white solid - Figure 66. 
 
Figure 66. Synthesis of TAM-Cit (2:1) from the reaction of TAM with citric acid in acetonitrile (ACN). 
 
The isolation and purification of the product involved extensive washings of the white 
solid with water, to take advantage of the difference in aqueous solubility between citric acid 
(CA) and TAM-Cit. Thus, it is expected that in the presence of a large excess of H2O, mostly 
the unreacted citric acid (used in excess) will be washed away from the crude solid, leaving 
behind any insoluble material namely TAM-Cit.  
The product TAM-Cit was prepared in a 63 % yield and was characterized by IR and 1H 
NMR spectra in CDCl3. In the aromatic region (7.0 ppm – 8.0 ppm) the compound displayed all 
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the signals from the TAM core. The assignment was straightforward and is shown in the 
appendix (Figure 120). The citrate moiety shows only one signal (≈ 2.8 ppm – 2.9 ppm) 
corresponding to the two methine groups in citric acid. Integrating the signal after careful data 
acquisition afforded a ratio TAM-Cit salt in a typical 2:1 stoichiometry. The comparison 
between IR spectrum of TAM-Cit and TAM, reveals that in TAM-Cit an extra peak at 1722 cm-
1
 characteristic of a carboxylic acid attributed to the citrate moiety, shown in appendix (Figure 
121).  
TAM-Cit (2:1) was successfully used in our group as guest molecule in several studies 
with CDs [172]. Additionally, the purification method developed, based solely on washings with 
water, illustrates a cheap and attractive way of obtaining a pure TAM derivative. 
 
N-desmethyltamoxifen hydrochloride (NDTAM.HCl) 
The second strategy to modify the chemical structure of TAM, dealt with a 
demethylation of the tertiary amine in TAM structure, to obtain N-desmethyltamoxifen 
hydrochloride (NDTAM.HCl). The synthetic procedure was based on the procedures described 
by Olofson [173] with some modifications implemented [174, 175]. The mechanism of demethylation 
of tertiary amines has been described elsewhere [176] and is shortly presented in Figure 67. 
 
Figure 67. Mechanism of demethylation of amines using alkyl chloroformates. 
 
It involves the use of a highly reactive species (α-chloroethylchloroformate) that is 
susceptible to nucleophilic attack by the tertiary amine resulting in the elimination of a methyl 
group as a chloroform molecule. The carbamate intermediate is subsequently decomposed by 
heating in methanol to the secondary amine hydrochloride. The structure of α-
chloroethylchloroformate is very similar to that of 2,2,2-trichloroethylchloroformate, which as 
been used in the demethylation of tertiary methylamines [ 177 ]. The reaction proceeded by 
solubilising NDTAM.HCl in toluene at 0 ºC, followed by the addition of α-
chloroethylchloroformate and refluxing the mixture, with periodic monitoring of reaction 
progress by TLC using CH2Cl2 : MeOH : NH3 (95/5/0.3) as mobile phase, against an authentic 
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sample of NDTAM.HCl used as a standard. The reaction reached completion in ≈ 8 h and the 
product precipitated from the crude mixture, when poured directly into an excess of diethyl 
ether (EtOEt) (Figure 68).  
 
 
Figure 68. Synthesis of NDTAM.HCl from the reaction of TAM in refluxing toluene, using α-
chloroethylchloroformate. 
 
The overall yield of the reaction was 50 % and the product was characterized by NMR, 
IR spectroscopy and TLC. 1H NMR spectrum in of NDTAM.HCl MeOH-d4 (Figure 69), 
revealed a clean product free from impurities and the integration of methyl group (position 5, 
NDTAM.HCl in Figure 68 attached to the nitrogen atom) accounted for 3 H (≈ 2.67 ppm) 
corresponding to one methyl group, as expected. This is the only difference with respect to 
TAM spectra, where for the same resonance 6 H are expected, corresponding to two methyl 
groups. The identity of the sample was verified against a commercial sample of NDTAM.HCl 
(Sigma-Aldrich), both by IR spectroscopy and by TLC: the overlaid IR spectra of commercial 
sample and NDTAM.HCl obtained, revealed a complete matching in all regions of the spectra 
(appendix, Figure 117). 
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Figure 69. 1H NMR spectrum (500 MHz, MeOD-d4, 25 °C) of NDTAM.HCl. 
 
In the literature, the preparation of NDTAM was described following at least three 
different procedures: In the first approach, TAM was solubilised in dichloroethane, in the 
presence of α-chloroethylchloroformate and was refluxed for 24 h. The crude mixture was then 
refluxed in MeOH for 3 h and the product was obtained from the residue, by recrystallization 
from EtOH and Et2O to give NDTAM (86 % yield) [174]. The second procedure described used 
refluxing dichloromethane (boiling point, bp ≈ 40 ºC) for 24 h to obtain an oil, which was then, 
refluxed in MeOH for extra 3 h followed by column chromatography affording NDTAM (91 % 
yield) [178]. Alternatively, TAM was refluxed in toluene (bp ≈ 111 ºC) in the presence of 2,2,2-
trichloroethylchloroformate and potassium carbonate. After 4h, the reaction was stopped to 
isolate the carbamate intermediate. This intermediate was stirred overnight in diglyme, acetic 
acid and zinc. Column chromatography was used followed by recrystallized from heptane to 
afford NDTAM (77 % yield) [174]. 
Although the yields reported are reasonably good these methodologies failed to 
distinguish if the actual product isolated is NDTAM.HCl or NDTAM. All of them involved 
refluxing MeOH to break the carbamate leading to the formation of the corresponding 
demethylated amine. Additionally, in the first approach, the only one avoiding column 
chromatography, is not clear in the description what solvent was used: 1,1-dichloroethane or 
1,2-dichloroethane. Probably, the use of higher boiling point 1,2-dichloroethane (≈ 84 ºC) as 
opposed to 1,1-dichloroethane (bp ≈ 57 ºC), would ease the release of CO2 during the reaction, 
thus avoiding the use of chromatographic methods and enabling the isolation of NDTAM by 
recrystallization. 
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In our hands, using the low boilng point CHCl3 at reflux (bp ≈ 61 ºC) the reaction did 
not progress as the product was isolated in the presence of many impurities, after 72 h including 
MeOH reflux for 1 h. Column chromatography and even preparative plate chromatography were 
of no use, since it resulted in isolating NDTAM.HCl and many impurities. A critical point for 
the monitoring of the reaction progress towards the desired product was the use of TLC and a 
mobile phase composed of CH2Cl2 : MeOH : NH3 (95:5:0.3, v/v), which enabled the distinction 
between: fast moving impurities (RF = 0.94) or intermediate formed (carbamate), TAM (RF = 
0.32), the product identified using a commercial sample (RF = 0.08) of NDTAM.HCl and non-
moving impurities (RF = 0) (Figure 70). Our successful strategy was to use a high boiling 
solvent (toluene) for an extended period of time (≈ 19 h / overnight) thus avoiding the need of 
methanol reflux step and proceed directly to the precipitation of NDTAM.HCl from EtOEt, 
isolated as a white solid of very good purity. In conclusion, demethylation of TAM using 1-
chloroethylclhoroformate in refluxing toluene could be carried out in a simple procedure, 
compared to previously reported. 
 
 
Figure 70. TLC monitoring of the demethylation reaction of TAM to obtain NDTAM.HCl. From left to right: 
i) commercial sample of NDTAM.HCl (NDTAM); ii) starting-material (TAM); iii) incomplete reaction after ≈ 
4h and iv) complete reaction after (19 h, no TAM left to react). 
 
NDTAM.HCl was used as guest molecule in complexation studies reported by our 
group [172] and additionally to react with fluorescein (isothiocyanate, FITC) in order to obtain 
NDTAM-FITC to study intracellular delivery and fate (see section 10.3.4). In addition, the 
method developed by our group presents a cheap and easy way of obtaining from affordable 
starting materials a very expensive TAM derivative. 
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Fluorescein labelling of NDTAM (NDTAM - FITC) 
The preparation of NDTAM-FITC in our group previously relied on commercial 
samples of NDTAM.HCl as starting material. This posed a big problem in the developments of 
this specific synthetic procedure: the high price of starting material NDTAM.HCl limited all 
small-scale trials, which in turn limited complete optimization of the purification procedures. 
However, after the successful synthesis of NDTAM.HCl described earlier (see section 10.3.2), 
more material was available and therefore more trials could be performed and different 
purification strategies explored. 
A general reaction explored in our group was the reaction between amines (R1-NH2) 
and isothiocyanate (R2-N=C=S), to form thioureas (R1-NH-C(=S)-NH-R2). This kind of 
reactivity is greatly explored to link biologically relevant samples to several fluorescence probes 
and these have found wide applications in chemical biology specifically in:: immunochemistry; 
fluorescence in situ hybridization (FISH); cell tracing; receptor labelling; fluorescent analog 
cytochemistry and fluorescence resonance energy transfer (FRET) [179]. 
In our group, the procedure to attach a molecule of NDTAM.HCl to isothiocyanate 
moiety in fluorescein isomer 1 (FITC) was tried previously [180]. This procedure had a series of 
limitations associated with the low yield and the non-reproducibility in the preparation 
regarding the purity of the NDTAM-FITC. Therefore, the method for preparation and isolation 
of NDTAM-FITC should be revised. The general procedure involved the solubilisation of FITC 
in EtOH, followed by addition of NDTAM.HCl and N,N-diisopropylethylamine (DIPEA) to 
neutralize the salt. The reaction proceeded for 44 h at 40 ºC. The residue was dried and applied 
to a preparative TLC plate. NDTAM-FITC was isolated in 60 % yield, corresponding to the 
second band (RF = 0.77) isolated from the preparative plate (Figure 71). 
 
 
Figure 71. Synthesis of NDTAM-FITC from reaction of NDTAM.HCl with FITC in EtOH, to form a thiourea 
linkage. 
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FITC has been successfully attached to primary amines exploring the same kind of 
chemical connectivity – formation of thiourea linkage. FITC has been connected to 
octadecylamine, in anhydrous THF, at 60 ºC in 3 h but no details on the purification method 
used were given [ 181 ]. Moreover, in another example, FITC was connected to randomly 
deacetylated chitosan polymer (50 %), in water at neutral (pH = 6.9), at room temperature (not 
specified) for 24h, but no reference is made to difficulties faced with solubilisation of FITC in 
water. Additionally, the isolated fraction corresponded only to 6.6 % (m/m) probably due to 
inefficient mixture of the reactants [182]. 
 
 
Figure 72. 1H NMR spectra (MeOD-d4, 500 MHz, 25 ºC) of i) NDTAM-FITC (2nd band scrapped from TLC 
plate B); ii) NDTAM.HCl and iii) FITC; B) inset picture, illustrates separation by preparative 
chromatography. 
 
In our hands, using the fluorescent dye (FITC, yellow coloured) as a raw material 
means that at any stage the solution is always deeply coloured and poses a challenge to any 
separation/purification technique. TLC was used for monitoring the progress of reaction, but 
was of little use because there was no clear separation between spots, although various mobile 
phases have been used. Other trials involved the use of column chromatography, but with no 
success for similar reasons. However, an efficient method to purify this mixture of products  
was achieved through the application of small amounts of untreated crude (right after the 
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reaction), directly to a preparative plate (≈ 12 mg / 20 cm x 20 cm plate, silica gel, 500 µm 
thickness) solubilised in MeOH or in mobile phase CHCl3/MeOH (3:1), which was the eluting 
solvent system. Five different bands were successfully isolated and through 1H NMR analysis, 
the target compound was identified corresponding to the second (2nd) fluorescence band isolated 
(NDTAM-FITC, RF = 0.77, Figure 72 B). All of the other coloured bands (1st, 3rd, 4th, 5th), 
corresponded to undesired fluorescent impurities and were discarded afterwards. The overall 
yield of the separation is ≈ 60 % (m/m) and ≈ 80 % purity estimated from the average of NMR 
integration of NDTAM.HCl (H1, H2, H3) with respect to FITC (Ph-Hx; 7.9 ppm: ≈ 1.6 H) 
considering the expected ratio Ph-Hx/H1/2/3 (Figure 72 A). 
Thus in our group perspective and considering that previously isolated NDTAM-FITC 
batches were not purified [180], the development of this purification method is important because 
this purified compound can now be applied in current / future works developed in our group.  
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6.2.2 Preparation of a gemcitabine derivative 
Gemcitabine (GEM) 
Gemcitabine (2,2’-difluorodeoxycytidine, dFdC or GEM) is a potent anticancer 
nucleoside drug analogue of deoxycytidine monophosphate (dCMP), a deoxyribonucleoside that 
is a component of deoxyribonucleic acid (DNA). dCMP is similar to ribonucleoside cytidine 
monophosphate (CMP), but with one hydroxyl group removed from the 2' position of the 
pentose unit. In GEM the hydrogens in position 2’ of dCMP are substituted by fluorine, as 
displayed in Figure 73.  
 
 
Figure 73. Chemical structure of gemcitabine (GEM), deoxycytidine monophosphate (dCMP) and 
ribonucleoside cytidine monophosphate (CMP) 
 
GEM hydrochloride salt is marketed as Gemzar® (ELI Lilly) and is used in 
chemotherapy treatment of pancreatic and non-small lung cancer and other solid tumours. After 
intravenous administration, GEM is activated by deoxycytidine kinase (dCK) to its 
phosphorylated forms (GEM mono-, di-, and triphosphate nucleotides), following sequential 
phosphorylation steps. The active metabolites are then responsible for the anticancer activity of 
this drug, which comprises inhibition actions by competing with dCTP on DNA synthesis in 
rapidly divided cells. GEM is also deaminated to its inactive uridine metabolite (dFdU) by 
deoxycytidine deaminase and this presents a serious drawback [183], because it inactivates the 
drug. Thus, the drug displays poor bioavailability and efforts to increase GEM biological 
stability towards deamination have been focused on chemical modification at the drug, 
involving reactions on two different sites, namely on the pyrimidine (4-N-site) and on the 
pentose (5’-site) (Figure 73) [184].  
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The preferred modification involves the coupling of the amine (GEM) with a carboxylic 
acid (R2-COOH) to obtain an amide bond (GEM-NH-CO-R2), preferred to the ester derivatives 
because is of its improved stability regarding chemical and enzymatic hydrolysis [185]
. 
This 
modification will produce a pro-drug with improved plasma lifetime after administration. Our 
aim has been to prepare an amide GEM prodrug that would be readily captured by βCD cavity 
for delivery. 
 
 
Gemcitabine-adamantanamide (GEM-ADA amide) 
The attachment of adamantyl (ADA) moiety into a gemcitabine (GEM) molecule is 
interesting from our perspective for two main reasons: firstly, the successful incorporation of an 
ADA moiety into GEM molecule, through an amide bond protects the unstable 4-N-site of 
GEM against undesired in vivo reactions (Figure 73). Secondly, ADA possess the exact 
geometry that fits βCD cavity forming a strong inclusion complex with estimated K > 104 M-1 
[186] and has been extensively studied as model guest in complexation with βCD derivatives [187]. 
Additionally, one is also interested in the preparation / application of CD-based polymers with 
cell-penetrating properties and GEM-ADA would be a suitable guest molecule to test with 
polymer carriers, given the potential increase in solubility / stability that arise from the use of 
CD-polymers. 
The modification of gemcitabine hydrochloride salt (GEM.HCl) with 1-
adamantanecarboxylic acid (ADA-COOH) was explored using different coupling conditions, 
following various reported amide coupling reagents [188, 189] and procedures [190]. The coupling 
reaction between GEM.HCl and ADA-COOH, was optimally performed in a mixture of 
DMF:DMSO (3:1) at 25 ºC over a period of 48 h in the presence of 1.1 molar eq. of HATU and 
of 2.8 molar eq. of DIPEA resulting in GEM-ADA amide (Figure 74). Surprisingly, none of the 
strategies tried to isolate the desired product GEM-ADA amide were successful in our hands. 
These included, several liquid-to-liquid extractions strategies and column chromatography 
performed on crudes isolated after reaction. From all this experiment can be concluded that 
GEM-ADA amide is temperature sensitive and is affected by the presence of methanol. 
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Figure 74. Synthesis of GEM-ADA amide, through the coupling reaction between gemcitabine (GEM.HCl) 
and 1-adamantanecarboxylic acid (ADA-COOH), activated by HATU/DIPEA. 
 
Table 7 describes several conditions tested that resulted in the best experimental trial 
(Table 7, # 7). In this trial (# 7), TLC monitoring using a suitable mobile phase comprised of 
CH2Cl2 : acetone : EtOH (5:4:1) enable the identification of HATU-activated ADA-COOH (RF 
= 0.99) that was subsequently converted into the UV-active desired product GEM-ADA amide 
(RF = 0.78). The pure product (GEM-ADA amide) was obtained by liquid-to-liquid extraction 
[EtOAc / aqueous NaCl (10 % m/v)] to clean the organic phase (EtOAc), from any unreacted 
GEM.HCl and HATU-related by-products. Subsequently, by using small volumes of warm 
water (60 ºC), the pure GEM-ADA amide could be extracted and, on cooling was collected in 
28.5 % yield, leaving behind an impurity as a light yellow residue. The pure GEM-ADA amide 
isolated was characterized by NMR spectroscopy in DMSO-d6. The 1H NMR (Figure 75) 
spectrum revealed: i) the characteristic ADA signals (three singlet between 2.2 ppm – 1.6 ppm); 
ii) the pyrimidine ring aromatic protons H5/H6 at 6.0 ppm and 8.2 ppm, respectively; iii) the 
pentose unit with signals H5’a/H5’b/H4’/H3’/H1’ in the aliphatic region (3.6 ppm – 4.3 ppm). In 
DMSO-d6 due to slow exchange on the NMR time scale with residual HDO in the solvent 5’-
OH (6.34 ppm) /3’-OH (5.33 ppm) /amide –NH (10.5 ppm) protons were identified. A 
presaturation experiment involving irradiation at the HDO frequency resulted in the loss of their 
intensity, thereby revealing the frequency of these exchangeable protons.  
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Figure 75. 1H NMR spectrum (DMSO-d6, 500 MHz, 25 ºC) of GEM-ADA amide. 
 
These structural features of GEM-ADA amide were corroborated by 2D HSQC NMR 
spectra, namely: the differently phased signals (CH2) corresponding to H5 /H5’ on the pentose 
ring and H2 /H2’ and H4 /H4’ of the ADA moiety (Figure 76). 
 
Figure 76. 2D NMR HSQC spectrum (DMSO-d6, 25 ºC) of GEM-ADA amide. 
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Additionally, the adamantyl moiety was located away from the pyrimidine and pentose 
moieties, because no nuclear Overhauser effect was observed during a typical 2D NOESY 
experiment, which detects through space interactions of spins up to a distance of ≈ 5 Å. 
Therefore, ADA moiety located in GEM-ADA amide is free to interact with a βCD derivative 
in a typical inclusion experiment. On the other hand, the above clearly excluded the possibility 
of attachment of ADA moiety to the 5’-OH site via an ester bond connection.  
 
Table 7. Coupling conditions used in the preparation of GEM-ADA amide: reaction between GEM.HCl and 
ADA-CO2H. 
Trial Coupling Conditions 
n (mmol) / n (mmol) Solvent  
ADA-CO2H / 
GEM.HCl Time / Temp.  Notes 
1 EDC.HCl / DMAP 0.267 / 0.05 
CHCl3 
(2 mL) 0.135 /  0.154 46 h / 25 ºC Solvent not appropriate 
2 EDC.HCl / DMAP 0.273 / 0.065 
DMF 
(2 mL) 0.141 / 0.164 95 h / 25 ºC Coupling conditions 
3 DIC / HOBt 0.166 / 0.166 
DMF 
(2 mL) 0.166 / 0.166 69 h / 35 ºC Coupling conditions 
4 EDC.HCl / NEM / HOBt 0.220 / 0.167 / 0.167 
DMF/DMSO (3:1) 
(175 µL) 0.183 / 0.167 116 h / 55 ºC 
Increase temperature 
and time of reaction 
5 HATU / DIPEA 0.184 / 0.482 
DMF/DMSO (3:1) 
(200 µL) 0.167 / 0.167l 26 h / 25 ºC 
Coupling conditions 
Reduced volume 
6 HATU / DIPEA 0.185 / 0.482 
DMF/DMSO (3:1) 
(200 µL) 0.169 / 0.175 48 h / 25 ºC Purification  
7 HATU / DIPEA 0.185 / 0.482 
DMF/DMSO (3:1) 
(200 µL) 0.169 / 0.168 48 h / 25 ºC Good trial 
8 HATU / DIPEA 0.194 / 0.482 
DMF/DMSO (3:1) 
(200 µL) 0.186 / 0.178  50 h / 25 ºC Product degradation 
9 HATU / DIPEA 0.185 / 0.482 
DMF/DMSO (3:1) 
(200 µL) 0.168 / 0.165 72 h / 25 ºC Product degradation 
 
During isolation of GEM-ADA amide, methanol was used to transfer small amounts of 
the product (mg) and a colour change in the solutions of GEM-ADA amide was observed: the 
initial solution (colourless) turned to yellow. The 1H NMR spectrum of this yellow solution 
revealed extra peaks in the region, between 6.0 ppm – 9.0 ppm and an increase in the area of the 
peaks corresponding to the ADA moiety bellow 2.0 ppm (* in Figure 77 B). 
 
  
102 
 
Figure 77. 1H NMR spectra (MeOD-d4, 500 MHz, 25 ºC) of A) GEM-ADA amide as it is after reaction isolation 
from warm water; and of B) GEM-ADA-amide after recovery using methanol, signals (*) due to extra species 
in solution. 
 
A reasonable possibility is the formation of other coupling products or mixtures of them 
(3-OH and 5-OH, ester products) [191], all appearing together in the same spectral region but this 
would only be plausible in case of inefficient purification of the desired compound. 
Probably, this unexpected behaviour regarding stability in MeOH could be explained by 
taking into account that methanol (MeOH), can effectively promote the formation of extra 
species in solution like hemiketals and ketals (Figure 78) [3].  
 
Figure 78. Formation of hemiketals and ketals through the reaction of methanol (CH3-
OH) with a kenote functionality.  
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This reversible reaction can account for the extra peaks in the aliphatic region of the 
spectra (*, below 2.0 ppm, Figure 77) and can explain the poor recovery of GEM-ADA amide 
(28.5 % yield).  
 
 
6.3 Conclusions and future perspectives 
The chemical modification of small molecules, tamoxifen and gemcitabine were 
implemented and found valuable for several reasons: i) they enable the synthesis in pure state of 
important TAM derivatives for inclusion study and confocal microscopy (NDTAM, TAM-Cit 
and NDTAM-FITC) and enabled anchoring of a βCD cavity suited moiety (GEM-ADA) for 
delivery via βCD carriers. This is of utmost importance in our group’s perspective, because 
expensive anticancer drugs became available for experimentation, while our know-how was 
expanded, through the preparation and purification of these useful compounds. Most of these 
compounds have been used by our group members, in fruitful collaborations. 
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7. CD-polymers (CDPs) based on positively charged CDs 
7.1 Introduction 
Most of animal tissue cells possess an overall negative charge, attributed to the presence 
of sialic acid in their cell membrane, which facilitates interaction with positively charged 
substrates [192]. CD polymer research towards new DDS is still an area in expansion and their 
accurate characterization still faces many challenges. This has been attributed to the lack of 
controlled topology, defined structure, uniform molecular weight distributions, extended 
systemic biocompatibility and lack of toxicological studies [110]. Cationic βCD-based polymers 
(CPβCDs) have been prepared from βCD, epichlorohydrin and choline chloride and were 
characterized as drug carriers, revealing that high molecular weight and low cationic charge 
density, induced good drug inclusion and dissolution properties [193].   
Amino-CD derivatives are examples of positively charged CDs that have been studied 
as biomimetic molecules [ 194 ]. Per(6-aminoalkylamino-6-deoxy)-CDs and per(6-guanidino-
alkylamino-6-deoxy)-CDs are amino-CDs, that can display both amine (-NH2) and ammonium 
salts (-NH4+R-, -NH2+R) depending on the pH of the solution. These CD derivatives have been 
prepared and studied previously by our group and it was found that they possess good cell 
penetrating properties (CPCDs) and display moderate interaction with DNA [195]. Additionally, 
per(6-guanidino-6-deoxy)-CDs showed strong interactions through cavity inclusion with model 
nucleotides (5’-AMP, 5’-dCMP, 5’-dAMP) (Figure 79), but no interactions with nucleosides 
(2’-dC, 2’-dA). This was attributed to the dipole-dipole interactions that are guiding the 
inclusion phenomena, between the negatively charged phosphorylated groups in nucleotides 
and, the positively charged groups in CDs [196]. The electrostatic interactions offer additional 
stabilization to these inclusion complexes, resulting in the unexpected encapsulation of the 
pentose moiety of the nucleotides.  
Therefore, nucleotide therapeutics can be achieved using CD-polymers containing 
CPCDs, opening a new and interesting field for the delivery of nucleotides and other anionic 
drugs.  
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Figure 79. Suggested models of inclusion for the complex between: adenosine 5’-
monophosphate (5’-AMP) with a) βguan and with b) γguan and between c) 
Deoxycytidine 5'-monophosphate (5’-dCMP) with βguan [196]. 
 
In this chapter it will be described the preparation of polymers based on a positively 
charged CDs, namely per(6-aminoethylamino-6-deoxy)-βCD, following different strategies. 
The CD-polymers prepared will be characterized and its ability to interact with model 
nucleotides such as adenosine 5’-monophosphate (5’-AMP) and gemcitabine monophosphate 
(GEM-MP) will be studied. 
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Figure 80. Structures of guest molecules: A) adenosine 5’-monophosphate (5’-AMP) and B) Gemcitabine 
Monophosphate (GEM-M). 
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Strategy for preparation of CD-Polymers (CDPs) 
CDPs based on positively charged CDs were prepared following two different strategies 
outlined in Figure 81: 
i) Reaction of a preformed polymer bearing suitable functional groups (e.g. 
poly-L-Lysine hydrobromide, pLys.HBr) of known average molecular 
weight, with a per-halogenated CD (e.g. heptakis(6-iodo-6-deoxy)-β-
cyclodextrin, βpI) followed by reaction excess 1,2-diaminoethane (DAE) to 
generate pLys/βpen polymers (Figure 81 a) 
ii) Direct reaction of heptakis(6-aminoethylamino-6-deoxy)-β-cyclodextrin 
(βpen), with epoxides [epichlorohydrin (EPI) and ethylene glycol diglycidyl 
ether (EGDE)] through ring-opening reactions in alkaline medium, to 
generate EPI/βpen and EGDE/βpen polymers (Figure 81 b)  
The first approach is a costly reaction due to expensive pLys.HBr, starting material, that 
potentially offers some control over the molecular weights of the final polymers, because the 
starting material has a determined range of average molecular weight (AMW). The second 
approach is a cheap alternative that would use readily available epoxides as linkers (EPI and 
EGDE), but would offer no control over the AMW of the polymers. The details on the 
preparation of the linker (EGDE), that is not commercially available and on the modifications to 
the CD macrocycle (βpI and βpen) will be given, later in the chapter. 
 
 
Figure 81. Polymerization strategies used in the preparation of CD-polymers based on: a) preformed polymer 
(pLys.HBr) and b) available linkers (EPI and EGDE). 
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7.2 Results and discussion 
7.2.1 Preparation of per(6-aminoethylamino-6-deoxy)-βCD (βpen) 
polymers from poly-L-lysine (pLys)  
Commercial poly−L-lysine hydrobromide (pLys.HBr) was used as a preformed 
polymer, following the first strategy outlined previously (Figure 81 a). This polymer is a 
polypeptide, composed by: i) a linear polymer connected by peptide backbone (amide bonds) 
and ii) a butylamine side chains displaying n repeating units, corresponding to lysine units 
(Figure 82). The 1H NMR spectrum of pLys.HBr is shown in Figure 82.  
 
 
Figure 82. 1H NMR spectrum (D2O, 500 MHz, 25 ºC) of poly-L-lysine hydrochloride, pLys.HBr (500 Da < 
AMW < 2000 Da). 
 
Polymerization trials 
To determine initial suitable polymerization conditions, a commercial batch of 
pLys.HBr (500 Da < AMW < 2000 Da) was used in three trials described in Table 8. The same 
amount of pLys.HBr (3.25 µmol) was first reacted with varying amounts of heptakis(6-iodo-6-
deoxy)-β-cyclodextrin (βpI) at different temperatures (step 1, Table 8); followed by reaction 
wirh 1,2-diaminoethane (DAE), to generate βpen from the βpI (step 2, Table 8). 
After the reaction is completed the work up procedure involved a dialysis step, through 
a snakeskin dialysis membrane (MWCO = 3500 Da), used to clear out from the polymeric 
sample any traces of βpen (MW = 1430 Da). To evaluate the success of each reaction condition, 
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1H NMR spectroscopy was used to determine the area anomeric proton signal (CD-H1,, ≈ 5 
ppm) and the area corresponding to the aliphatic peaks of pLys (Hβ/γ/δ < 2 ppm). The 
experimental conditions that lead to polymers with the highest βpen content were those 
described for trial 3 (Table 8).  
 
Table 8. Polymerization trials between pLys.HBr (500 Da < AMW < 2000 Da) and βpI. 
Trial βpI DMF / KOH * Step 1 Step 2 
1 16 µmol 3 mL 70 ºC / 14 h 80 ºC / 8 h 
2 21 µmol 1 mL 40 ºC / 14 h 80 ºC / 8 h 
3 32 µmol 1 mL 60 ºC / 14 h 80 ºC / 8 h 
* - pLys.HBr (500 Da < AMW < 2000 Da) (3.25 µmol) 
 
Consequently, following trial 3 conditions, three more trials were performed changing 
the AMW of the pLys.HBr used as starting material: a low (500 Da – 2000 Da), an intermediate 
(1000 Da – 5000 Da) and a high AMW pLys.HBr (4000 Da – 15000 Da) were used in the 
reaction. The intermediate pLys.HBr fraction (1000 Da – 5000 Da) revealed higher content of 
βpen and was used in the preparation of all pLys / βpen polymers. 
In order to narrow further the AMW of the intermediate pLys.HBr (1000 Da < AMW < 
5000 Da) fraction, this was sequentially dialysed using benzoylated (MWCO = 2000 Da) and a 
snakeskin (MWCO = 3500 Da) dialysis tubing. Three fractions were obtained: pLys A (1000 Da 
< AMW < 2000 Da, 35 % m/mT); pLys B (2000 Da < AMW < 3500 Da, 52 % m/mT) and pLys 
C (3500 Da < AMW < 5000 Da, 14 % m/mT) and the number of lysine units (# Lys, Table 9) 
comprising in each pLys fraction was estimated taking into account: i) the molecular weight of 
one Lys chain (MW (C6H12N2O) = 128 g/mol; ii) the MWCO limits imposed by the dialysis 
membranes (MWCO = 2000 Da and 3500 Da) used and iii) by the AMW of the starting 
pLys.HBr (1000 Da < AMW < 5000 Da). 
 
Table 9. Fractioning of a batch of commercial pLys.HBr (1000 Da < AMW < 5000 Da; mT = 100 mg) by 
dialysis to obtain pLys of different average molecular weights (AMW). 
Fraction AMW limits (Da) # Lys groups (-NH2) % Mass recovered (m/mT) 
pLys A (1000* < AMW < 2000) 8* < # < 16 35 % 
pLys B (2000 < AMW < 3500) 16 < # < 27 52 % 
pLys C (3500 < AMW < 5000) 27 < # < 39 14 % 
* - lower limit: pLys A = lower AMW (1000) / MW of Lys (128) ≈ 8 # Lys. 
 
The number of lysine units in the backbone (# Lys) of each fraction, should determine 
the maximum number of βpen units possible to be grafted onto each polymer backbone, 
assuming a highly efficient reaction. For every CD attached, the overall AMW of the polymer is 
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expected to increase by the mass of one βpen molecule (1430 g/mol). The 1H NMR spectrum of 
starting material, pLys.HBr (1000 Da < AMW < 5000 Da) is comparable to those of fractions 
pLys A, B and C (Figure 83 A, B and C, respectively). All fractions isolated display signals in 
the same spectral regions as the starting material pLys.HBr and the mass recovered (m/mT) is 
represented as a percentage of the total mass of pLys.HBr used (mT = 100 mg). 
 
Figure 83. 1H NMR spectra (D2O, 500 MHz, 25 ºC) of A) pLys A (1000 Da < AMW < 2000 Da); B) pLys B 
(2000 Da < AMW < 3500 Da); C) pLys C (3500 Da < AMW < 5000 Da). 
 
Figure 83 A shows that the increased resolution of the peaks of fraction A, compared to 
the resolution of peaks in B and C, is probably due to the presence of small molecular weight 
oligomers in this fraction pLys A (1000 Da < AMW < 2000 Da). Inspection of the 1NMR 
spectra reveals three major regions with assignable signals: 4.4 ppm – 4.0 ppm, 3.0 ppm – 2.9 
ppm and 1.8 ppm – 1.3 ppm. The assignment was aided by Chemdraw ® software prediction of 
1H NMR resonances and by comparison with the spectrum of L-lysine itself. Therefore, the 4.4 
ppm – 4.0 ppm region was assigned to Hα’ and Hα’’ signals, the 3.0 ppm – 2.9 ppm region to Hε, 
Hε’ and Hε’’ signals and the 1.8 ppm – 1.3 ppm to all other protons (Hβ, Hγ, Hδ of all kinds). The 
only group that remained separate is Hα, attributed to the N-terminal residue, with an expected 
signal between ≈ 3.5 ppm - 3.6 ppm. The integration of these signals (Hα), corresponding to the 
end-groups of the various oligomers present in each polymer (A, B and C), in comparison with 
the integrals of the rest of signals (Hβ, Hγ, Hδ), would give the number of Lys units comprising 
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each polymer. Small peaks around 3.6 ppm – 3.5 ppm could be found and these were integrated 
in C (Figure 83 C) and with less accuracy in A (Figure 83 A), whereas in B (Figure 83 B) the 
region was masked with foreign peaks. In this manner, approximate numbers for monomers 
were determined and these fall within the expected range of AMW provided by the dialysis 
membrane molecular weight cut-off limits (MWCO). Table 10 shows the results for the 
estimated value for # pLys (NMR) and the # pLys (“dialysis”), estimated after “dialysis” 
fractioning, following the procedure described in section 10.4.9. 
 
Table 10. Estimated number of lysine units (# Lys) attached to polymer backbone: NMR based vs dialysis 
membrane based estimation. 
Polymer AMW limits (Da) # Lys (NMR) # Lys (Dialysis) Average (# Lys ) 
pLys.HBr (1000 < AMW < 5000) - - 24 
pLys A (1000 < AMW < 2000) 12 8 < # Lys < 16 12 
pLys B (2000 < AMW < 3500) - 16 < # Lys< 27 22 
pLys C (3500 < AMW < 5000) 35 27 < # Lys < 39 33 
*Expected number of protons for pLys (Hβ/δ/γ) = 6 H. 
 
7.2.2 Preparation of pLys/βpen polymers 
The previously isolated polymer fractions pLys A, pLys B and pLys C were reacted 
with pβI following the reaction conditions outlined in Figure 84. The preparation of pLys / βpen 
polymers involved the reaction of pLys B (2000 Da < AMW < 3500 Da) with an excess of βpI, 
in alkaline water (KOH) and DMF for 48 h and at 60 ºC (Figure 84). In this first step, it is 
expected that the nucleophilic side chain amino groups, attached to pLys backbone will be able 
to substitute one or more iodo groups of βpI leading to the desired connectivity (pLys-βpI). The 
subsequent reaction in the presence of excess of 1,2-diaminoethane (DAE) performed for 12 h 
at 70 ºC, leads to the conversion of all remaining unreacted 6-iodo-βCD sites into per(6-
aminoethylamino-6-deoxy)-βCD (βpen), leading to the desired pLys/βpen polymer. 
After attachment of βpen on pLys B (see section 10.4.9) three fractions corresponding 
to increasing AMW ranges were obtained through dialysis treatment: BA’ (1000 Da < AMW < 
2000 Da); BB’ (2000 Da < AMW < 3500 Da) and BC’ (3500 Da < AMW < 5000 Da). A 
summary of overall results is presented in Table 11. 
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Figure 84. Preparation of pLys/βpen polymers: i) deprotection of pLys.HBr (1000 Da < AMW < 5000 Da) 
(KOH, H2O) to obtain pLys; ii) fractioning of pLys.HBr (1000 Da < AMW < 5000 Da) into different fractions 
A / B / C of varying AMW; iii) attachment of βpI units, followed by iv) conversion to pLys/βpen polymer by 
reaction with DAE. 
 
The smaller molecular weight fraction of all polymers of pLys/βpen A’ (1000 Da * < 
AMW < 2000 Da) was discarded completely, as most of impurities resulting from the 
polymerization reaction were small molecular weight molecules (residual solvents DMF and 
DAE; traces of HI released from βpI attachment to pLys; βpI impurities (triphenylphosphine 
oxide, PPh3) and small molecular weight oligomers). Likewise, the higher molecular weight 
fraction pLys/βpen C’ (3500 Da < AMW < 5000 Da *) was also not used, because only small 
amounts were collected. Finally, the only usable fraction was pLys/βpen BB’ (≈ 12 mg, Table 
11), isolated from the reaction of the intermediate fraction B’ (2000 Da < AMW < 3500 Da) 
after the fractioning dialysis procedure (see section 10.4.9). 
 
Table 11. Results of polymerization reaction for each starting pLys polymer (A/B/C), after dialysis treatment 
to obtain different pLys/βpen fractions (A’/B’/C’). 
  Starting pLys fraction  
pLys/βpen AMW Range (Da)* B 
A’ 1000* < AMW < 2000 BA’ (-) 
B’ 2000 < AMW < 3500 BB’ (12.1 mg) 
C’ 3500 < AMW < 5000* BC’ (-) 
*- limits defined by the commercial AMW of pLys.HBr 
 
A second polymer batch pLys/βpen T2 was prepared following a similar reaction 
procedure, but using commercial pLys.HBr (1000 Da < AMW < 5000 Da) used as received 
without fractioning of pLys.HBr (see section 10.4.8). The work-up procedure involved only an 
extended dialysis (snakeskin dialysis, MWCO = 3500 Da) step (12 h), followed by collection of 
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the inner contents of the membrane (3500 Da < AMW < 5000 Da) to afford pLys/βpen (T2) 
(11.4 mg). 
pLys/βpen BB´ and pLys/βpen T2 were characterized in the following section and used 
in complexation / inclusion experiments (7.2.7). 
 
 
7.2.3 Characterization of pLys/βpen polymers 
pLys/βpen T2 and pLys/βpen BB’ were characterized by NMR and their spectra 
recorded in D2O are respectively shown in Figure 85 C and in Figure 85 B. The first indication 
that the polymerization reaction was successful arrived from the comparison between 1H NMR 
spectra of each polymer batch with that of βpen shown in Figure 85 A.  
 
 
Figure 85. 1H NMR spectra (D2O, 500 MHz, 25 ºC) of A) starting material βpen and two polymer batches: B) 
pLys/βpen BB’ and of C) pLys/βpen T2. 
 
The 1H NMR spectrum of pLys/βpen T2 (Figure 85 C) revealed features of both βpen 
and of starting material pLys.HBr. βpen signals cover the area 3.9 ppm – 2.5 ppm, but the most 
characteristic is the anomeric peak (CD-H1, ≈ 5.1 ppm), which is sharp in βpen (Figure 85 A) 
but broad in pLys/βpen T2 (Figure 85 C). The presence of pLys is revealed by the characteristic 
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peaks Hβ/δ/γ (≈ 1.0 ppm to 2.0 ppm) of the alkyl chain connected to the lysine pending groups on 
the polymer. In the region between 2.5 ppm to 4.5 ppm of pLys/βpen T2, the signals of βpen 
and pLys overlap (Figure 85 C). Similar spectral features were observed for pLys/βpen BB’ 
(Figure 85 B), namely: the presence of βpen, pLys signals, broad regions that overlap in the 1H 
NMR spectrum of pLys/βpen BB’, which difficult the analysis. 
The estimation of the relative number of βpen units in pLys/βpen T2 and in pLys/βpen 
BB’ can be obtained considering the ratio R, between the area of the Lys group (Hβ/δ/γ = 6H) and 
the areas of the anomeric proton CD-H1 (≈ 5 ppm). Thus, for pLys/βpen T2 (RT2 = 18.1 / 6 = 
3.02) and for pLys/βpen BB’ (RBB’ = 4.1 / 6 = 0.68), which means that there are 4.4 times more 
Lys units with βpen attached in the pLys/βpen T2 than in pLys/βpen BB’. 
Moreover, assuming that for every 3.02 Lys units, there is one βpen attached in 
pLys/βpen T2 and recalling the average number of Lys for the starting material used pLys.HBr 
(1000 Da < AMW < 5000 Da) (Table 10) that is ≈ 25 Lys residues, thus:  βpen cups = 25 / 3.02 
≈ 8. Consequently, for pLys/βpen BB’ polymer: βpen cups = 8 x ¼ ≈ 1.8, on average. 
Therefore, the above procedures resulted in a βpen rich pLys/βpen T2 polymer, with a wide 
range of molecular weights as opposed to a Lys/βpen BB’ polymer, with less βpen decoration 
but much narrower size distribution.  
The higher βpen content in pLys/βpen T2 can be attributed to a higher molecular weight 
distribution of pLys.HBr (1000 Da < AMW < 5000 Da), used in its preparation of pLys/βpen 
T2. This is in opposition to the molecular weight of the fraction of pLys used in the preparation 
of pLys/βpen BB’, which was narrowed down to pLys B (1000 Da < AMW < 3500 Da) through 
dialysis treatment. 
 
Solubility, size and zeta potential 
The initial reaction of βpI with pLys B and pLys C, after dialysis treatment resulted in 
six different polymer batches, namely: pLys/βpen AB’, pLys/βpen BB’, pLys/βpen CB’, 
pLys/βpen AC’, pLys/βpen BC’ and pLys/βpen CC’ (Table 12). Although, only pLys/βpen BB’ 
was used in inclusion experiments, the residual amounts of all other pLys/βpen polymers were 
collected and were used in solubility tests performed in water, using concentration of 0.5 
mg/mL at 25 ºC. Table 12 shows that some solutions, prepared from the freeze-dried solids 
(pLys/βpen), revealed cloudiness indicating poor solubility in water.  
In the literature, the opalescence/cloudiness of solution observed during the preparation 
of nano- and micro-gels for drug delivery, was attributed to the hydrophilicity of the nanogels 
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[124]
. γCD solutions revealed the same phenomenon, attributed to the ability of CDs to aggregate 
[197, 198]
. Thus, it is expected that polymeric materials based on CD despite being water-soluble, 
may be prone to aggregation even in much diluted solutions. The two polymers of interest 
(pLys/βpen BB’ and pLys/βpen T2) are water-soluble. However, cloudiness was observed for 
solutions of pLys/βpen BB’ as opposed to pLys/βpen T2, which was a completely clear solution 
under the same conditions.  
 
Table 12. Solubility of pLys/βpen polymers prepared from pLys A and pLys B fractions, tested in C = 0.5 
mg/mL (25 ºC). 
Polymer pLys.HBr fraction Aspect of solution 
pLys/βpen AB’ B Clear 
pLys/βpen BB’ B Clear, with residue 
pLys/βpen CB’ B Cloudy, with residue 
pLys/βpen AC’ C Clear 
pLys/βpen BC’ C Clear 
pLys/βpen CC’ C Cloudy 
 
Dynamic light scattering (DLS) was used to determine the size and surface charge of 
the polymeric particles in aqueous solutions. All DLS experiments are based on the following 
assumptions: i) all particles are spherical; ii) particles have a homogenous / equivalent density 
and iii) the refractive index of the particles in the sample are known. Polymeric samples hardly 
meet all the DLS criteria for an ideal spherical particle and in addition to this, a typical DLS 
experimental result can be represented by at least three modes of size representation.  
The size distribution (diameter, d, nm) of pLys/βpen BB’ polymer, obtained from the 
DLS experiment was plotted as a function of: i) the number of particles; ii) the volume of the 
particles and iii) the intensity of the light scattered: i) the size/number distribution for 
pLys/βpen (BB’) (Figure 86 A) shows two populations of sizes namely, a very small size ≈ 0.7 
nm (9 %) and a moderate size ≈ 91 nm (14 %); ii) the size/volume representation (Figure 86 B) 
reveals a very small size population ≈ 0.8 nm (8 %) and a broader size population distribution 
with two maxima, at ≈ 105 nm (1.5 %) and ≈ 955 nm (5 %) and iii) the size/intensity (Figure 86 
C) reveals a very small size population ≈ 1 nm (0.5 %) and a larger size population ranging 
from ≈ 164 nm (5 %) to a ≈ 615 nm (4 %). The result can be justified by the fact that larger 
particles scatter light more intensely than small ones. Thus, this representation was not chosen. 
The results for the size of the particle differ, depending on the graphical representation 
of the results chosen. Additionally, filtration of the samples prior to DLS analysis was reported 
as a means to obtain reasonable DLS results from po
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aggregates [199], but this procedure was not used and the size / number representation of the 
biggest population was determined and is shown in Table 13, for each polymeric material. 
 
 
Figure 86. DLS results for pLys/βpen BB’ polymer recorded in 0.5 mg/mL at 25 ºC: Size distribution by A) 
number; B) volume of particle and C) intensity of scattered light. 
 
Recalling the AMW fractioning performed (Table 9), it is expected that the size of 
polymers prepared from the bigger fraction pLys C (3500 Da < AMW < 5000 Da) is larger than 
the size of polymers prepared from a smaller fraction pLys B (2000 Da  < AMW < 3500 Da). 
The results show that for each polymer, there is no direct correspondence between the estimated 
AMW distribution of pLys fraction used as starting material and the size of the biggest particle 
detected in the final product. For example, the size of pLys/βpen BB’ (≈ 91 nm, 14 %), prepared 
from pLys B (2000 Da < AMW < 3500 Da), is much bigger than the size of pLys/βpen BC’ (≈ 
3.1 nm, 17 %) prepared from a bigger size range pLys C (3500 Da < AMW < 5000 Da). The 
conformation of poly-L-Lysine has been determined [200] in aqueous solvents and it is dependent 
on factors like the solvent, pH value and temperature. Three different conformations were 
determined: i) a loosely PII-helix conformation 10 ºC (pH = 4); that becomes more tightly 
packed an ii) α-helix 10 ºC (pH = 11.6) conformation and is extended to iii) a β-sheet 
conformation by increase in the temperature 60 ºC (pH = 11.6). These data suggest that the 3D 
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structure of the polymeric products is difficult to predict and it affects the size distribution; 
therefore, DLS results should be interpreted with caution. 
 
Table 13. Size and zeta potential for pLys/βpen B’ and pLys/βpen C’ determined by DLS (25 ºC). 
Sample AMW pLys fraction (Da) Conc. (mg/mL) Size / Number pH Zeta Potential (mV) 
βpen - 0.57 91 nm / 20 % 7 + 10.6 
pLys/βpen AB’ 2000 < AMW < 3500 0.50 91 nm / 9.4 % 5 - 8.3 
pLys/βpen BB’ 2000 < AMW < 3500 0.50 91 nm / 14 % 9 -3.3 
pLys/βpen CB’ 2000 < AMW < 3500 0.50 141 nm / 18 % 8 -3.7 
pLys/βpen AC’ 3500 < AMW < 5000 0.50 190 nm / 17 % 7 + 16.8 
pLys/βpen BC’ 3500 < AMW < 5000 0.50 3.1 nm / 17 % 7 + 13.3 
pLys/βpen CC’ 3500 < AMW < 5000 0.50 7.5 nm / 13 % 7 + 24.6 
 
Table 13 also displays zeta-potential (ζ, mV) results recorded at a specific pH that 
enabled the determination of the surface charge displayed by a particle. pLys/βpen polymers 
containing βpen units grafted to their backbone, are expected to display both amine (-NH2) and 
ammonium groups (-NH3+) depending on the pH of the solution, but the number of 
amine/ammonium is expected to increase for the same number carboxylic acid/carboxylate 
groups for the same polymeric backbone size. Polymers prepared from pLys B (2000 Da < 
AMW < 3500 Da) display a hard to rationalize negative charge as opposed to the positive 
charge particles of polymers prepared from pLys C (3500 Da < AMW < 5000 Da). pLys/βpen 
AC’, BC’ and CC’ possess higher positive than βpen particles in solution: charge (from + 13.3 
mV up to + 24.6 mV) than that of βpen particles (+ 10.6 mV). This agrees with a high content 
of βpen moieties that display ammonium ions at pH = 7. pLys/βpen AB’, BB’ and CB’ possess 
negative charge, which can be explained by a poor NH2/NH3+ these polymers.  
 
 
7.2.4 Preparation of cross-linked polymers (EPI / βpen and EGDE 
/βpen) 
The preparation of cross-linked polymers involved the use of suitable monomers based 
on the structure of epichlorohydrin (EPI), a crosslinking agent. It is cheap, readily available and 
has been widely used in the preparation of CD polymers based on βCD [193]. Furthermore, EPI is 
slightly soluble in water thus the reaction can be carried out in water. 
The methodology used to polymerize βpen units to each other is described in Figure 87. 
It is based on the nucleophilicity of the primary amino groups of βpen that are expected to ring 
open EPI and initiate a polymerization process, under basic conditions (NaOH). βpen was 
dissolved in aqueous diluted NaOH and EPI was added slowly to the reaction mixture, at 60-70 
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ºC. However, under aqueous basic conditions (NaOH), there is the possibility of deprotonation 
of the secondary hydroxyl groups (2-OH / 3-OH) leading to undesired secondary reactions. In 
turn, this leads to the formation of alkoxide anions expected to compete with the polymer 
growth reaction, between βpen and EPI. In such an event, the cavities will be blocked from their 
wider side, a not desired outcome. 
After 29 h the reaction was stopped, the products were recovered by precipitation from 
acetone, extensively dialysed through a benzoylated dialysis tubing (MWCO = 2000 Da) to 
remove small MW side products and afford EPI/βpen polymers and finally, freeze-fried. 
 
 
Figure 87. Preparation of EPI/βpen polymers, from reaction of EPI with βpen. 
 
Three batches of EPI/βpen were thus prepared by varying the amounts of linker used 
according with the data displayed in Table 14. The characterization of EPI/βpen P3/P4/P5 
polymers and their use in several complexation / release experiments will be described in 
section 7.2.3. Unlike pLys / βpen polymers, due to the availability of raw materials (EPI and 
βpen), more material could be readily available and the characterization of these polymers was 
facilitated.  
 
Table 14. Description of the polymer reaction conditions using EPI and βpen. 
Polymer Ratio (EPI/βpen) n (EPI)  n (βpen) Temp. (ºC) Time Amount 
P3 5 650 µmol 130 µmol 70 – 75 ºC 29 h 240 mg 
P4 10 1760 µmol 180 µmol 70 – 75 ºC 2.5 h 229 mg 
P5 20 3530 µmol 177 µmol 70 – 75 ºC 2.5 h 225 mg 
 
In order to increase the hydrophilicity of the polymer, a symmetrical linker, ethylene 
glycol diglycidyl ether (EGDE) was prepared (see section 7.3.1) and used in the polymerization 
reaction with βpen, following a procedure similar to the one described for the preparation of 
EPI/βpen polymers. It is expected that the extra epoxide ring attached and EG linkage present in 
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EGDE unit, would offer equivalent reactivity of both ends and maybe higher AMW polymeric 
materials. The reaction is represented schematically in Figure 88.  
 
 
Figure 88. Preparation of EGDE/βpen polymers, from reaction of EGDE with βpen. 
 
Four batches of EGDE/βpen polymers were prepared (Q1, Q2, Q3, Q4) varying the molar 
ratio between EGDE/βpen and the results are displayed in Table 15. EGDE/βpen polymers were 
characterized (see section 7.2.5), used in complexation studies and release experiments; the 
results were compared with those of EPI/βpen polymers. 
 
Table 15. Description of the polymer reaction conditions using EGDE and βpen. 
Polymer Ratio (EGDE/βpen ) n (EGDE) n (βpen ) Temp. (ºC) Time (h) Amount 
Q1 1 106 µmol 106 µmol 70 – 75 ºC 72 h 106 mg 
Q2 5 523 µmol 105 µmol 70 – 75 ºC 72 h 157 mg 
Q3 10 1050 µmol 109 µmol 70 – 75 ºC 72 h 241 mg 
Q4 20 1050 µmol 54 µmol 70 – 75 ºC 72 h 188 mg 
 
 
7.2.5 Characterization of cross-linked polymers 
Solubility, size and zeta-potential 
The solubility and the appearance of aqueous solutions of EPI/βpen and EGDE/βpen, 
regarding the presence of aggregates, turbidity, gel formation was evaluated in diluted solutions 
(≈ 0.6 mg/mL) at 25 ºC. The results are summarized in Table 16 and these are in agreement with 
those found for pLys/βpen polymers, whereby all polymers enter the water phase but their 
aqueous solutions revealed cloudiness / turbidity.  
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Table 16. Aspect of the solutions of EPI/βpen and 
EGDE/βpen polymers tested for C = 0.6 mg/mL (25 ºC). 
Polymer Soluble 
EPI/βpen P3 Soluble; clear 
EPI/βpen P4 Soluble; cloudy 
EPI/βpen P5 Soluble; clear 
EGDE/βpen Q1 Soluble; clear 
EGDE/βpen Q2 Soluble; clear 
EGDE/βpen Q3 Soluble 
EGDE/βpen Q4 Soluble 
 
The size distribution (diameter, d, nm) and zeta-potential (ζ, mV) for EPI/βpen and 
EGDE/βpen polymers were determined by DLS and are shown in Table 17. For DLS analysis 
polymeric solutions were not centrifuged. Additionally, only the most intense peak was 
represented as a percentage of the total size distribution (Table 17). The results are compared to 
those of βpen (Entry 1, Table 17). The results show that EGDE/βpen polymer particles are 
much bigger than EPI/βpen polymer particles. The size of EPI/βpen polymers particles seems to 
increase only above a ratio of EPI/βpen = 20, for P5 (≈ 51 nm) and remain constant (≈ 33 nm) 
for ratios of EPI/βpen = 5 and 10 respectively for P3 and P4.. All EGDE/βpen and EPI/βpen 
polymers are positively charged and the charge is roughly the same for P3 (+ 34 mV) and P4 (+ 
32 mV) but slightly higher for P5 (+ 43 mV). Moreover, the polymers maintain a higher (3-4 
fold) positive charge, compared to βpen, as planned.  
 
Table 17. Size and zeta potential for EPI/βpen and EGDE/βpen polymers determined by DLS (25 ºC). 
  Concentration Size / Number pH Zeta Potential 
# Sample (mg/mL) (d, nm / %) - (ζ, mV) 
1 βpen 0.57 91 nm / 20 % 7.2 + 10.6 
2 EPI/βpen P3 0.64 32 nm / 28 % 7.1 + 34.0 
3 EPI/βpen P4 0.66 33 nm / 29 % 6.9 + 32.0 
4 EPI/βpen P5 0.63 51 nm / 28 % 7.1 + 43.0 
5 EGDE/βpen Q2 0.65 79 nm / 25 % 7.1 + 34.0 
6 EGDE/βpen Q3 0.65 122 nm / 21 % 7.1 + 45.5  
 
 
Structure of the polymers 
NMR spectroscopy was used to evaluate the polymerization products. Figure 89 
compares the 1H NMR spectra of EPI/βpen (P3/P4 and P5, Figure 89 A, B and C) with that of 
βpen (Figure 89 D) used as starting material. The 1H NMR spectrum of βpen (Figure 89 D) 
shows well-resolved signals with the characteristic anomeric peak (CD-H1, ≈ 5 ppm), the 
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internal protons (CD-H3/5, ≈ 4 ppm); CD-H2 and CD-H4 (3.8 ppm – 3.9 ppm) and CD-H6/6’ is 
overlaid with alkyl chain (H7/8). The broadness of the EPI/βpen (CD-H1) in Figure 89 A is a 
characteristic signal such pLys/βpen polymers. This broad signals are in contrast, when 
compared with the signals of βpen (a sharp and defined spectrum). 
 
 
 
Figure 89. 1H NMR spectra (D2O, 500 MHz, 25 ºC) of EPI/βpen polymers A) P3; B) P4; C) P5 and D) starting 
material, βpen. 
 
EPI/βpen is different from pLys/βpen, because the broad signals of EPI/βpen spread 
over the region, where signals of βpen are also expected (2.4 ppm to 4.6 ppm). The potentially 
useful signals of the hydroxyl groups (-OH), generated upon ring-opening reaction of epoxides, 
cannot be observed in D2O, because they are in fast exchange with HDO in the NMR time scale. 
Furthermore, the 1H NMR signals of the linkers overlap with the signals of polymeric βpen. 
Therefore, it will not be possible to estimate the relative ratio of CD units in each polymer, 
using the well-defined peak of CD-H1 in βpen, like previously done for pLys/βpen polymers.  
The polymeric character of EPI/βpen P3, P4 and P5 was also assessed from the 13 C 
NMR spectra, comparatively to 13C NMR spectrum of βpen (Figure 90). Broad signals in the 
13C NMR spectra of polymers (Figure 90 A, B, C) were observed, which agree with the multiple 
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connections typical of many polymeric matrix and are in opposition to the sharp peaks observed 
for βpen. 
 
 
Figure 90. 13C NMR NMR spectra (D2O, 125 MHz, 25 ºC) of EPI/βpen polymers A) P3; B) P4; C) P5 and D) 
starting material, βpen. 
 
In addition, 2D HSQC NMR experiment was performed on a sample of EPI/βpen P3 
and it revealed that in the aliphatic broad region of the 1H NMR spectrum (Figure 90 A, 2.4 
ppm – 4.6 ppm), there are many differently phased contours (–CH and –CH2) corresponding to 
the cross-linked matrix of EPI / βpen P3 polymer (Figure 91). A Chemdraw prediction based on 
a tentative polymer structure revealed good agreement between the 13C NMR chemical shifts 
expected for EPI/βpen P3 (35 ppm – 85 ppm) and those actually observed in the 2D HSQC 
(Figure 91). 
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Figure 91. 2D HSQC NMR spectrum (D2O, 25 ºC) of EPI/βpen P3. 
 
Similarly, the 1H NMR spectra of EGDE/βpen polymers Q1, Q2 and Q3 shown 
respectively in Figure 92 A, B, C were compared to the 1H NMR spectrum of βpen (Figure 92 
D). Once again, broad signals and overlaid regions were observed in the aliphatic region of 
EGDE/βpen polymers (2.4 ppm – 4.2 ppm), indicating the success of the polymerization 
reactions. Although it is possible to identify the presence of βpen unit connected to the 
EGDE/βpen polymers, by the presence of resolved and isolated signal of the anomeric proton 
(CD-H1, ≈ 5 ppm), the relative ratio of CD units in EGDE / βpen cannot be estimated for EGDE 
/ βpen polymers from the NMR spectra. Therefore, other experimental methods will be used to 
estimate the amount of βpen content in each polymer. 
 
  
123 
 
Figure 92. 1H NMR spectra (D2O, 500 MHz, 25 ºC) of EGDE/βpen polymers A) Q1; B) Q2; C) Q3 and starting 
material βpen. 
 
 
X-ray powder diffraction (XRD) 
XRD is a useful technique to judge the degree of crystallinity of any solid sample, 
characterized by an X-ray diffraction pattern, which gives a graphical representation, of X-ray 
intensity as a function of the angle of diffraction (2θ). Any crystalline sample is characterized 
by well-defined diffraction pattern (sharp lines at specific 2θ values) and a corresponding graph 
with very sharp peaks, which contrasts with a poor diffraction pattern (broad shaded regions) 
and a 2θ graph with broad peaks/regions typical of an amorphous sample. 
The diffraction patterns and 2θ graphs of EPI/βpen P5 was determined and compared to 
that of βpen (Figure 93). Although βpen is not a crystalline material, it revealed a semi-
crystalline phase with very sharp peaks (Figure 93 A). After reaction, βpen loses its crystallinity 
and gives rise only to broad peaks in EPI/βpen P5 (Figure 93 B). The similarities between the 
maximum values observed for (2θ ≈ 20) in βpen and in EPI/βpen P5, agrees with the expected 
structural similarity between βpen and EPI/βpen P5. The remaining polymeric batches 
(EPI/βpen and EGDE/βpen polymers) revealed similar features in comparison to βpen, thus 
verifying the amorphous nature of the polymeric materials prepared. 
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Figure 93. Graphical representation of 2θ curves for A) βpen and B) EPI/βpen P5 and of both diffraction 
patterns shown as insets. 
 
The X-ray results indicate that the polymerization reaction was successful in linking 
βpen units to a polymeric backbone. After, polymerization βpen loses its semi-crystalline 
features (sharp peaks, Figure 93 A) and an amorphous material is formed, EPI/βpen P5 (broad 
peaks, Figure 93 B), in agreement with NMR results. 
 
Elemental Analysis 
Elemental analysis was used to determine the relative percentage of nitrogen (% N), 
present in each cross-linked polymers (EPI/βpen and EGDE/βpen). Since the only source of 
nitrogen (N) in the polymer comes from βpen, the higher the nitrogen content (% N) in a 
polymer the more βpen units it will contain. The nitrogen content of βpen (% Nβpen = 10.83), 
estimated for a molecular formula of βpen.7HCl.7H2O (C56H133N14Cl7O35), was used as a 
reference in the estimation of the CD content of each polymer. The quotient (R, Table 18) 
between the nitrogen content of the polymer (% N) and that of βpen (% Nβpen), gives a relative 
amount of βpen attached to the polymer backbone and an estimation of the amount of CD in 
each polymer. Table 18 displays elemental analysis results for EPI/βpen and EGDE/βpen. 
 
Table 18. Elemental analysis data for EPI/βpen and EGDE/βpen polymers. 
Polymeric Samples βpen / Linker C (%) H (%) N (%) R = N / Nβpen 
βpen - 39.9 7.1 10.8 1.00 
EPI/βpen P4 (1:10) 41.7 7.7 7.9 0.68 
EPI/βpen P5 (1:20) 42.0 7.5 7.0 0.60 
EGDE/βpen Q1 (1:1) 43.6 7.9 9.9 0.85 
EGDE/βpen Q2 (1:5) 45.3 8.4 7.6 0.66 
EGDE/βpen Q3 (1:10) 47.5 8.6 6.5 0.56 
EGDE/βpen Q4 (1:20) 45.0 8.0 5.0 0.43 
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The results show that for EPI/βpen P4 (1:10); R = 0.68 > EPI/βpen P5(1:20); R = 0.60 
indicating that: the higher the linker content, the smaller is the number of CDs attached to the 
polymer backbone. Additionally, comparing EPI/βpen P4 (1:10); R = 0.68 to EGDE/βpen Q3 
(1:10); R = 0.56 it seems that: the extra epoxide ring in EGDE structure promotes a high 
crosslinking of the polymers, instead of promoting further points of attachment for new βpen 
units. 
 
Average Molecular Weight 
The determination of polymer average molecular weight (AMW) is important because 
the magnitude of AMW often determines most of polymer macroscopic properties like the glass 
transition temperature (Tg), the modulus (or stiffness) and tensile strength [201]. The AMW value 
of a polymer depends on the experimental technique used. Suitable techniques are dynamic light 
scattering (DLS), size exclusion chromatography (SEC), vapour pressure osmometry (VPO) and 
viscometry [202]. Often these techniques rely on standards to calibrate the instrumental apparatus 
like polymers of “known” molecular weight, resulting in AMW average values with reasonable 
uncertainties. An alternative method that offers more reliable results is mass spectrometry MS, 
using matrix-assisted laser desorption ionization with time of flight detection (MALDI-TOF). 
MS (MALDI-TOF) provides direct access to molecular weight data rather than average values 
and could allow the direct observation of different end groups. However, accurate and 
reproducible results are often dependent on the matrix selection and methods for the preparation 
of sample [203]. 
From our perspective, the determination of AMW value is important because it would 
enable: i) the calculation of the exact amount of polymeric material to be used for the release 
experiments and ii) it would be possible to relate the ratio between host – guest molecules, with 
the expected stoichiometry of the interaction if available. Table 19 shows AMW values for 
EPI/βpen and EGDE/βpen polymers determined by: vapour pressure osmometry (VPO), static 
light scattering (SLS) and mass MS (MALDI-TOF). 
AMW determined by VPO revealed an AMW = 2130 Da for EPI/βpen P3, which agrees 
with MALDI-TOF MS results for EPI/βpen P4, P5 and for EGDE/βpen Q1, Q2 and Q3 indicating 
small average molecular weight, heavily cross-linked polymers containing few CD units. The 
AMW of EGDE/βpen Q1, Q2 and Q3 determined by static light scattering (SLS) revealed very 
high molecular weight polymers, which is contradictory with the result obtained from MALDI-
TOF MS analysis for the same polymer batch. However, the inconsistency in these results can 
be understood in the light of the limited water solubility revealed by polymeric solutions, given 
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that the method used to record SLS results relies on the preparation of a series of aqueous 
solutions with varying concentrations.  
Therefore, the most reliable results were based on MALDI-TOF MS revealing that all 
EPI/βpen and EGDE/βpen polymers, on average, are represented as a distribution of masses of 
small average molecular weight ranging from ≈ 2500 to ≈ 3400 Da (Table 19). The small 
increase in the molecular weight of the polymers, noticed as the amount of linker (EPI or 
EGDE) added increases, corresponds to an increase in the crosslinking of the polymeric 
materials (EPI or EGDE), which corroborates the elemental analysis results. 
 
Table 19. Average molecular weight of EPI/βpen and EGDE/βpen polymers determined by different analytical 
methods; 
Polymer MALDI-TOF MS (AMW) 
Vapour Pressure 
Osmometry(VPO) 
Static Light 
Scattering (SLS) 
EPI/βpen P3 - 2130 - 
EPI/βpen P4 2557 - - 
EPI/βpen P5 2596 - - 
EGDE/βpen Q1 2640 - 19800 
EGDE/βpen Q2 2935 - 60600 
EGDE/βpen Q3 3012 - 81000 
EGDE/βpen Q4 3381 - - 
 
The attachment of βpen units to both polymers would promote the increase in AMW, 
by at least 1430 g/mol corresponding to the molecular weight of one βpen unit. The MALDI-
TOF MS of EPI/βpen P4 (Figure 94 A) revealed the loss of βpen and at least one more peak at ≈ 
5000 m/z, indicating the presence of a small percentage of higher molecular weight polymer. 
Likewise, the MALDI-TOF MS of EGDE/βpen Q4 (Figure 94 B) revealed the loss of βpen and 
the presence of small percentage of high molecular weight polymer fractions, with peaks 
corresponding to ≈ 7000 m/z and ≈ 11000 m/z. However is the regular heptet observed, with the 
corresponding to 7 fragments, attributed to the loss of EGDE (≈ 174). This indicates that instead 
of acting as a polymer linker in connecting different βpen units, EGDE is probably blocking all 
seven amino groups, limiting the success of the polymerization strategy and increasing the 
crosslinking degree in EGDE/βpen polymers. 
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Figure 94 – MS (MALDI-TOF) of A) EPI/βpen (10:1) P4 and of B) EGDE/βpen (20:1) Q4. 
 
The preparation of positively charged polymers through the incorporation of βpen into 
polymer matrices, based on preformed polymers and on the usage of linkers proved to be of 
limited success. Although the connectivity of the βpen to each polymer was achieved, the small 
amount of material collected poses restrictions on both the characterization and application 
studies of these promising CD-polymers, which were nevertheless studied in selected cases, 
regarding their ability to act as host and as release rate modulators of model guest molecules 
and nucleotides. 
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7.2.6 Inclusion complexes of βpen with selected guest molecules 
βpen as a model host 
In order to evaluate the ability of EPI/βpen and EGDE/βpen polymers to interact with 
potential useful molecules, βpen (Figure 95 A) was used as model host because: i) βpen is part 
of EPI/βpen and EGDE/βpen polymeric structures and ii) βpen as been prepared and 
characterized in our group by NMR spectroscopy. The model guests used for evaluate the 
complexation with bpen and with CD-polymers prepared were adenosine 5’-monophosphate 
(5’-AMP, Figure 95 B) and 4-aminobenzoic acid (PABA, Figure 95, C).  
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Figure 95. Structures of host (βpen) and guest molecules (5’-AMP and PABA). 
 
PABA has been used because: i) at physiological pH, it is mostly present as a 
carboxylate anion which maximizes the interaction with positively charged CD like βpen; iii) 
PABA has the perfect size/shape to fit the cavity of βpen and it shows a very simple 1H NMR 
spectrum; finally, iv) PABA find most of its applications as UV filter in sunscreens. On the 
other hand, 5’-AMP was used because it is a readily available, cheap nucleotide and revealed 
interactions through formation of inclusion complexes with per(6-guanidino)-CDs (α-, β-, γ-
guan), following several stoichiometries and modes of interaction [196]. If successful, a similar 
strategy can be applied and used to study the interaction of gemcitabine monophosphate with 
CD-polymers.  
NMR spectroscopy was used to study the intermolecular interactions between the model 
guest molecules (5’-AMP and PABA) and the host βpen macrocycle. 1H NMR and 2D ROESY 
NMR experiments were performed in phosphate buffered saline (PBS, pH = 7.4) at 25 ºC.  
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4-Aminobenzoic acid (PABA) with βpen 
The 1H NMR spectrum of βpen was recorded before and following the addition of the 
guest (PABA). A chemical shift difference was observed in the aliphatic region (3.7 ppm – 3.9 
ppm), corresponding to the region of βpen internal protons (CD-H3/H5). 2D ROESY NMR 
experiment revealed strong dipolar interactions, between PABA-H3/3’ and βpen CD-H3 and 
between PABA-H2/2’ and CD-H5 (Figure 96 A). These intermolecular interactions support by a 
preferred mode of interaction, with the carboxylate moiety of PABA molecule oriented towards 
the primary side of βpen, leaving the amino group facing the secondary side of the host 
molecule (Figure 96 B).  
 
 
Figure 96. A) 2D NMR ROESY (25 ºC) spectrum expansion revealing intermolecular dipolar interactions 
between βpen and PABA. B) Mode of inclusion proposed for the complexation between these two molecules, 
based on NMR data. 
 
Adenosine 5’-monophosphate (5’-AMP) with βpen 
5’-AMP interaction with βpen was evaluated by NMR spectroscopy. The 1H NMR of 
βpen was recorded before the addition of 5’-AMP, which promotes a change in the chemical 
shift of βpen internal protons resonances (CD-H3/5). After addition of 5’-AMP in 4-fold excess 
to maximize interactions, the 1H NMR spectrum revealed shielding of CD-H3/5 and deshielding 
of CD-H2/4 and CD-H6/6’/7/8. The 2D ROESY NMR experiment (Figure 97 A) revealed that the 
internal protons of βpen (CD-H3/5), showed many interactions with different protons of 5’-
AMP, namely with: i) the ribose protons (H1’/2’/3’/4’/5’, Figure 97 C, D) and with ii) the protons 
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from the nucleobase (H2, H8) (Figure 97 B). All of these interactions both with the 
primary/secondary side of βpen cavity and with multiple sites of the 5’-AMP molecule suggest 
a complexation equilibrium involving multiple species and perhaps a complex stoichiometry. 
 
 
Figure 97. A) 2D ROESY NMR spectrum (25 ºC) with an expansion revealing multiple intermolecular dipolar 
interactions between βpen and 5’-AMP. B) Region of the spectra corresponding to CD-H3/5 interactions. 
 
The table of multiple intermolecular dipolar interactions (Table 20 A), between every 
proton of βpen and of 5’-AMP was obtained from the intensity of the contour peaks in a 2D 
ROESY experiment (Figure 97 A).  
 
Table 20. 5’-AMP / βpen complex: i) table of intermolecular dipolar interactions between 5’-AMP and βpen; 
ii) proposed model of inclusion for this complex, following a 2:1 stoichiometry (G:H).  
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The continuous variation method (Job’ plots) was applied to determine the 
stoichiometry of complexation, between βpen (host, H) and 5’-AMP (guest, G). 1H NMR 
spectroscopy was used to evaluate proton chemical shift changes (∆δ), resulting from the 
addition of a G solution to an initial solution of H, both kept constant  and equal to 10 mM, 
prepared in deuterated phosphate buffer saline (PBS). The resulting Job’ plots (Figure 98) 
revealed that there is inclusion of 5’-AMP into βpen resulting in:  
i) shielding of βpen internal proton (CD-H5) observed by a positive chemical shift 
change (+ ∆δ), attributed to inclusion 
ii) deshielding of the aminoethylamino group (CD-H7 /CD-H8) justified by a 
negative chemical shift change (- ∆δ), due to the presence of phosphate anion 
group facing the primary side of the macrocycle 
 
The Job’ plots maximum (CD-H5) and minimum (CD-H7 /CD-H8) were observed to 
([H] / ([H] + [G]) = 0.3, corresponding to a stoichiometry of complexation 5’-AMP / βpen = 2:1 
and confirming the multiple interactions observed from the 2D ROESY experiment (Figure 97 
A). 
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Figure 98. Job plot for titration of βpen in the presence of 5’-AMP. 
 
Considering the above data, a suggestion of an inclusion model is depicted in Table 20 
B. The model is consistent with the inclusion of one 5’-AMP with the phosphate group toward 
the positively charged amino side as previously observed [196], but illustrates the known 
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tendency of the nucleotides to dimerise via head-to-head stacking of the flat aromatic base 
moieties.  
 
7.2.7 Inclusion complexes of polymers with selected guest 
molecules 
EPI/βpen P3  with PABA 
Following the successful complexation experiment of βpen with PABA, the same guest 
molecule (PABA) was used to determine if βpen cavities in EPI/βpen P3 polymer (see chapter 
7.2.6) were available and free for inclusion. The initial 1H NMR spectrum of EPI/βpen P3 was 
broad and unresolved and after the addition of an excess of PABA (≈ 4.8 molar eq.) to the 
polymer solution, a slight change in the peaks of aliphatic broad region of the spectra was 
observed. 2D ROESY NMR experiment (Figure 99 A) revealed strong dipolar intermolecular 
interactions, between βpen internal protons (CD-H3/H5) and PABA aromatic signals (H2/2’/H3/3’) 
suggesting that βpen cavity grafted to EPI/βpen P3 backbone interacts with PABA and is 
therefore free to load other molecules, like nucleotides (5’-AMP). A proposed model of 
inclusion for the complexes with PABA is depicted in Figure 99 B.  
 
 
Figure 99. A) 2D NMR ROESY spectrum (25 ºC) expansion revealing intermolecular dipolar interactions, 
between EPI/βpen P3 and PABA; B) Mode of inclusion proposed for the complexation between these two 
molecules. 
 
This successful result shows that EPI/βpen polymers can be used as carriers for other 
molecules such as 5’-AMP and will be explored as host systems and tested as modifiers of 
release of 5’-AMP through a dialysis membrane (see section 7.2.9). 
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pLys.βpen BB’ with PABA 
PABA was likewise used as model guest to evaluate the availability of βpen cavities in 
pLys/βpen BB’ polymers for inclusion. 1H NMR spectrum of pLys / βpen BB’ was recorded, 
followed by addition of an excess of PABA. The presence of PABA in solution is observed by 
its characteristic aromatic peaks, but the detection of CD-H3/H5 chemical shifts was not possible 
from the 1H NMR spectra of pLys.βpen BB’, due to the big overlap in the aliphatic region (3.7 
ppm - 3.9 ppm). The assignment of the region between 3.7 ppm – 3.9 ppm to the resonances of 
CD-H3/H5 was obtained from 2D HSQC spectrum (Figure 100 A) and 2D ROESY NMR 
spectrum (Figure 100 B) revealed dipolar interactions, between PABA-H2,2’,3,3’ and the internal 
protons of the βpen (CD-H3/H5), grafted to pLys.βpen BB’ (3.7 ppm - 3.9 ppm, blue region 
Figure 100 A and Figure 100 B). Likewise, the successful inclusion of PABA into βpen cavities 
of pLys/βpen BB’ polymer, indicates that these cavities are also accessible for inclusion of other 
suitable guest molecules. 
 
 
Figure 100. 2D NMR experiments (25 ªC) of pLys/βpen BB’ (1.2 mg / 0.5 mL D2O) in the presence of an excess 
of PABA: A) 2D NMR HSQC and B) 2D NMR ROESY. 
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pLys/βpen T2 with 1-adamantanamine hydrochloride (ADA-NH3Cl) 
The evaluate the usefulness of pLys/βpen polymers as versatility host systems, the 
inclusion studies were extended to 1-adamantananime hydrochloride (ADA-NH2.HCl). In 
addition, it is structurally very similar to 1-adamantanecarboxylic acid (ADA-COOH), a starting 
material used in the preparation of gemcitabine-adamantanamide (GEM-ADA amide), a 
molecule that revealed limited solubility in water and posed stability problems in methanol 
solutions. 
The 1H NMR characteristic signals of ADA-NH2.HCl in D2O are expected in the 
aliphatic region of the spectrum (< 2.3 ppm) [187]. The 1H NMR spectrum of pLys/βpen T2 
solubilised in D2O was recorded before and after the addition of ADA-NH2.HCl: all regions of 
the spectrum revealed broad peaks and overlapping regions. As previously, 2D ROESY NMR 
experiment revealed strong intermolecular interactions between, the internal protons of βpen 
(CD-H3/H5, 3.8 ppm – 4.0 ppm) and those of ADA-NH2.HCl  (1.6 ppm – 2.4 ppm), which are 
attributed to the formation of an inclusion complex (Figure 101 B): positively charged amino-
end of ADA-NH2.HCl, will be facing the secondary side of βpen cavities in the polymer. This 
agrees with the expected electrostatic repulsion between the positively charged amino group of 
ADA-NH2.HCl and the positively charged primary side of the βpen in the polymer with the 
several aminoethylamino chains.  
 
 
Figure 101. A) 2D NMR ROESY spectrum (25 ºC) of pLys/βpen T2 in the presence of ADA-NH2.HCl; B) the 
proposed model of inclusion for this complex.  
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7.2.8 Inclusion studies of polymers with gemcitabine-
adamantanaminde (GEM-ADA amide) 
pLys/βpen BB’ with GEM-ADA amide 
The initial 1H NMR spectrum of a pLys/βpen BB’ polymer solution was recorded, 
followed by the addition of GEM-ADA amide. 2D ROESY NMR experiment (Figure 102 A) 
revealed strong intermolecular interactions, between ADA-moiety of GEM-ADA amide (1.6 
ppm – 2.2 ppm) and the internal protons of βpen in the polymer (CD-H3/H5, 3.7 ppm – 3.9 
ppm). The proposed model of inclusion (Figure 102 B) suggests that GEM-ADA amide in 
included in βpen cavities of pLys/βpen BB’, through insertion of ADA moiety into the 
secondary side of the CD macrocycle. 
 
 
Figure 102. A) 2D NMR ROESY spectrum (25 ºC) of pLys/βpen BB’ (1.0 mg / 0.5 mL D2O) in the presence of 
an excess of GEM-ADA amide and B) proposed model of inclusion for the complex between GEM-ADA amide 
and pLys / βpen BB’. 
 
These preliminary trials reveal that pLys/βpen polymers are suitable for inclusion of 
charged molecules, which offers advantages regarding the potential stability of sensible 
formulations based on gemcitabine. Additionally, the attachment of an ADA moiety to the 
GEM.HCl structure offered additional chemical protection to GEM structure and added a ADA 
moiety suitable for inclusion into CD polymers, such pLys.βpen BB’. 
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7.2.9 Polymers as release rate modifiers of selected nucleotides 
One of the fundamental characteristics of a polymeric material in a formulation is its 
ability to modulate the release rate of a drug. CD-polymers are known to modify the release 
rates of several drugs and the manner by which this is achieved has been described [109].  
To evaluate the ability of CD-polymers to complex and delay the release of nucleotides 
into solution, a modified Franz cell was used to study the release of a model nucleotide (5’-
AMP) through a permeable membrane (benzoylated dialysis tubing, MWCO = 2000 Da) in 
phosphate buffer saline (PBS, pH = 7) at 37 ºC (see section 9). A Franz cell apparatus is shown 
in Figure 103 and comprises: a donor and a receptor compartment, separated by a hollow 
junction to which a dialysis membrane (MWCO = 2000 Da) is attached, it is filled with media 
and is kept at constant temperature (37 ºC) under constant magnetic stirring. The analyte to be 
tested (5’-AMP, 1 mM in PBS) is added to the donor side and at a given time intervals, the 
content of the receptor is sampled, replacing each time the volume taken with fresh solvent 
(PBS). It was assumed that: i) the benzoylated dialysis tubing (MWCO = 2000 Da) is permeable 
to 5’-AMP; ii) 5’-AMP diffuses from the donor to the receptor at a constant rate for a given 
temperature and concentration of 5’-AMP. 
 
 
Figure 103. Modified Franz-cell set up used for the determination 
of the release rates, with two compartments separated by a 
hollow junction to which is attached a benzoylated dialysis tubing 
MWCO = 2000 Da. 
 
The rate of release can be calculated by determining the amount of 5’-AMP released 
into the receptor, if equal volumes are collected, at fixed time intervals (0, 60, 120, 180, 240, 
300 and 360 min), followed by replacement with fresh PBS in the compartment each time. The 
drawn liquid were subsequently analysed with HPLC. 
UV-Vis spectroscopy was used for identifying a suitable wavelength (λ) for the 
detection 5’-AMP. Figure 104 A shows the UV-Vis spectrum of an aqueous solution of 5’-AMP 
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(62 µM) prepared in PBS and λ was chosen close to the maximum of absorption (λ = 258 nm). 
Consequently, a calibration curve for 5’-AMP (Figure 104 B) revealed a linear response for 5’-
AMP prepared in concentrations ranging from 5 µM to 250 µM, with detection wavelength (λ = 
254 nm). 
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Figure 104. A) UV-Vis absorption spectrum of 5’-AMP (62.5 µM; PBS) and B) calibration curve for 5’-AMP 
determined by HPLC analysis with UV-detection at λ = 254 nm. 
 
Several trials were executed to evaluate the capacity at polymers prepared to release 5’-
AMP in aqueous buffered solutions (1 mM, PBS, pH = 7.4), through a dialysis membrane using 
the modified Franz-cell (Figure 103).  
Figure 105 A shows the release rates of: i) 5’-AMP (1 mM, PBS) used as a blank 
experiment; ii) 5’-AMP (1 mM, PBS) in the presence of EPI/βpen P5 (3.2 mg/mL, PBS) and iii) 
5’-AMP (1 mM, PBS) in the presence of βpen.HCl (1 mM, PBS) used as model complexation 
agent. Comparison shows that the release rates of: 5’-AMP (18.0 µM/h) > 5’-AMP + βpen.HCl 
(13.8 µM/h) > 5’-AMP + P5 (9.0 µM/h). Therefore, 5’-AMP will diffuse through the 
benzoylated dialysis tubing (MWCO = 2000 Da) 1.3 times faster than 5’-AMP in the presence of 
an equimolar solution of βpen.HCl, which can be explained by the formation of an inclusion 
complex between 5’-AMP and βpen.HCl. However, 5’-AMP in the presence of EPI/βpen P5 
(9.0 µM/h) is released twice as slow in the donor side, than 5’-AMP alone (1 mM; 18.0 µM/h) . 
That can be explained by: i) inclusion / complexation with βpen present in EPI/βpen P5 and ii) 
the possible entanglement, between different polymer chains, can physically delay the diffusion 
of 5’-AMP through the membrane. Given the cloudiness that is noticed during the preparation 
of polymeric aqueous solutions, namely those of EPI/βpen (Table 16), it is reasonable to expect 
that aggregation can affect the release rate of 5’-AMP in solution, even starting from diluted 
solutions like 1 mM in donor compartment.  
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Figure 105. Release rates experiments: trial 1: 5’-AMP as a blank; AMP + βpen.HCl and 5’-AMP + P5. Effect 
of changing the polymer content of linker (EGDE/βpen Q2, Q3 and Q4) on the release rate of 5’-AMP, through 
a dialysis membrane.  
 
Similar results were found when the release rate of 5’-AMP (1 mM, PBS) used as a 
reference, was determined in the presence of EGDE/βpen Q2, Q3 and Q4 (1.6 mg/mL, PBS) 
polymers Figure 105 B: i) the release of 5’-AMP (16.2 µM/h) agrees with the value found 
previously (average = 17.1 µM/h); ii) 5’-AMP is retained longer in EGDE/βpen polymers, with 
similar release rates: Q2 (10.8 µM/h), Q3 (13.8 µM/h) and Q4 (15.0 µM/h); iii) EGDE/βpen Q2, 
Q3 and Q4 polymers show higher release rates than EPI/βpen P5, meaning that EGDE/βpen 
polymers are less effective in retaining 5’-AMP than EPI/βpen polymers. A reason for these 
changes in the release rate of different CD-polymers might be related to the different βpen 
content in each polymer. 
Therefore, the release rate of 5’-AMP (1 mM, PBS) was determined in the presence of 
different amounts of βpen.HCl, keeping 5’-AMP a constant concentration (1 mM, PBS)  (Figure 
106 A). The results showed that: i) the release rate of 5’-AMP (19.8 µM/h) is comparable to the 
previous trials (average = 18.0 ± 1.8 µM/h) and ii) the release rates of 5’-AMP is affected by the 
presence of increasing amounts of βpen.HCl: 19.2 µM/h; 5’AMP + βpen.HCl (R = 0.65) > 10.2 
µM/h; 5’-AMP + βpen.HCl (R = 1.03), considering R = nβpen / n5’-AMP. This indicates that the 
presence of more βpen enhances the retention of 5’-AMP on the donor compartment, due to 
inclusion into the βpen units of the polymer. 
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Figure 106. Release profile experiments of 5’-AMP: effect of addition of 
increasing amount of βpen / 5’-AMP, with R = nβpen / n5’-AMP. 
 
Additional trials using increasing amount of polymer EGDE/βpen Q3 (1, 2.5 and 7.5 
mg/mL in the donor compartment revealed that: i) solutions became cloudy during preparation 
and ii) release rates results under these conditions were not reproducible. In addition, the 
limitations found in the determination of the accurate number of βpen content in each polymer 
limits the proper analysis of release rate results, because a direct correspondence to the number 
of CD cavities responsible for inclusion cannot be made. However, it is expected that a high 
content of βpen.HCl in the polymers promote a stronger binding of 5’-AMP and decreased rate 
of release through the membrane. 
Finally, following the strategy outlined for the determination of the release rate of 5’-
AMP, the release rate of gemcitabine monophosphate (GEM-MP, 1 mM, PBS) was determined 
in the presence of pLys/βpen polymer BB’ using the same experimental set up (Figure 103). A 
calibration curve for GEM-MP (Figure 107 A) previously determined in our group was used as 
a reference, against which the concentrations of GEM-MP from the release experiment were 
calculated. Therefore, 5’-AMP (1 mM, PBS) and GEM-MP (1 mM, PBS) release rates through 
the benzoylated dialysis tubing (MWCO = 2000 Da) were determined (Figure 107). The release 
rate for 5’-AMP (27.6 µM/h) is higher than the one found for GEM-MP (22.2 µM/h, 1 mM, 
PBS), which is due to stronger interactions of GEM-MP with the pLys/βpen BB’ polymer. 
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Figure 107. A) Calibration curve for GEM-MP determined by HPLC analysis with UV-detection at λ = 254 
nm. B) Host-molecules: adenosine 5’-monophosphate (5’-AMP) and gemcitabine monophosphate (GEM-MP). 
 
In summary, the release rate of 5’-AMP through a benzoylated dialysis membrane 
(MWCO = 2000 Da) can be modified modified simple by adding βpen.HCl to the donor 
compartment. However, with positively charged polymers like EPI/βpen P5, EGDE/βpen Q2, Q3 
or Q4 the release rate of 5’-AMP through the membrane can be decreased leading to a modified 
release of the host molecule. Interestingly, preliminary trials using pLys/βpen BB’ to modify the 
release of 5’-AMP and GEM-MP suggest that the polymer can interact with the membrane, 
resulting in increase of rate. Our studies were limited by the aggregation phenomena, limited 
amount of polymers obtained and the relative uncertainty in the determination of the βpen 
content / molecular weight of the polymers. However, we have explored methods and 
approaches towards polymers with multiple bpen cavities and charges, potentially useful for 
delivery of negatively charged drugs. 
 
 
7.3 Preparation of monomers 
7.3.1 Ethylene glycol diglycidyl ether (EGDE) 
Epoxides are cyclic ethers rings, with three atoms that due to high bond strain in its 
ring, are much more reactive than other ethers, namely towards nucleophilic substitution via 
ring opening [3]. The ring opening reaction of an epoxide generates an alkoxy (or hydroxyl) and 
when combined with other good leaving group, or a second epoxide ring, offers a difunctional 
and versatile monomer for polymerization reactions. 
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Ethylene glycol diglycidil ether (EGDE, Figure 108) is not commercially available, but 
can be found from Sigma-Aldrich as a polymer with average molecular weight, ranging from 
500 g/mol to 6000 g/mol [204]. However, Peng et. al. [205] reported the preparation of EGDE, from 
the controlled reaction between ethylene glycol (EG) and epichlorohydrin (EPI) in mild 
conditions. EGDE was isolated in ≈ 27 % yield, from a crude oil obtained by liquid-to-liquid 
extraction, subsequent distillation followed by column chromatography. However, no TLC data 
regarding the separation of the EGDE and any related impurities was described.  
 
 
Figure 108. Synthesis of EGDE starting from EPI and EG. 
 
In our hands based on the Peng’s reported procedure [205], EGDE was obtained as a pure 
compound isolated from a mixture of three products, after reaction in mild (35 ºC – 40 ºC, 1 h) 
alkaline conditions (H2O / NaOH) in the presence of tetra-butyl-ammonium chloride (Bu4NCl), 
a phase-transfer catalyst used to enhance the solubility between two immiscible reactants, EG 
and EPI (Figure 108).  
After 1 h, the reaction was stopped; liquid-to-liquid extraction was used followed by 
column chromatography to isolate the desired crude mixture. TLC monitoring during column 
elution (silica gel; EtOAc : EtOEt (5:1)) revealed three different products: fraction 1, 2 and 3 
(Figure 109 A). 1H NMR analysis of each fraction revealed that EGDE corresponded to fraction 
3 (Figure 109 B). EGDE, isolated as a yellow oil, was further characterized by 13C NMR with 
assignments corroborated by both 2D COSY and HSQC experiments, which agree with 
literature data [205]. Fractions 1 and 2 (impurities) were discarded based their 1H NMR spectra, 
not related to the 1H NMR features expected for EGDE. 
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Figure 109. TLC monitoring of column fractions (1, 2, 3) collected during EGDE purification: (A) initial 
purification stage with collection of three different fractions and (B) a later stage in the separation, where the 
desired EGDE isolated as a clean  product (fraction 3). 
 
The poor yield obtained (12 %) deserved some attention and a series of modifications 
were performed to the original procedure, trying to improve the reaction yield: 
i) the molar ratio (EPI/EG) was changed from the reported EPI/EG = 6 down to 
EPI/EG = 2, which lead to an economy of the reactants 
ii) the reaction was performed in the absence of water, to avoid undesired and 
competing reactions such as the nucleophilic attack of – OH to an epoxide 
ring, resulting in faster reactions rates in the presence of water (precipitation / 
cloudiness would start much faster) 
Therefore, as a general strategy to stop the reaction and avoid heavy precipitation, 
whenever the cloudiness of the solution and viscosity started to increase (visual detection), the 
trials were stopped and the reaction crude separated. Interestingly, a failed trial revealed that if 
the temperature of the reaction mixture rises above ≈ 40 ºC, even if for a short while, massive 
precipitation leads to untreatable reaction crudes. The overall yield of EGDE remained low (12 
%) in spite of these efforts.  
One of the reasons for the poor yields described and achieved is the lack of selectivity 
on the ring opening reaction and the possibility of competitive reactions that lead to the 
formation of mono-glycidyl ethers and several oligomers [205]. This can be schematically 
illustrated in Figure 110. 
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Figure 110. Schematic representation of the multiple possibilities of nucleophilic substitution reactions (SN2) 
between an alkoxide species (R – O-) and an epoxide ring (EPI). 
 
Thus, EGDE was successfully obtained as mixture of three products, which is typical of 
any polymerization reaction. Comparatively to the reported literature, although EGDE was 
obtained in smaller yield our approach is preferred because: i) a TLC method for the reaction 
monitoring was developed and ii) the time-consuming distillation method was avoided. 
 
7.3.2 Per(6-iodo-6-deoxy)-βCD (βpI) 
In order to generate and incorporate CDs in any polymer backbone, versatile building 
blocks are required. Heptakis(6-iodo-6-deoxy)-βCD (βpI) and/or heptakis(6-bromo-6-deoxy)-
βCD (βpBr) are two per-halogenated CDs prepared from βCD following a typical per-
halogenation reaction (Figure 111), suitable for preparation of CD containing polymers as they 
are multifunctional CDs. 
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Figure 111. Synthesis of a per-substituted derivative βpX (X = I or Br) starting from βCD. 
 
The reaction followed a modified procedure based on the work reported by Defaye [33]. 
It involves, the reaction between N-bromosuccinimide (NBS) [ 206 ] and triphenylphosphine 
(PPh3) in dry dimethylformamide (DMF), followed by addition of βCD. Depending on the 
halogen (-X) donor used, different derivatives can be achieved namely: i) per-iodo derivatives 
using iodine (I2), and ii) per-bromo derivatives using bromide (Br2) or NBS. 
βCD was therefore converted into βpBr (94.3 % yield) and into βpI (88.3 % yield). The 
exact same synthetic procedure (see section 7.3.2) was applied to prepare α-, β- and γ-CD 
leading to a multigram preparation of all per-halogenated CDs. The advantage in the strategy 
applied involved the TLC (silica, dioxane / NH3 / iPrOH (10:7:3, v/v)) monitoring of the 
reaction progress until completion (Figure 112). It revealed: i) the presence of any unreacted 
βCD; ii) the formation of the desired product βpBr; iii) the presence of the typical intermediate 
products: under-brominated derivatives, triphenylphosphine oxide (PPh3=O) and over-
brominated derivatives.  
The purification steps involved water (H2O) and methanol (MeOH) washings, resulting 
in a light brown solid (βpBr). It was found that with H2O, most of the UV-active impurities 
(PPh3=O) could be removed. However, methanol (MeOH) is not selective and washes away 
most of UV-active impurities, over-brominated CD products and the desired product βpBr. 
Therefore, given that βpBr is soluble in MeOH, a compromise should be reached between the 
number of washings, the amount of MeOH used to wash the product. 
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Figure 112. TLC monitoring of the bromination of βCD (NBS method). 
 
βpBr was obtained as a light yellow solid, it was characterized by 1H NMR and 13C 
NMR spectra. Typical NMR features of βpBr in DMSO-d6 are: i) the absence of 1H NMR 
signals due to OH6 resulting from substitution by Br and ii) 13C NMR reveals a large chemical 
shielding of C6 signal that, after per-substitution, shift from 60.3 ppm in βCD to 34.5 ppm in 
βpBr. Additionally, if the purification procedure is not successful, traces of undesired impurity 
(PPh3=O) can be revealed by their 1H NMR characteristic signals in the aromatic region (7 – 8 
ppm) and the purification refined. 
Previously reported methods [207, 33] fail to describe any TLC data, which was critical to 
evaluate reaction progress and assess purification achieved. In our group perspective, these 
findings were even more relevant as all per-halogenated (I, Br) CDs have been prepared in 
multigram scale, which in our laboratory experience was never achieved before. This was 
possible due to a short collaboration, between our group and Cyclolab in Hungary. 
The major advantage of the bromination and iodination procedures is the insertion of 
good leaving groups in the narrow periphery of CDs, making βpBr and βpI useful derivatives 
towards nucleophilic substitution reactions. βpBr and βpI were used in the preparation of per(6-
aminoethylamino-6-deoxy)-βCD (βpen) (see next section) and in the preparation of polymers 
based on pLys structure, described in section 7.2.1.  
 
7.3.3 Per(6-aminoethylamino-6-deoxy)-βCD (βpen) 
The synthesis of per(6-aminoethylamino-6-deoxy)-βCD (βpen) and its hydrochloride 
salt (βpen.HCl) from per-halogenated CDs (βpI or βpBr), followed a patented strategy 
developed in our group [208] with minor modifications. The reported preparation involves the 
reaction of βpBr with an excess of 1,2-diaminoethane (DAE), acting both as solvent and 
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reactant, in an autoclave, under pressure (7 atm) at 80 °C for 3 - 4 days. βpen was isolated as a 
βpen.HCl salt in 18 % yield, after precipitation in cold acetone, acidification and dialysis at pH 
= 7.0 (Sigma dialysis cellulose tubing, benzoylated) for extra 3 days. A modified general 
procedure was adopted herein (Figure 113). It involved the reaction of βpI (or βpBr), with an 
excess of DAE at 80 ºC. 
 
 
Figure 113. Synthesis of βpen (freebase) and βpen .HCl from βpBr or βpI. 
 
The reaction was monitored by TLC (silica, iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v)) 
and after nearly 24 h it reached completion, with the simultaneous consumption of βpBr . βpen 
(freebase) can be precipitated from the reaction mixture, when poured directly into an excess of 
DMF, followed by washings with ethanol (EtOH). Alternatively, βpen (freebase) can then be 
easily converted into its hydrochloride salt (βpen.HCl), by solubilisation in dilute HCl (0.1 M) 
until pH ≈ 7 – 8 followed by freeze-drying. βpen.HCl is yellowish compound and has better 
water solubility than βpen (freebase), that is white powder and is sparingly water-soluble.  
βpen (freebase) was analysed by MALDI-TOF MS and characterized by NMR. The MS 
of βpen (freebase) revealed excellent agreement with the expected value and the mass fragments 
detected correspond to the aminoethylamino tails lost (Appendix, Figure 116). The 1H NMR 
and 13C NMR spectra in D2O agree with reported data [208], but the appearance of the 13C is 
greatly affected by the pH of the βpen solution (freebase) and the best results were obtained at 
pH ≈ 4 corresponding to the formation of the βpen.HCl in solution, with all amino groups 
charged thus the molecule is symmetrical and the spectrum is simple.  
In summary, the modifications implemented to the original procedure enable:  
i) the monitoring of the reaction progress by TLC, that reaches completion with 
the complete consumption of the starting material βpBr (or βpI) 
ii) a faster reaction lasting only 1 day as opposed to at least 3 - 4 days, 
performed in a small glass flask avoiding the use of the autoclave 
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iii) the isolation of the pure βpen (freebase) by precipitation in DMF, directly 
from the reaction mixture 
In addition, βpen possesses simultaneously i) good nucleophilic properties due to the 
presence of primary and free amino groups and ii) positively charge, due to both primary and 
secondary amino groups. The methodology developed offers a selective purification method for 
the removal of water-insoluble βpBr (or βpI) from reaction mixtures, through the generation of 
water-soluble (βpen). This strategy will be used in the preparation of positively charged CD 
polymers.  
Finally is worth noting that it has earlier been shown that, βpen and similar derivatives 
are charged in neutral pH and display two pKa values (pKa1 = 6.5 and pKa2 = 9.5), while 
protonation occurs at the secondary amino groups [195]. 
 
7.4 Conclusions and future perspectives 
CD-polymers based on a positively charged CD (βpen) were prepared using two 
different strategies: i) based on a commercial preformed polymer (pLys.HBr) and ii) based on 
readily available monomers such as EPI and EGDE. Although it was possible to prepare, 
characterize and use these CD-polymers their extensive application was impaired because of 
lack of low reproducibility in the preparation and difficulties in the scale-up due to limited 
availability of the expensive raw-materials pLys.HBr. 
Despite these limitations, all polymers revealed good water solubility properties and the 
successful attachment of βpen to polymeric backbone, demonstrated by NMR spectroscopy, 
enabled: i) the evaluation of release rates of nucleotides through a dialysis membrane in a Franz 
cell set up and ii) the study of inclusion / complexation with model molecules.  
Regarding the complexation ability polymers EPI/βpen P3 and pLys/βpen BB’ can 
complex p-aminobenzoic acid (PABA). In addition, polymer pLys/βpen T2 can successfully 
complex 1-adamantanamine (ADA-NH3Cl) and polymer pLys/βpen T2 proved a suitable host 
for anticancer gemcitabine modified with adamantyl group (GEM-ADA amide).  Additionally, 
polymers EPI/βpen P5 and EGDE/βpen Q1, Q2, Q3, Q4 could modify the rate of release of 
adenosine 5’-monophosphate (5’-AMP) by decreasing its rate of release through a dialysis 
membrane. However, polymer pLys/βpen BB’ showed the opposite effect towards a nucleotide 
drug gemcitabine monophosphate (GEM-MP); these results merit optimization, as each type of 
nucleotide constitutes a unique case. In this sense, these preliminary results are promising 
towards new CD-polymers for drug delivery systems.  
 
  
 
 
 
 
 
 
EXPERIMENTAL 
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8. Materials 
All solvents were reagent grade and were used as received. Deuterated NMR solvents 
D2O, DMSO-d6, CDCl3 and MeOD-d4 were purchased from Deutero GmbH (Kastellaun, 
Germany). Dry dimethylformamide (DMF), gemcitabine hydrochloride (GEM), 1-
adamantanamine hydrochloride (ADA-NH3Cl), 1-adamantanecarboxylic acid (ADA-COOH), 
tamoxifen (TAM), sodium hydroxide (NaOH), 4-toluenesulfonyl chloride (TsCl), hydrochloric 
acid (HCl), triphenylphosphine (PPh3), potassium hydroxide (KOH), N-bromosuccinimide 
(NBS), sodium methoxide (CH3ONa), 1,2-diaminoethane (DAE), epichlorohydrin (EPI), 
ethylene glycol (EG), ammonium chloride (NH4Cl), magnesium sulphate (MgSO4), N,N'-
diisopropylethylamine (DIPEA), 1-[bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-
b]pyridinium 3-oxid hexafluorophosphate (HATU), gemcitabine hydrochloride (HCl), sodium 
chloride (NaCl), 1-chloroethylchloroformate (CECF), citric acid (CA), fluorescein 
isothiocyanate isomer 1 (FITC), preformed polymers poly-L-lysine hydrobromide (pLys.HBr, 
500 Da < AMW < 1000 Da; 1000 Da < AMW < 5000 Da and 4000 Da < AMW < 15000 Da), 
benzoylated cellulose dialysis membrane (MWCO = 2000 Da) was purchased from Sigma 
Aldrich (Germany). Snake skin pleated dialysis tubing (MWCO = 3500 Da) was purchased from 
Thermo Scientific. 5,10,15,20-tetrakis(m–hydroxyphenyl)-21,23H-porphyrin (mTHPP) was 
purchased from Innochem Ltd (Carnforth, Lancashire, UK). β-cyclodextrin (βCD) and 
per(2,3,6-trimethyl)-β-cyclodextrin (pMβCD) was purchased from Cyclolab (Budapest, 
Hungary). 
 
 
9. Methods 
Chromatography 
Sample was applied to TLC plates using glass capillaries or calibrated micropipettes (1 
– 5 µL). TLC plates were examined under ultra-violet light of λ = 365 nm or λ = 254 nm) and 
were visualized using one to the following revealing solutions (RS):  
• RS A – 4 % H2SO4 / EtOH (v/v), prepared by solubilising concentrated sulphuric 
acid (H2SO4, 2 mL) into  ice-cold ethanol (EtOH, 50 mL). 
• RS B – anisaldehyde solution: prepared by mixing p-anisaldehyde (9.2 mL), with 
acetic acid (AcOH, 3.75 mL), ethanol (EtOH, 338 mL) and sulphuric acid (H2SO4, 
12.5 mL). 
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Preparative chromatography was performed using glass plates (20 cm x 20 cm) coated 
with silica gel GF (thickness = 500 µm). Flash column chromatography was performed using a 
glass column (length (L), cm x outer diameter (OD), cm) and silica gel (pore size 60 Å, 70-230 
mesh, 63-200 µm).  
 
pH measurements 
The pH was measured using an MP200 Mettler Toledo pH meter. Before each 
measurement, the electrode system was calibrated in hydrogen ion concentration units (pH = - 
log[H+]) using buffer reference standard solutions (Scharlau) at 25 ºC. Alternatively, universal-
indicator paper (range pH 1.0-11.0, Sigma-Aldrich) was used for pH checking on reaction 
progress. 
 
UV-Vis / fluorescence spectroscopy (UV-Vis / Fluor) 
UV-Vis spectra were collected on: i) an Agilent Cary 60 UV-Vis spectrometer, using a 
quartz cuvette (1 cm path length) or ii) on a JASCO double beam spectrophotometer (V-560). 
The baseline was corrected using the solvent spectrum as a reference. Fluorescence spectra were 
recorded using a: i) Varian Cary Eclipse fluorescence spectrometer or ii) a JASCO 
spectrofluorimeter (FP-777) using a quartz cell with 1 cm path length. 
 
Infrared spectroscopy (IR) 
Infrared (IR) spectra were collected on a Thermo Scientific Nicolet 6700 FTIR, with N2 
purging system and a common deuterated triglycine sulphate (DTGS) detector. Spectra were 
acquired using a single reflection ATR (Attenuated Total Reflection) SmartOrbit accessory 
equipped with a single-bounce diamond crystal, with a spectral range (10000 – 55 cm-1) and a 
45º angle of incidence. 32 scans were collected in the range 4000–400 cm−1 and taken a 
resolution of 4 cm−1.  
 
Nuclear magnetic resonance (NMR) 
All NMR experiments were recorded at 298 K. 1D and 2D NMR spectra were acquired 
either on a Bruker Avance III spectrometer at 250.13 MHz for 1H and 62.90 MHz for 13C or on 
a Bruker Avance DRX 500 spectrometer at 500.13 MHz for 1H and 125.77 MHz for 13C. 1H 
NMR spectra recorded in D2O were referenced on the HOD signal at δ = 4.79 ppm. 2D ROESY 
spectra were acquired with presaturation of the residual water resonance and a mixing (spin-
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lock) time of 350 ms at a field of ~2 kHz with the TPPI (time proportional phase increments) 
method, using a 1024 K time domain in F2 (FID resolution 5.87 Hz) and 460 experiments in F1. 
2D NOESY spectra were acquired using mixing times of 1-1.5 s, TPPI detection and HDO 
presaturation. Processing was carried out with zero-filling to 2K in F1 using sine or qsine (F2) 
and qsine (F1) window functions, respectively. All chemical shifts (δ) are reported in parts per 
million (ppm) and coupling constants (J) are reported in Hz. Structural assignments of 
compounds and inclusion complexes were corroborated by 2D NMR experiments namely 
through: correlation spectroscopy (COSY), Heteronuclear Single-Quantum Coherence (HSQC), 
heteronuclear multiple-bond correlation (HMBC), total correlation spectroscopy (TOCSY), 
nuclear Overhauser effect spectroscopy (NOESY) and rotating frame nuclear Overhauser effect 
spectroscopy (ROESY). 
 
Mass Spectrometry (MS) 
Matrix assisted laser desorption ionization with time of flight detection (MALDI-TOF) 
mass spectra (MS) were recorded on an AutoflexBruker mass spectrometer, operating in a linear 
mode and in positive polarity using either 4-hydroxy 2,5-dihydroxybenzoic acid (DHB) or α-
cyano-4-hydroxycinamic acid (HCCA) to prepare the matrix solutions (Ronzoni Institute, 
Milan, Italy) under service contract. 
 
Elemental analysis 
The elemental analysis assays were performed using a Perkin Elmer 2400 CHN 
elemental analyser. 
 
X-Ray powder diffraction (XRD) 
The analysis was determined using a Rigaku R-AXIS IV imaging plate detector 
mounted on a Rigaku RU-H3R rotating anode X-Ray generator. The dry solid sample was 
ground to a fine powder and was placed inside a glass capillary (Hampton Research, USA) with 
the following dimensions: length (L) x outer diameter (OD) x wall thickness (WT) = (80 x 1 x 
0.01) mm. Samples were collected at a distance (d; mm) from the detector and were irradiated 
during (t, min). 
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Vapour pressure osmometry (VPO) 
Experiments were performed using a vapour pressure osmometer K–7000 from Knauer. 
The solvent used in all measurements was water and the temperature was 40 °C. Polyvinyl 
pyrrolidone (AMW = 10 kDa) was used as a standard and concentrations were reported in 
molality (mol solute / kg solvent). The experiments were performed on a stage at the University 
of Iceland, Faculty of Pharmacy. 
 
Static light scattering (SLS) 
Molecular weight determinations were performed using a Malvern Zetasizer Nano ZS 
instrument running a Static Light Scattering (SLS) method. The samples were studied at 
different concentrations at 25 °C applying the Rayleigh equation. The measurements were a 
kind contribution from Cyclolab S.A. Budapest, Hungary. 
 
Dynamic light scattering (DLS) 
DLS measurements of size (d, nm) and zeta potential (ζ, mV) were performed using a 
Zetasizer Nano Series (Malvern Instruments Ltd), equipped with a MPT-2 autotitrator and 
disposable folded capillary cells (DTS 1060 / DTS 106). The wavelength of detection was 633 
nm and temperature of all experiment was 25 ºC. Titration experiments were conducted in 
water, with the pH ranging from 3.0 < pH < 8.0. Experimental data was processed using 
Zetasizer software version 6.34 (Malvern Instruments Ltd). 
 
High performance liquid chromatography (HPLC) 
HPLC measurements were performed using a Shimadzu system composed of: i) an UV-
Vis detector (SPD-10A); ii) a pump (LC-10AT VP) with a degasser (DGU-14A) and iii) a C18 
Supelco HPLC column (L x OD) = 25 cm x 4.6 mm, with 5 µm particle size. No temperature 
control was used and all injections were 20 µL. The detection wavelength of adenosine 5’-
monophosphate (5’-AMP) and gemcitabine monophosphate (GMP) was λ = 254 nm using a 
mobile phase of acetonitrile : water (75:25, v/v). 
 
Modified Franz cell set-up 
The modified Franz cell device was constituted by two compartments, a donor (D) and 
a receptor (R), each of a fixed volume (3.5 mL) and separated by a hollow junction (diffusion 
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area = 3.14 cm2) to which a semi-permeable membrane (benzoylated dialysis tubing MWCO = 
2000 Da) was attached. The system was thermostated with warm water (37 ºC ± 0.5 ºC) through 
both cells for 30 min, before each experiment. All the R volume (3.5 mL) was collected at a 
fixed time intervals (60 min; 120 min; 180 min; 240 min; 300 min; 360 min), followed by 
replacement with fresh R phase maintained at (37 ºC ± 0.5 ºC).  
 
Confocal microscopy 
A Biorad MRC 1024 ES laser scanning confocal microscope was used. The coverslips 
were washed twice with PBS or RPMI and placed over the 639 oil immersion quartz objective 
(NA 1.3). Intracellular CD-mTHPP fluorescence was excited using the 568 nm line of an argon–
krypton laser (30 % of total laser power). CD-mTHPP fluorescence was collected with the use 
of a long-pass filter at ≥ 585 nm, whereas FITC-type fluorescence was collected through a 
bandpass filter centred at 522 (± 35) nm. During image acquisition a Kalman level 3 (three 
iterations per image) smoothing routine was applied each time to eliminate spurious signal. The 
contribution of cell autofluorescence was checked each time in untreated cells and was, in all 
cases, found to be negligible.  
Cells were washed with PBS and mounted on microscope slides for confocal 
fluorescence live cell imaging. The slides were placed under the 60· oil immersion quartz 
objective (NA 1.3) of a Biorad MRC 1024 ES laser scanning confocal microscope. Intracellular 
NDMTAM-FITC was excited using the 488 nm line of an argon–krypton ion laser, whereas the 
internalized probes were excited by the 568 nm line of the same laser. NDTAM-FITC 
fluorescence was collected through a band-pass filter centred at 522 (± 35) nm, while organelle 
probe fluorescence was collected after a long-pass filter at ± 585 nm. During image acquisition 
a level 3 (three iterations per image) Kalman smoothing routine was applied in all occasions to 
eliminate spurious signals. 
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10. Synthesis 
10.1 CD derivatives 
10.1.1 6-O-Monotosyl-β-cyclodextrin (βmTs) 
β-cyclodextrin (βCD, 2.0 g, 1.76 mmol) was 
added in small portions, to a sodium hydroxide solution 
(NaOH, 0.4 M, 60 mL) and was vigorously stirred in an 
ice bath (0 ºC – 5 ºC). After βCD was completely 
dissolved, 4-toluenesulfonyl chloride (TsCl, 0.8 g, 4.2 
mmol, 2.43 molar eq.) was added to the mixture and the 
whole was stirred for 2 h in the ice bath (0 ºC – 5 ºC). 
Afterwards, a second portion of TsCl (1.2 g, 6.3 mmol, 
3.58 molar eq.) was added to this mixture and it was 
stirred for 3 h more. The reaction was stopped, the crude was filtered through a plug of celite 
545 coarse (20 g – 25 g) to separate unreacted TsCl. The alkaline filtrate (12 < pH < 13) was 
kept at 0 ºC – 5 ºC and under constant magnetic stirring was adjusted to pH = 1.5, by the 
addition of hydrochloric acid (HCl, 0.1M). The product precipitated as a white solid, it was 
filtered, washed with cold water (100 mL) and dried in the vacuum oven at 60 ºC for 24 h. The 
filtrate was left to rest in the fridge overnight (12 h – 18 h) and the filtration step was repeated 
to collect any remaining product (second crop). The purity of the product 6-O-monotosyl-β-
cyclodextrin (βmTs) was assessed by TLC (silica gel 60; dioxane : NH3 : iPrOH (10:7:3, v/v); 
RS A; RF = 0.47) and it was obtained as a white solid (40 %, 0.89 g). 1H NMR (DMSO-d6, 250 
MHz, 25 ºC): δ (ppm) 7.72 (d, J = 8 Hz, Ha, 2H), 7.40 (d, J = 8 Hz, Hb, 2H), 6.00 - 5.75 (m, 2-
OH, 3-OH, 14H), 4.76 (d, H1, 7H), 4.60 – 4.00 (m, 6-OH, 7H), 3.80 – 3.40 (m, H3, H5, H6, H6’, 
28H, overlapping with residual HDO), 3.40 – 3.00 (m, H4, H2, 7H, overlapping with residual 
HDO), 2.39 (s, CH3, 3H). 13C NMR (DMSO-d6, 62.5 MHz, 25 ºC): δ (ppm) 144.9 (Ca), 133.0 
(Cd), 130.1 (Cb/Cb’), 128.0 (Cc/Cc’), 102.0 (C1), 81.5 (C4), 74.3 – 71.3 (C2, C3, C5), 60.0 (C6), 
21.1 (CH3). Characterization data presented agrees with literature [209].  
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10.1.2 Heptakis(6-bromo-6-deoxy)-β-cyclodextrin (βpBr) 
[N-Bromosuccinimide (NBS) method] 
In a water bath at room temperature (20 ºC – 25 ºC), dry 
dimethylformamide (DMF, 100 mL) was added to a flask, equipped 
with a drying tube filled with potassium hydroxide (KOH) and was 
vigorously stirred. Triphenylphosphine (PPh3, 39.4 g, 0.15 mol) was 
added to the DMF, in small portions and a temperature drop (25 ºC to 
17 ºC) was noticed. N-bromosuccinimide (NBS, 28.6 g, 0.16 mol) was 
added in portions, while the temperature was kept bellow 40 ºC, by 
addition of ice to the water bath. During the addition of NBS, the colour of the solution changed 
(white to dark red) and its viscosity increased which was controlled by addition of DMF to 
ensure a constant and vigorous stirring. β-cyclodextrin (βCD, 11.4 g, 0.01 mol, white powder) 
was added to the mixture at once leading to an increase in the temperature and to a colour 
change (dark red to dark green). Afterwards, this solution was transferred to an oil bath (70 ºC – 
80 ºC) and the reaction progress was monitored by TLC (silica gel 60; dioxane : NH3 : iPrOH 
(10:7:3, v/v), RV A). The reaction was stopped after consumption of the starting material 
(βCD). The mixture was cooled in a water bath (20 ºC – 25 ºC) for 10 min, until the temperature 
droped down to 40 ºC – 50 ºC. Methanol (MeOH, 50 mL) was added and the solution was 
poured into a large excess of MeOH (500 mL). The pH of the methanolic solution was checked 
(2 < pH < 3, universal paper) and adjusted to (7 < pH < 8, universal paper), by addition of 
sodium methoxide (CH3ONa, 3.21 g). The mixture was stirred for 5 min and left to stand for 10 
– 15 min leading to the precipitation of the product as a light brown solid. The product was 
extensively washed with MeOH/water to remove impurities: over-brominated, under-
brominated products and traces of PPh3. The purity of the product heptakis(6-bromo-6-deoxy)-
β-cyclodextrin (βpBr) was assessed by TLC (silica gel 60; dioxane : NH3 : iPrOH (10:7:3, v/v); 
RS A; RF = 0.68) and it was obtained as a light yellow powder (94.3 %, 14.9 g). 1H NMR 
(DMSO-d6, 500 MHz, 25 ºC): δ (ppm) 6.04 (d, J = 7.0 Hz, 2-OH, 7H), 5.91 (br s, 3-OH, 7H), 
4.98 (d, J = 3.0 Hz, H1, 7H), 4.01 (d, J = 10.0 Hz, H6, 7H), 3.83 (t, J = 8.5 Hz, H5, 7H), 3.66 (q, 
H3, H6´, 14H), 3.48 – 3.35 (m, H2, H4, 14H). 13C NMR (DMSO-d6, 125 MHz, 25 ºC): δ (ppm) 
102.1 (C1), 84.6 (C4), 72.3 (C3), 72.1 (C2), 71.0 (C5), 34.5 (C6). Characterization data presented 
agrees with literature [33].  
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10.1.3 Heptakis(6-aminoethylamino-6-deoxy)-β-cyclodextrin (βpen) 
Heptakis(6-bromo-6-deoxy)-β-cyclodextrin (βpBr, 3.04 g, 1.93 
mmol) was dissolved in 1,2-diaminoethane (DAE, 15.0 mL) and a light 
brown solution was obtained. The mixture was warmed to 80 ºC, kept 
under vigorous magnetic stirring and under an argon atmosphere. The 
reaction was monitored by TLC (silica gel 60; dioxane : NH3 : iPrOH 
(10:7:3, v/v), RS A). After 24 h the reaction crude was left to cool to 
room temperature (20 – 25 C) and poured into an excess of 
dimethylformamide (DMF, 75 mL). A white solid was obtained that was 
filtered through a filter paper (Whatman, nº 5), washed with ethanol (EtOH, 50 mL) and was 
dried in an oven (vacuum, 80 ºC) for 24 h. The product heptakis(6-aminoethylamino-6-deoxy)-
β-cyclodextrin (βpen) was obtained as a white solid (1.78 g; 64.7 %). 
1H NMR (acidic D2O (pH ≈ 4), 500 MHz, 25 ºC): δ (ppm) 5.04 (br s, 7H, H1), 3.88-3.86 
(m, 14H, H5/H3), 3.56-3.54 (m, 14H, H4/H2), 2.99 (br s, 14H, H6/H6’), 2.89-2.79 (m, 28H, 
H7/H8). 13C NMR (D2O, 125 MHz, 25 ºC): δ (ppm) 101.5 (C1), 82.5 (C4), 73.0 (C5), 71.7 (C2), 
70.7 (C3), 50.2 / 49.2 (C7/C8), 40.0 (C6). Characterization data presented agrees with the 
literature [210, 211]. MS (MALDI-TOF): m/z calcd for C56H112N14O28 1428.78 [M]. Found: 1430.3 
[M+H]+ (100 %), 1452.3 [M+Na]+ (77  %). 
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10.1.4 β-cyclodextrin-meso-tetrakis(m-hydroxyphenyl)-porphyrin 
conjugate (CD-mTHPP) 
5,10,15,20-tetrakis(m-hydroxyphenyl)-21,23H-
porphyrin (mTHPP, 61 mg, 0.089 mmol) was dissolved 
in dry dimethylsulfoxide (DMSO, 2 mL) and the 
mixture was stirred at 40 °C, in an argon atmosphere 
and protected from light. Sodium hydroxide (NaOH, 
23.5 mg, 0.59 mmol) was added and the reaction 
mixture was stirred for 15 min. 6-O-monotosyl-β-
cyclodextrin (βmTs, 125.5 mg, 0.097 mmol) solubilised 
in dry DMSO (4 Ǻ molecular sieves, 24 h) (1.0 mL) and 
added to the reaction mixture in portions over 1 h (0.25 
mL / 15 min). The reaction was monitored by TLC 
(silica gel 60; iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v); 
RS A) until all βmTs was consumed. The reaction was 
stopped after 72 h. The desired product appeared as a brown spot (RF = 0.61), showed red 
fluorescence under ultraviolet light irradiation (λex = 254 nm) and turned green upon spraying 
with RS A. A mixture of EtOH : H2O (1:1, v/v ~2 mL) and hydrochloric acid (HCl (1 M), 1.1 
mL) was added to the crude mixture (until the pH ~ 6.0) and it was dialysed (benzoylated 
dialysis membrane, MWCO = 2000 Da), against distilled water for ~ 24 h. The solvent (H2O) was 
removed in ratovapor, using EtOH to avoid bumping and the dried material was collected and 
washed with ethyl acetate (EtOAc, 100 mL), to remove most of unreacted mTHPP and mTHPP 
salts. The solid obtained was subjected to column chromatography using a long column (L x 
OD = 60 cm x 2.4 cm) packed with silica gel 60 (80 g) and using iPrOH : EtOAc : H2O : NH3 
(5:3:3:1, v/v) as the mobile phase. Loading had to be restricted to a small portion of crude (~20 
mg) per column. The first fraction collected was unreacted mTHPP (20 mg in total), followed 
by CD-mTHPP. Subsequently, the solvent (mobile phase - iPrOH : EtOAc : H2O : NH3) was 
evaporated under vacuum and the residue (1 – 2 mL) was adjusted to pH ≈ 5 and dialyzed for 18 
h (benzoylated dialysis membrane, MWCO = 2000 Da). The purity of the product β-cyclodextrin-
5,10,15,20-tetrakis(m-hydroxyphenyl)-porphyrin conjugate (CD-mTHPP) was assessed by TLC 
(silica gel 60; iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v); RV A; RF = 0.61) and was obtained as 
a black powder (43 mg, 40 %, calculated based on reacted porphyrin). 1H NMR (DMSO-d6, 500 
MHz, 25 ºC): δ (ppm) 9.80 (s, Ph-OH, 3H), 8.88 (s, Py-H, 8H), 8.00 – 7.00 (s, Ph-H, 16H), 6.00 
– 5.50 (br d, CD-OH2/CD-OH3, 14H), 4.90 (s, CD-H1 connected mTHPP, 1H), 4.80 (s, CD-H1, 
6H), 4.50 – 4.20 (br m, CD-OH6, 6H), 4.10 (s, CD-H5 connected to mTHPP, 1H), 3.90 - 3.00 
(m, CD-H2 / H3 / H4 / H5 / H6/ H6’, 42H, overlapping with residual HDO), -3.00 (s, -NH, 2H). MS 
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(MALDI-TOF): m/z calcd for C86H98N4O38 1795.70 [M]. Found: 1796.8 [M+H]+ (100 %), 
1817.0 [M+Na]+. Anal. Calcd. (%) for C86H98N4O38.9H2O. NH4Cl: C: 51.34, H: 6.02, N: 3.48. 
Found: C: 51.18; H: 5.93; N: 3.11. UV-Vis (DMSO, C = 3.6 µM) = 420 (0.48); 514 (0.03); 551 
(0.02); 590 (0.02), 645 (0.01). UV-Vis (4 % DMSO/PBS, C = 3.6 µM) = 422 (0.19); 517 (0.02); 
553 (0.01); 589 (0.01), 644 (0.01). 
 
Recovery of pure CD-mTHPP from pMβCD complexes  
The complexed CD-mTHPP in the form of pMβCD/CD-mTHPP collected from any 
complexation experiment study, was solubilised in water and was dialysed (benzoylated dialysis 
tubing, MWCO = 2000 Da) for 8 h. The resulting clear, dark red solution was dried until a small 
residue (1 – 2 mL) was obtained. It was transferred to a glass tube, it was vortexed and a large 
volume of diethyl ether (EtOEt, 10 – 12 mL) was added gradually. The desired product (CD-
mTHPP) precipitates as a dark red / black solid free from any pMβCD, which is washed away 
by the supernatant EtOEt (discarded). The product purity was assessed by TLC (silica gel 60; 
iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v); RV A; RF = 0.61) and can be reused. 
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10.2 Monomers - linker 
10.2.1 Ethylene glycol diglycidyl ether (EGDE) 
Epichlorohydrin (EPI, 20 mL, 0.255 mol), sodium 
hydroxide (NaOH, 9.55 g, 0.239 mol) and 
tetrabutylammonium chloride (TACl, 0.55 g, 2 mmol) 
were solubilised in water (1 mL) at room temperature (20 
– 25 ºC) to obtain a light yellow solution. Ethylene glycol 
(EG, 1.115 mL, 20 mmol) was added slowly in two portions (2 x 560 µL) and the reaction 
mixture was kept in a water bath (T = 10 ºC) and after 10 min turned cloudy. The crude mixture 
was finally transferred to an oil bath (35 – 40 ºC) and was stirred for 30 min. The reaction was 
stopped and the white precipitate was filtered and washed with water (20 mL) and with 
chloroform (150 mL). The organic phase was collected, washed with saturated ammonium 
chloride (NH4Cl, sat. sol., 3 x 120 mL) until the pH ≈ 5. It was dried over magnesium sulphate 
anhydrous (30 min) and evaporated under vacuum in the rotary evaporator (50 ºC) until a light 
yellow residue was obtained. The desired product was purified from the light yellow crude 
obtained (666 mg) by column chromatography using a column (OD x L = 2.6 cm x 53 cm), 
packed with silica gel (73 g) and using EtOAc : EtOEt (5:1, v/v) as mobile phase. The purity of 
the desired product ethylene glycol diglycidyl ether (EGDE) was assessed by TLC (silica gel 
60; EtOAc : EtOEt (5:1, v/v); RV B; RF = 0.57) and was obtained as an oil (12 % yield; 79.9 
mg) stored in the freezer. 1H NMR (CHCl3-d1, 500 MHz, 25 ºC): δ (ppm) 3.83 – 3.76 (m, H3’, 
2H), 3.75 – 3.59 (m, H4, 4H), 3.48 – 3.36 (m, H3, 2H), 3.16 (m, H2, 2H), 2.78 (t, H1, 2H), 2.60 
(br s, H1’, 2H). 13C NMR (CHCl3-d1, 125 MHz, 25 ºC): δ (ppm) 72.0 (C3), 70.7 (C4), 50.8 (C2), 
44.2 (C1). Characterization data presented agrees with literature [205]. 
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10.3 Selected anticancer molecules 
10.3.1 Gemcitabine-adamantanamide (GEM-ADA amide) 
In a small flask (10 mL) 1-
adamantanecarboxylic acid (ADA-COOH, 30.4 mg; 
0.17 mmol) was solubilised in dry mixture of 
DMF:DMSO (3:1, v/v) (200 µL), followed by 
addition of N,N'-diisopropylethylamine (DIPEA, 84 
µL; 0.48 mmol) and 1-[bis(dimethylamino) 
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU.PF6, 70.3 
mg; 0.19 mmol). This light yellow solution was stirred for 60 min at 10-15 C and it turned dark 
brown in colour. Gemcitabine hydrochloride (GEM.HCl, 50.3 mg; 0.17 mmol) was added to the 
mixture and the temperature was raised to 25 ºC. The flask was then flushed with argon (Ar), 
reaction was periodically checked by TLC (silica gel 60; CH2Cl2 : acetone : EtOH (5:4:1, v/v); 
RV B) revealing the activated ADA-COOH (RF = 0.99) being converted into the UV-active 
desired product GEM-ADA amide (RF = 0.78). The reaction was stopped after 48 h and a dark 
orange colour developed. Liquid-to-liquid extraction was used: ethyl acetate (EtOAc, 2 mL) 
was first added to the mixture and it was transferred to a separation funnel, followed by addition 
of aqueous sodium chloride (NaCl, 10 % m/v, 6 x 2 mL). The aqueous layer (NaCl 10 %, 12 
mL) was washed with EtOAc (6 x 10 mL) and all organic layers were combined and dried. The 
product gemcitabine-adamantanamide (GEM-ADA amide) was recovered from the organic 
layer with warm purified water (60 ºC) and a white solid was obtained (GEM-ADA amide, 20.4 
mg, 28.5 %). 1H NMR (DMSO-d6, 500 MHz, 25 ºC): δ (ppm) 10.2 (br s, amide -NH, 1H), 8.22 
(d, H6, 1H), 7.29 (s, H1’, 1H), 6.34 (s, 5’-OH, 1H), 6.16 (s, H5, 1H), 5.33 (s, 3’-OH, 1H), 4.17 
(m, H3’, 1H), 3.87 (s, H5’, 1H), 3.78 (s, H4’, 1H), 3.66 (s, H5’’, 1H), 1.97 (s, ADA-H3, 3H), 1.89 
(s, ADA-H2, 2’, 6H), 1.66 (s, ADA-H4, 4’, 6H). 13C NMR (DMSO-d6, 125 MHz, 25 ºC): δ (ppm) 
178.9 (Ca), 164.1 (C4), 154.8 (C2), 145.2 (C6), 123.6 (t, JCF = 23 Hz, C2’), 97.0 (C5), 85.1 – 84.8 
(C1’), 81.7 (C4’), 69.1 – 68.8 (C3’), 59.4 (C5’), 42.5 (ADA-C1), 37.8 (ADA-C2), 36.3 (ADA-C4), 
28.1 (ADA-C3).  
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10.3.2 N-desmethyltamoxifen hydrochloride (NDTAM.HCl) 
Tamoxifen (TAM, 151 mg, 0.410 mmol) was dissolved 
in toluene (6 mL) at 0 °C followed by addition of 1-
chloroethylchloroformate (CECF, 100 µL, 0.93 mmol). After 
15 min stirring at 0 °C, the reaction was heated to reflux with 
periodic monitoring of its progress by TLC (silica gel 60; 
CH2Cl2 : MeOH : NH3 (95:5:0.3, v/v) and UV-Vis irradiation at 
365 nm. The reflux was continued until all TAM is consumed 
(19h). Toluene was evaporated in the rotary evaporator (60 ºC) 
until an oily yellow residue (2 – 3 mL) was obtained. The desired product was then precipitated, 
by addition of an excess of diethyl ether (EtOEt, 25 mL), followed by extensive washings with 
EtOEt to recover NDTAM.HCl as a white solid (81 mg; 50 % yield). The purity of N-
desmethyltamoxifen hydrochloride (NDATM.HCl) was assessed by TLC (silica gel 60; CH2Cl2 
/ MeOH / NH3 (95:5:0.3, v/v); RF = 0.08). The identity of the product was confirmed by 
comparison of its spectra with those of an authentic sample of NDTAM.HCl (Sigma). 1H NMR 
(MeOD-d4, 500 MHz, 25 ºC) δ (ppm) 7.31 – 7.03 (m, Ph-Ha/Ph-Hb, 10 H), 6.78 – 6.58 (dd, Jcc’ 
= 8 Hz, Ph-Hc/Hc’, 4 H), 4.06 (t, H3, 2 H, J = 4.3 Hz), 3.29 (t, H4, 2 H, J = 5.0 Hz), 2.67 (s, H5, 3 
H), 2.39 (q, H2, 2 H), 0.84 (t, H1, 3 H). 13C NMR (CDCl3, 125 MHz, 25 ºC): δ (ppm) 132.1 – 
113.3 (Ph-Ca/Cb/CC), 63.1 (C3), 48.4 (C4), 33.6 (C5), 29.3 (C2), 13.7 (C1). Characterization data 
presented agrees with literature [178]. 
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10.3.3 Tamoxifen citrate (TAM-Cit, 2:1) 
Tamoxifen (ΤΑΜ, 51.5 mg, 0.09 mmol) was 
solubilised in acetonitrile (ACN, 2 mL) and the solution was 
stirred at room temperature (20 ºC – 25 ºC) in an oil bath. 
Citric acid (CA, 55.0 mg, 0.26 mmol) was added to the 
solution and cloudiness was developed as the solid (CA) 
deposits in the bottom of the flask. The reaction was stirred 
vigorously for 40 min and it changes its aspect, turning from 
clear with solid in the bottom, to cloudy with white solid 
dispersed as very fine white particles. Reaction was stopped 
and the solid was filtered through a paper filter (Whatman 
number 4) and was extensively washed with water (H2O, 3 x 
20 mL) to wash from the final product any excess of unreacted 
CA. A white solid was obtained (24.7 mg, 63.3 %) in a form of 
TAM-Cit with a stoichiometry of tamoxifen / citrate (2:1). 1H 
NMR (CDCl3, 500 MHz, 25 ºC): δ (ppm) 7.35 – 7.11 (m, Ph-
Ha/Ph-Hb, 10 H), 6.80 – 6.5 (dd, J = 8.0 Hz, Ph-Hc, 4H), 
4.22(s, H3, 3H), 3.29 (s, H4, 3H), 2.78 (s, H5, H5’, 6H), 2.67 (br 
d, CH2-citric acid, 4H), 2.46 (q, H2, 2H), 2.67 (t, H1, 3H). 13C NMR (CDCl3, 125 MHz, 25 ºC): 
δ (ppm) 136 – 109 (Ph-Ca/Cb/Cc), 62.5 (C3), 56.9 (C4), 46.2 (citric acid - C2/C2’), 44.0 (C5/C5’), 
29.3 (C2), 13.8 (C1). Characterization data presented agrees with literature [212]. 
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10.3.4 N-desmethyltamoxifen-fluorescein (NDTAM-FITC) 
Fluorescein isothiocyanate isomer 1 (FITC, 10 mg, 
25.7 µmol) was solubilised in ethanol (EtOH, 2 mL) to get a 
clear yellow solution, followed by the addition of N,N-
diisopropylethylamine (DIPEA, 10 µL, 57.4 µmol). The colour 
changed from yellow to orange. N-desmethyltamoxifen 
(NDTAM.HCl, 9.4 mg, 23.9 µmol) was added to the mixture 
and the reaction was stirred at 40 ºC, protected from the light 
and under inert atmosphere (argon). After 44 h, the reaction 
was stopped and it was dried in the ratory evaporator (40 ºC) to 
an orange residue. The residue (≈ 12.0 mg) was solubilised 
methanol (MeOH, 1 mL) and the solution was applied to a 
preparative TLC plate (silica gel 60; 20 cm x 20 cm plate, 500 
µm thickness), using CHCl3 / MeOH (3:1) as a mobile phase. 
Five different bands were collected and NDTAM-FITC was 
isolated in a 70 % (m/m) as an orange powder. The purity of the product N-desmethyltamoxifen-
fluorescein (NDTAM-FITC) was assessed by TLC (silica gel 60; CHCl3 : MeOH (3:1, v/v); RF 
= 0.77), corresponding to the second band and was obtained as an orange solid (10.5 mg, 62 % 
m/mT purity, with mT = total mass applied to the TLC plate). 1H NMR (MeOD-d4, 500 MHz, 25 
ºC): δ (ppm) 7.66 (s, Ph-Hx, 1H), 7.35 – 6.50 (Ph-Ha/b/c, Ph-Hd,e,f, 22H), 4.23 (s, H3, 2H), 3.42 – 
3.26 (H4, H5, MeOD, 5H), 2.45 (q, H2, 3H), 0.84 (t, -CH3, 3H). 
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10.4 CD-Polymers 
10.4.1 Epichlorohydrin/βpen (EPI/βpen, 5:1, P3)  
 
 
 
 
 
Heptakis(6-aminoethylamino-6-deoxy)-β-cyclodextrin (βpen , 185 mg, 129.5 µmol) 
was solubilised in water (2 mL) and a light yellow solution was obtained. Its pH was to ≈ 11 - 
12 by addition of a diluted solution of sodium hydroxide (NaOH, 0.1 M). The solution was 
stirred in an oil bath (70 ºC – 75 ºC) under argon atmosphere for 0.5 min. Epichlorohydrin (EPI, 
50 µL, 648 µmol) was added dropwise to the mixture and after 29 h the reaction was stopped. 
The pH of the mixture was adjusted to ≈ 7.0, acetone (10 mL) was added and a pale yellow 
solid precipitated followed by extensive washings with acetone (4 x 10 mL). The solid was 
decanted, solubilised in water (1 mL) and was dialysed at pH = 7 in a benzoylated dialysis 
tubing (MWCO = 2000 Da), for 24 h with continuous water exchange. After freeze-dried a 
yellow solid corresponding to polymer EPI/βpen (P3, 240 mg) was obtained. 1H NMR (D2O, 
500 MHz, 25 ºC) δ (ppm) 5.5 – 4.9 (br m, CD-H1), 4.5 – 2.3 (CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) 
and (EPI-CH,CH2 aliphatic chains). 
 
10.4.2 Epichlorohydrin/βpen (EPI/βpen, 10:1, P4) 
Prepared like P3 with the following modifications: βpen (251.5 mg; 175.9 µmol); 
sodium hydroxide NaOH (0.05 M, 6 mL); EPI (138 µL, 1.76 µmol); 2.5 h reaction. EPI/βpen 
(P4, 229 mg) was obtained. 1H NMR (D2O, 500 MHz, 25 ºC) δ (ppm) 5.5 – 4.9 (br m, CD-H1), 
4.5 – 2.3 (CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EPI-CH,CH2 aliphatic chains). 
 
10.4.3 Epichlorohydrin/βpen (EPI/βpen, 20:1, P5)  
Prepared like P4 with the following modifications: βpen (252.5 mg; 177 µmol); EPI 
(277 µL, 3.53 µmol). EPI/βpen (P4, 225 mg) was obtained. 1H NMR (D2O, 500 MHz, 25 ºC) δ 
  
164 
(ppm) 5.5 – 4.9 (br m, CD-H1), 4.5 – 2.3 (CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EPI-CH,CH2 
aliphatic chains). 
 
 
10.4.4 Ethylene glycol diglycidyl ether/βpen (EDGE/βpen, 1:1, Q1) 
 
 
 
 
 
Heptakis(6-aminoethylamino-6-deoxy)-β-cyclodextrin (βpen, 151.1 mg, 106 µmol) was 
solubilised in diluted sodium hydroxide solution (NaOH, 0.05 M, 5 mL) and a light yellow 
solution was obtained. The solution was stirred in an oil bath (70 ºC – 75 ºC) under argon 
atmosphere for 0.5 min. Ethylene glycol diglycidyl ether (EGDE, 16.5µL, 106 µmol) was added 
to the mixture and after 72 h the reaction was stopped. The pH of the mixture was adjusted to ≈ 
7.0, acetone (10 mL) was added and a pale yellow solid precipitated followed by extensive 
washings with acetone (4 x 10 mL). The solid was decanted, solubilised in water (1 mL) and 
was dialysed at pH = 7 in a benzoylated dialysis tubing (MWCO = 2000 Da), for 24 h with 
continuous water exchange. After freeze-dried a yellow solid corresponding to polymer 
EGDE/βpen (Q1, 106 mg) was obtained. 1H NMR (D2O, 500 MHz, 25 ºC) δ (ppm) 5.4 – 4.8 (br 
m, CD-H1), 4.3 – 2.3 (CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EGDE-CH,CH2 aliphatic chains).  
 
10.4.5 Ethylene glycol diglycidyl ether/βpen (EDGE/βpen, 5:1, Q2) 
Prepared like Q1 with the following modifications: βpen (150 mg; 105 µmol); sodium 
hydroxide NaOH (0.05 M, 5 mL); EGDE (83 µL, 523 µmol). EGDE/βpen (Q2, 157 mg) was 
obtained. 1H NMR (D2O, 500 MHz, 25 ºC) δ (ppm) 5.4 – 4.8 (br m, CD-H1), 4.3 – 2.3 (CD-
H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EGDE-CH,CH2 aliphatic chains). 
  
10.4.6 Ethylene glycol diglycidyl ether/βpen (EDGE/βpen, 10:1, Q3) 
Prepared like Q2 with the following modifications: βpen (155 mg; 109 µmol); sodium 
hydroxide NaOH (0.05 M, 5 mL); EGDE (166 µL, 1.05 mmol). EGDE/βpen (Q3, 241 mg) was 
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obtained. 1H NMR (D2O, 500 MHz, 25 ºC): δ (ppm) 5.4 – 4.8 (br m, CD-H1), 4.3 – 2.3 (CD-
H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EGDE-CH,CH2 aliphatic chains). 
 
10.4.7 Ethylene glycol diglycidyl ether/βpen (EDGE/βpen, 20:1, Q4) 
Prepared like Q3 with the following modifications: βpen (76.6 mg; 54 µmol); sodium 
hydroxide NaOH (0.05 M, 2.5 mL); EGDE (166 µL, 1.05 mmol). EGDE/βpen (Q4, 188 mg) 
was obtained. 1H NMR (D2O, 500 MHz, 25 ºC): δ (ppm) 5.4 – 4.8 (br m, CD-H1), 4.3 – 2.3 
(CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’) and (EGDE-CH,CH2 aliphatic chains). 
 
10.4.8 Poly-L-lysine/βpen (pLys/βpen, T2) 
A stock of poly-L-lysine hydrobromide (pLys.HBr, 
1000 < MWCO < 5000) was prepared by solubilising pLys.HBr 
(25 mg) in water (2 mL). Its pH was adjusted to pH ≈ 11, by 
addition of aqueous potassium hydroxide (KOH, 0.24 mM, 
200 µL) to neutralize the hydrobromide salt (HBr) and obtain 
pLys (1000 - 5000). pLys (1000 - 5000) (1.1 mL, 12.5 mg, ≈ 
4.17 µmol*) was freeze dried, dimethylformamide (DMF, 3 
mL) was added, followed by heptakis(6-iodo-6-deoxy)-β-
cyclodextrin (βpI, 53 mg, 27.8 µmol). The solution was stirred 
in an oil bath (70 ºC – 75 ºC) and after 29 h the reaction was 
stopped, followed by addition of 1,2-diaminoethane (DAE, 2 
mL) to insure in 12 h at 70 ºC – 75 ºC the in situ generation of 
βpen. This reaction was monitored by TLC (silica gel 60; 
iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v); RV A) revealing 
that pLys / βpen (1000 - 5000) is not eluted (RF = 0) as opposed to βpI (RF = 0.66). The reaction 
was stopped after 12 h at 70 ºC – 75 ºC, its contents dried and the residue was dialysed at pH ≈ 
(8 – 9) in a snakeskin dialysis (MWCO = 3500 Da) for 12 h with continuous water exchange. 
The contents of the dialysis membrane were dried and a yellow solid corresponding to polymer 
pLys/βpen (2000 Da < AMW < 3500 Da) (T2, 11.4 mg) was obtained, dried by freeze-drying. 
1H NMR (D2O, 500 MHz): δ (ppm) 5.3 – 4.8 (br m, CD-H1), 4.4 – 2.5 (CD-
H2,H3,H4,H5,H6,6’,H7,7’,H8,8’ and pLys-Hα,ε), 2.0 – 1.0 (pLys-Hβ,δ,γ). (* Considering AMW[pLys 
(1000 - 5000)] = 3000 g/mol). 
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10.4.9 Poly-L-lysine/ βpen (pLys/βpen, BB’) 
Fraction pLys/βpen B’ (2000 Da < AMW < 3500 Da) (52 mg, ≈ 18.9 µmol*) resulting 
from the fractioning of pLys.HBr was dissolved into dimethylformamide (DMF, 2 mL). 
Aqueous potassium hydroxide (KOH, 2.85 mM, 30 µL) was added and the solution was stirred 
at 30 ºC for 4 h (solution turned cloudy). More DMF (2 mL), KOH (2.85 mM, 30 µL) were 
added and the pH was checked and adjusted to (≈ 7 – 8). Heptakis(6-iodo-6-deoxy)-β-
cyclodextrin (βpI, 60 mg, 31.5 µmol) was added and reaction proceeded for 48 h at 60 ºC. The 
reaction was monitored by TLC (silica gel 60; iPrOH : EtOAc : H2O : NH3 (5:3:3:1, v/v); RV A) 
and revealed that the desired product pLys/βpen (BB’) was not eluted (RF = 0) as opposed to the 
remaining βpI (RF = 0.66). The reaction was stopped and 1,2-diaminoethane (DAE, 3 mL) was 
added to the reaction mixture and it proceeded for 12 h more, until all remaining βpI was 
consumed (TLC data). The reaction was stopped and was fractioned by using fractioning 
procedure described for pLys.HBr. Fractioning of polymers was followed by freeze-drying to 
obtain pLys/βpen BB’ (2000 Da < AMW < 3500 Da) (12.1 mg, 23 % m/m). 1H NMR (D2O, 500 
MHz) δ (ppm) 5.3 – 4.8 (br m, CD-H1), 4.4 – 2.5 (CD-H2,H3,H4,H5,H6,6’,H7,7’,H8,8’ and pLys-
Hα,ε), 2.0 – 1.0 (pLys-Hβ,δ,γ). (* Considering AMW of pLys/βpen B’ = 2750 g/mol.). 
 
Dialysis fractioning of pLys.HBr (1000 Da < AMW < 5000 Da) 
Commercial poly-L-lysine hydrobromide (pLys.HBr, 1000 Da < AMW < 5000 Da), 
pLys.HBr (100 mg = mT) was solubilised in water (1 mL), its pH was adjusted to pH ≈ 7, by 
addition of KOH (0.1 M), and was dialysed against destiled H2O (2 x 300 mL) using two 
dialysis membranes in the following order: i) benzoylated dialysis tubing (MWCO = 2000 Da) 
and ii) skinsnake dialysis tubing (MWCO = 3500 Da). Three fractions of pLys were isolated: 
fraction A (pLys A) isolated from the liquid lost through membrane (MWCO = 2000 Da); 
fraction B (pLys B) collected from liquid lost through the second membrane (MWCO = 3500 
Da) and fraction C (pLys C) recovered from the contents of the second membrane (MWCO = 
3500 Da). The contents of each fraction were freeze-dried to obtain fractions A/B/C with 
different molecular weight ranges, taking into consideration the lower MW limit (1000 Da) and 
upper MW limit (5000 Da) of commercial pLys.HBr (1000 Da < AMW < 5000 Da). 
Fractioning of pLys.HBr (1000 Da* < AMW < 5000 Da *) (100 mg = mT): pLys fraction A 
(1000 Da * < AMW < 2500 Da) (35 mg, 35 % m/mT); pLys fraction B (2000 Da < AMW < 
3500 Da) (52 mg, 52 % m/mT) and pLys fraction C (3500 Da < AMW < 5000 Da *) (14 mg, 14 
% m/mT). 
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11. Evaluation of Properties 
11.1 Linear range of concentrations  
11.1.1 mTHPP in DMSO (4 % DMSO/PBS) 
A stock solution of 5,10,15,20-tetrakis(m-hydroxyphenyl)-porphyrin (mTHPP, 100 µM) 
was prepared solubilising mTHPP (3.39 mg, 4.99 µmol) in dimethylsulfoxide (DMSO, 50 µL). 
Six diluted solutions of varying concentrations (C1 = 0.99 µM; C2 = 1.96 µM; C3 = 2.91 µM; C4 
= 3.84 µM; C5 = 4.76 µM; C6 = 5.66 µM) were prepared by taking volumes of stock mTHPP 
(100 µM, DMSO: V1 = 10.0 µL; V2 = 20.0 µL; V3 = 30.0 µL; V4 = 40.0 µL; V5 = 50.0 µL; V6 = 
60.0 µL) into DMSO (1 mL). The UV-Vis spectra of each solutions (1 - 6) was recorded and the 
maximum intensity (Soret band) was plotted as a function of the concentration, followed by 
linear regression used to fit experimental data to the best line (y = mx + b). (The experiment was 
repeated in 4 % DMSO/PBS were prepared by diluting the same volumes of mTHPP stock (100 
µM, DMSO) in a mixture of 4 % DMSO/PBS (1 mL)). 
 
11.1.2 CD-mTHPP in DMSO (4 % DMSO/PBS) 
Like described for mTHPP in DMSO (4 % DMSO/PBS), but starting from a stock 
solution of CD-mTHPP (100 µM, DMSO) prepared by: i) first, solubilising CD-mTHPP (2.8 
mg, 1.56 µmol) in DMSO (0.5 mL) and then ii) by diluting it further, by adding 32 µL of this 
stock to a total volume of DMSO (968 µL). 
 
11.2 UV-Vis / fluorescence pH dependence  
11.2.1 Preparation of PBS solutions of varying pH 
A stock solution of phosphate buffered saline (PBS; pH = 7.4) was prepared by 
solubilising: sodium chloride (NaCl, 0.40 g, 6.85 mmol), potassium chloride (KCl, 0.01 g, 0.14 
mmol), potassium dihydrogen phosphate (KH2PO4, 12.0 mg, 0.09 mmol) and disodium 
hydrogen phosphate (Na2HPO4, 72.0 mg, 0.51 mmol) in 50 mL of distilled water (H2O) and the 
pH was checked (pH = 7.4). Through the addition of HCl (0.1 M) to the initial PBS solution, the 
pH was adjusted to pH = 2 and a small volume (2 mL) was widrawn, stored in a vial and kept in 
the fridge. Then, following the gradual addition of sodium hydroxide solution NaOH (0.1 M) to 
this starting solution (pH = 2), other aqueous buffered solutions (pH = 3, 4, 5, 6, 7, 8, 9, 10, 11) 
were prepared and stored.  
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11.2.2 mTHPP in 4 % DMSO/PBS of varying pH 
The mTHPP stock (50 µM, DMSO) was prepared by: i) first, solubilising mTHPP (2.2 
mg, 3.24 µmol) in DMSO (0.5 mL) and then ii) by diluting it further, by adding 7.7 µL of this 
stock in a total volume of DMSO (993 µL). Diluted solutions of mTHPP (2 µM; 4 % 
DMSO/PBS*) were prepared, by adding 80 µL of mTHPP stock (50 µM, DMSO) to vials 
containing phosphate buffered solution (PBS*, 1920 µL) of varying pH = 2, 3, 4, 5, 6, 7, 8, 9, 
10, 11. For every solution at different pH, the UV-Vis and fluorescence spectra were recorded 
and spectral changes plotted as a function of the pH. 
 
11.2.3 CD-mTHPP in 4 % DMSO/PBS of varying pH 
Like described for mTHPP in 4 % DMSO/PBS of varying pH, but starting from a stock 
solution of CD-mTHPP (50 µM, DMSO) prepared by: i) first, solubilising CD-mTHPP (2.8 mg, 
1.56 µmol) in DMSO (0.5 mL) and then ii) by diluting it further, by adding 16 µL of this stock 
to a total volume of DMSO (984 µL). 
 
11.3 Stoichiometry of pMβCD complexes 
11.3.1 Titration pMβCD/CD-mTHPP (UV-Vis / Fluorescence) 
A diluted solution of CD-mTHPP (2 µM, 4 % DMSO/PBS), prepared by adding 80 µL 
of a stock of CD-mTHPP (50 µM) into 1920 µL of PBS. Small aliquots (5 µL) of a concentrated 
solution of pMβCD (300 µM, 4 % DMSO/PBS) was added stepwise to the initial guest solution. 
The UV-Vis and fluorescence spectral changes were recorded before and after each addition, 
until no more changes are observed. The stoichiometry and binding constants of the 
complexation were determined, by plotting Soret maximum and fluorescence as a function of 
the molar equivalents of pMβCD added.  
 
11.3.2 Titration pMβCD/mTHPP (UV-Vis / fluorescence) 
Like described for Titration pMβCD/CD-mTHPP (UV-Vis / Fluorescence), but starting 
from a stock solution of mTHPP (50 µM, DMSO). 
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11.3.3 Estimation of the binding constant 
pMβCD/CD-mTHPP (1:1) equilibrium  
Non-linear least square fitting of the UV-Vis titration data using the GraphPad Prism 
2.01 software using a suitable equation for 1:1 binding, as follows: If G is the guest, H is the 
host, and HG is the formed complex, the association constant, K, can be defined as: 
K = [HG]/[H][G], (Eq. 1) 
[G] = [G0]−[HG] (Eq. 2) 
[H] = [H0]−[HG] (Eq. 3) 
where, [H0] and [G0] being the total host and guest concentrations, respectively. 
Combining all (Eq.2) and (Eq. 3) in (Eq. 1), [HG] can be written as:  
2
]0][0[4)]/1]0[]0([[)/1]0[]0([][
2 HGKHGKHG
HG
−++−−++
=  (Eq.4) 
The experimental data were fitted to the equation ][∆HG HGε=∆Α  (Eq. 5), with ∆A = 
the observed difference in absorbance, yielding K(1:1) =  3.8 (± 1.59) X 106  M-1 (goodness of fit, 
R2 = 0.9954). 
 
pMβCD/mTHPP (2:1) equilibrium  
For the 2:1 case, we assume negligible [HG] concentration, thus 
K = [H2G]/[H]2[G] (6) 
[G0] = [G]+[H2G] (7) 
[H0] = [H]+2[H2G] (8) 
Set mole fractions, αo = [Η]/[Η0], α2 = 2[H2G]/[H0] and (α0 + α2) = 1. Assuming that 
the free guest, mTHPP, does not contribute to the observed absorbance due to its nearly zero 
solubility,  
max
2max 2
]0[][2
∆Α
Η∆Α
=⇒∆Α=∆ GHA α , with )]0[1](0[][
max∆Α
Η∆Α
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max2
]0[]0[][
∆Α
Η∆Α
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Therefore, 
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By plugging in values for concentrations and absorbance differences observed near the 
break point of the 2:1 binding curve, [H0] = 2 X 10-6 M, ∆ΑΜmax = 0.526, ∆Α = 0.585, the 
binding constant is obtained was K(2:1) = 4.9 X 10-12 M-2. 
 
 
11.4 Structural features by pMβCD complexes by NMR 
11.4.1 pMβCD/mTHPP (2:1) 
The initial 1H NMR spectrum of pMβCD (8.67 mM, 0.5 mL, D2O) was recorded. A 
diluted solution of mTHPP (50 µM, MeOD-d4) was added stepwise in small volumes (12.5 µL) 
to the initial pMβCD solution and 1H NMR was recorded, until no more peaks corresponding to 
pMβCD were observed in the spectra. Finally, 2D NMR experiments were recorded to 
determine the structural features of the complex pMβCD/mTHPP. [Final concentration: 
pMβCD/mTHPP (8.67 mM / 5.6 mM, R = 1.54) in 11 % MeOD / D2O].  
 
11.4.2 pMβCD/CD-mTHPP (1:1) 
The 1H NMR spectra of pMβCD (5.0 mM, D2O) was recorded. A small amount of CD-
mTHPP (2.1 mg; 1.67 µmol) was solubilised in DMSO (20 µL), followed by the addition of  
0.45 mL of pMβCD (5.0 mM, D2O). All NMR spectra including 2D NMR experiments were 
recorded at 25 ºC. [Final concentration: pMβCD/CD-mTHPP (4.79 mM / 2.49 mM, R = 0.52) 
in 4 % DMSO / D2O]. 
 
11.5 Inclusion / complexation studies of selected molecules 
11.5.1  Job plots (NMR) for 5’-AMP : βpen 
Continuous variation Job plots of the βpen cavity protons (CD-H3, H5) chemical shifts 
were evaluated from 1H NMR (deuterated PBS, 25 ºC) in the presence of varying amounts of 
adenosine 5’-monophosphate (5’-AMP). Initial concentrations of βpen.HCl and 5’-AMP were 
10 mM prepared in PBS. For a total volume corresponding to one NMR tube (1 mL), different 
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volumes of βpen (10 mM) were mixed with 5’-AMP (10 mM), in the following ration (R = 
Vβpen / V5’-AMP): 0.2/0.8, 0.4/0.6, 0.6/0.4, 0.8/0.2 mL) were mixed. Chemical shift changes of 
cavity protons (H3, H5) were plotted as a function of the mole fraction of βpen.HCl in the NMR 
tube and the stoichiometry was determined.  
 
11.5.2 5’-AMP : βpen 
βpen.HCl (11.7 mg; 6.94 µmol) was solubilised in deuterated PBS (pH = 7.4; 0.45 mL) 
to obtain a clear slight yellow solution. The 1H NMR spectrum was recorded. Adenosine 5’-
monophosphate, 5’-AMP (2.40 mg; 6.91 µmol) was added to the previous NMR tube and the 
solid added completely solubilises. The 1H NMR spectrum was recorded again followed by 2D 
ROESY NMR experiment (spinlock time = 350 ms). [Final concentration: βpen.HCl/5’-AMP 
(15.4 mM / 15.4 mM, R = 1.00) in PBS]. 
 
11.5.3 PABA : βpen 
βpen.HCl (6.33 mg; 3.76 µmol) was solubilised in deuterated PBS (pH = 7.4; 0.6 mL) 
to get a clear slight yellow solution. The 1H NMR spectrum was recorded. Excess of p-
aminobenzoic acid, PABA (2.13 mg; 15.5 µmol) was added to the previous NMR tube and the 
solid added completely solubilises. The 1H NMR spectrum was recorded again followed by 2D 
ROESY NMR experiment (spinlock time = 350 ms). [Final concentration: βpen.HCl/PABA 
(6.3 mM / 25.8 mM, R = 1.00) in PBS]. 
 
11.5.4 ADA-NH3Cl : CD-mTHPP  
In a dry vial CD-mTHPP (2.01 mg; 1.12 µmol) and pMβCD (1.45 mg; 1.01 µmol) were 
solubilised in DMSO-d6 (20 µL), vortexed for 1 - 2 min followed by the addition of D2O (480 
µL) to obtain a clear dark red 4 % DMSO/D2O solution. The 1H NMR spectrum was recorded 
followed by addition of ADA-NH3Cl (6.7 µL; 54.3 mM, 4 % DMSO/D2O). 1H NMR spectrum 
and 2D NMR spectra (HSQC / NOESY) were subsequently recorded. [Final concentration: 
pMβCD/CD-mTHPP (2.00 mM / 2.21 mM, R = 0.91) + ADA-NH3Cl (0.71 mM) in 4 % DMSO / 
D2O]. 
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11.5.5 GEM-ADA amide : CD-mTHPP 
In a dry vial CD-mTHPP (1.0 mg; 0.557 µmol) and pMβCD (1.2 mg; 0.839 µmol) were 
solubilised in DMSO-d6 (20 µL), vortexed for 1-2 min followed by the addition of D2O (480 
µL) to obtain a clear dark red solution (4 % DMSO/D2O). 1H NMR (relaxation delay, d1 = 5 s) 
was recorded, followed by addition of GEM-ADA amide (T9) (0.5 mg; 1.175 µmol) stirring (5 
min; not soluble), followed by sonication for 60 min. 1H NMR spectrum and 2D NMR spectra 
(2D ROESY / NOESY) were subsequently recorded. [Final concentration: pMβCD/CD-
mTHPP (1.67 mM / 1.14  mM, R = 1.46 ) + GEM- ADA amide (2.45 mM) in 4 % DMSO / 
D2O]. 
 
11.5.6 NDTAM.HCl : CD-mTHPP 
In a dry vial CD-mTHPP (0.96 mg; 0.53 µmol) and pMβCD (1.4 mg; 0.98 µmol) were 
solubilised in DMSO-d6 (20 µL), vortexed for 1-2 min followed by the addition of D2O (480 
µL) to obtain a clear dark red solution (4 % DMSO/D2O). The 1H NMR (relaxation delay, d1 = 
5 s) and 2D HSQC experiments were recorded, followed by addition of NDTAM.HCl (0.17 mg; 
0.43 µmol) and repetition of the same NMR experiments. 2D NOESY experiment was recorded 
using a different molar ratio namely: CD-mTHPP (1.7 mg; 0.93 µmol); pMβCD (1.4 mg; 0.98 
µmol); NDTAM.HCl (0.17 mg; 0.43 µmol). [Final concentration: pMβCD/CD-mTHPP (1.96  
mM / 1.06  mM; R = 1.85) + NDTAM.HCl (0.86 mM) in 4 % DMSO / D2O]. 
 
11.5.7 PABA : EPI/βpen P3 
P3 (6.13 mg) was solubilised in deuterated PBS (pH = 7.4; 0.5 mL) to get a clear slight 
yellow solution with a residue in the bottom of the tube. The 1H NMR was recorded. Para-
aminobenzoic acid, PABA (2.0 mg; 14.6 µmol) was added to the previous NMR tube and the 
solid added completely solubilises. The 1H NMR was recorded again followed by 2D ROESY 
NMR experiment (spinlock time = 350 ms). 
 
11.5.8 PABA : pLys/βpen BB’ 
pLys/βpen BB’
 
(1.2 mg; 0.6 µmol) was solubilised D2O (0.5 mL) to get a clear 
colourless solution. The 1H NMR spectrum was recorded. Para-aminobenzoic acid, PABA (20 
µL; D2O) of a 30.6 mM solution prepared by solubilising PABA (4.2 mg; 30.6 µmol) in D2O (1 
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mL). The 1H NMR spectrum was recorded again followed by 2D ROESY NMR experiment 
(spinlock time = 350 ms) and 2D HSQC. 
 
11.5.9 GEM-ADA amide : pLys/βpen BB’ 
pLys/βpen BB’
 
(1.0 mg; 0.5 µmol) was solubilised D2O (0.5 mL) to get a clear 
colourless solution. The 1H NMR spectrum was recorded. GEM-ADA amide (0.6 mg; 1.4 
µmol) was added to the previous solution and the 1H NMR spectrum was recorded again 
followed by 2D ROESY(spinlock time = 350 ms) and a 2D HSQC NMR experiments. 
 
11.5.10 ADA-NH3Cl : pLys/βpen T2 
pLys/βpen T2 (5.0 mg) was solubilised D2O (0.6 mL) to get a clear light yellow 
solution. The 1H NMR spectrum was recorded. 1-Adamantanamine, ADA-NH3Cl (12 µL, 55.9 
mM, D2O) was added to the previous NMR tube and the solid added completely solubilises. The 
1H NMR spectrum was recorded again followed by 2D ROESY (spinlock time = 350 ms) NMR 
experiment. 
 
11.5.11 5’-AMP : pLys/βpen T2 
pLys/βpen T2 (5.0 mg) was solubilised D2O (0.6 mL) to get a clear light yellow 
solution. The 1H NMR spectrum was recorded. Adenosine 5’- monophosphate, 5’-AMP (96 µL, 
20.2 mM, D2O) was added to the previous NMR tube. The 1H NMR spectrum was recorded, 
followed by 2D ROESY (spinlock time = 350 ms) NMR experiment. 
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11.6 HPLC calibration curve of 5’-AMP 
HPLC with UV-Vis detection at λ = 254 nm was used to determine the calibration 
curve of 5’-AMP. A stock solution A, containing 5’-AMP (8.1 mg; 23.3 µmol) was solubilised 
in phosphate buffer saline (PBS, pH = 7.4). Five solutions were prepared by diluting small 
volumes of solution A (1 mL; 5 mL; 2.5 mL; 1 mL; 0.5 mL) respectively into (100 mL; 25 mL; 
25 mL; 25 mL; 25 mL) to get five solutions of concentrations of (Cx = 233.0 µM; 46.7 µM; 23.3 
µM; 9.3 µM; 4.6 µM) respectively. All solutions were injected in duplicate (2 x) in the HPLC 
system and the analytical response (area under the peaks) was measured and plotted as a 
function of Cx (µM). 
 
 
12. Cell experiments 
Cell experiments were conducted on human prostate cancer cell line (DU145) and on 
breast cancer cell line (MCF7). Cell medium used Roswell Park Memorial Institute (RPMI) 
medium and phosphate buffered saline (PBS). Incubation times used were 3 h or 15 h. Imaging 
was performed by confocal spectroscopy at λexc = 647 nm and λem~680 nm. 
 
12.1 CD-mTHPP 
A stock solution of CD-mTHPP (10 mM; DMSO) was prepared solubilising CD-
mTHPP (0.82 mg; 0.45 µmol) into DMSO (46 µL). The stock solution was diluted twice: CD-
mTHPP (400 µM; 4 % DMSO/PBS) and CD-mTHPP (8 µM; cultured media). DU145 cells 
were incubated for 15 h in the presence of CD-mTHPP (8 µM; cultured media). A second set of 
experiments was performed in RPMI instead of PBS. 
 
12.2 pMβCD/CD-mTHPP 
A stock solution of pMβCD/CD-mTHPP (10 mM in CD-mTHPP; DMSO) and was 
prepared by solubilising CD-mTHPP (0.72 mg; 0.40 µmol) and pMβCD (0.30 mg; 0.21 µmol) 
into DMSO (400 µL). This stock solution was diluted twice: CD-mTHPP (400 µM; 4 % 
DMSO/PBS) and CD-mTHPP (8 µM; media). DU145 cells were incubated for 15 h in the 
presence of CD-mTHPP (8 µM; cultured media). A second set of experiments was performed in 
RPMI instead of PBS. 
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13. Additional characterization data 
13.1 Conjugate CD-mTHPP 
 
Figure 114. 2D HSQC NMR experiment (DMSO-d6, 500 MHz, 25 ºC) of CD-mTHPP. 
 
 
13.2 Per(6-aminoethylamino-6-deoxy)-βCD (βpen) 
 
Figure 115. 13C NMR spectrum (D2O, 500 MHz, 25 ºC) spectra of βpen (white powder) in D2O (10 < pH < 11) 
and of βpen.HCl (pH ≈ 4). 
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Figure 116. MS (MALDI-TOF) βpen freebase (5 mg/mL), using 2,5-dihydroxybenzoic acid (DHB) as a matrix. 
 
 
13.3 N-Desmethyltamoxifen hydrochloride (NDTAM.HCl) 
 
Figure 117. 1H NMR spectrum (MeOD-d4, 500 MHz, 25 °C) of NDTAM.HCl. 
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Figure 118. 13C NMR spectrum (CDCl3, 500 MHz, 25 °C) of NDTAM.HCl. 
 
 
 
Figure 119. IR spectra of commercial NDTAM.HCl (blue line) and of NDTAM.HCl experimentally obtained 
(red line). 
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13.4 Tamoxifen citrate (TAM-Cit, 2:1) 
 
Figure 120. 1H NMR spectrum (CDCl3, 500 MHz, 25 ºC) of TAM-Cit (2:1). 
 
 
 
Figure 121. IR spectra of commercial TAM (blue line) and of TAM.Cit (2:1) (red line). 
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13.5 Gemcitabine-adamantanamide (GEM-ADA amide) 
 
Figure 122. IR spectra of commercial GEM.HCl (light blue), ADA-COOH (red line) and of GEM-ADA amide 
(blue line). 
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